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Abstract 
The regenerative capacity of human myocardium is unable to compensate adequately for 
the significant loss of hea11 muscle that occurs in acute myocardial infarction (Ml). 
However, recent studies indicate that the adult hea11may contain populations of cells that 
have stem cell characteristics and which could have regenerative potential. In order to 
better examine the biology of such cells, this study developed a mouse model of MI that 
combined low mortality, reproducible infarct size and the opportunity for reperfusion 
studies. One potential barrier to the expression of regenerative capacity at the time of 
acute Ml is inflammation, which, as well as contributing to myocardial injury, may 
prevent the activation and function of putative stem cells. The C5/C5a axis in the 
complement cascade is a key mediator of the inflammatory events involved in Ml and 
therefore represents an attractive target. An antibody to the C5a receptor was used in vivo 
in the murine model of Ml. Although the neutrophil infiltration at the time of Ml was 
significantly reduced (p<0.05), the size of Ml was unchanged in comparison to control, 
suggesting that other regenerative strategies must be explored. Therefore in pursuit of a 
mechanism by which the hem1 may regenerate, cells were isolated and assayed in vitro 
for their stem cell capacity. Cells expressing platelet derived growth factor receptor alpha 
(PDGFRA) were candidates for such stem cells, both as these are present in the 
proepicardium and epicardium in the embryo, and that Pdgfra_1_ mice demonstrate cardiac 
abnormalities. A combined approach was employed, using genetically modified mice 
expressing Green Fluorescence Protein (GFP) under the transcriptional control of the 
Pdgji·a locus, expression of surface antigens as well as the ability of candidate stem cells 
to demonstrate self renewal and proliferation in a colony fom1ing unit fibroblast assay 
(CFU-F). A Sea-l +/PECAM-/PDGFRA GFr+ fraction isolated from the adult heart was 
found to be enriched for colony fom1ing activity. Two populations were found which 
formed colonies, the PDGFRA GFPHIGH population which had 'stem cell' like properties in 
tenm of proliferation, prolonged self renewal and multipotent in vitro differentiation, and 
the PDGFRA GFPMEDIUM population which had 'progenitor cell' like properties in that 
although it had proliferative ability, the potential of this population to continue to self 
renew and differentiate into multiple lineages was limited. The number of candidate stem 
IV 
cells and progenitor cells in the heatt increased post infarct as evidenced by an increase in 
number of PDGFRA GFPHtGH and PDGFRA GFPMEDtUM cells, together with a greater colony 
forming ability of the PDGFRA GFPHIGH cells. These effects were magnified in a 
proregenerative transgenic model, Pdgfi·aGFP/I ;m/GF. in which there was over expression 
of insulin-like growth factor I (IGF-1), supporting the argument that Sca-1'/PECAM-
/PDGFRA GFP+ cells may have a role to play in the regenerative capacity of the adult 
heart. 
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Chapter 1 
Introduction 
2 
1.1 Coronary heart disease 
There has been a steady rise in the prevalence of cardiovascular disease over the last 
century. The World Health Organisation (WHO) estimate that cardiovascular disease is 
currently the leading cause of death worldwide, claiming 14.7 million lives in 1990 and 
17 million in 1999 (Bonow et al., 2002). Ischaemic heart disease (IHD) is actually on its 
own the single leading cause of death worldwide. (Bonow et al., 2002). Of pa1ticular 
concern is that the burden of cardiovascular disease in developing countries is projected 
to match that in the developed world due to accelerated economic development, and 
lifestyle changes which promote atherosclerosis leading to a rise in ischaemic heart 
disease (Bayes de Luna, 1999). The keystone in therapy for ischaemic heart disease 
primarily involves revascularisation. This involves thrombolytic drug therapies, 
percutaneous intervention and surgery. However, the progressive nature of coronary 
mtery disease dictates that a large percentage of individuals with ischaemic heart disease 
go on to develop ischaemic heart failure as they exhaust the medical and surgical options 
available (Hellem1ann et al., 2002). 
The prognosis of hemt failure is poor, with median survival after onset of 1.7 years in 
men and 3.2 years in women (Braunwald and Bristow, 2000). Hemt failure is a condition 
that primarily affects the elderly and with the progressive aging of the population, the 
prevalence of heart failure is certain to increase over the next decade, contributing an 
enormous burden on health services and cost to society, currently accounting for 2% of 
all health care spending (McMurray and Pfeffer, 2005). Therapy for heart failure aims to 
relieve symptoms, avoid hospital admissions and to prolong life. The mainstay of drugs 
used to achieve this have included diuretics, angiotensin converting enzyme (ACE) 
inhibitors and B blockers (McMurray and Pfeffer, 2005). Other interventions can include 
implantable cardiove1ter defibrillators (ICD) to reduce the risk of sudden death from 
ventricular arrhythmia (Bristow et al., 2004; Moss et al., 2002) and resynchronisation 
therapy to enhance pump function of the heart (Cieland et al., 2005). In tenns of surgery, 
the gold standard for end stage hemt disease is transplantation, however due to donor 
shortages and morbidity associated with lifelong immunosuppressive therapy, other 
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surgical options including mechanical ventricular assist devices are being developed, as a 
means to 'bridge' people until donor organs become available and also as a destination 
therapy. These have been shown to have significant benefits in terms of mortality 
compared to optimal medical therapy (Rose et al., 200 I). As technology improves, 
mechanical assist devices are showing improvements in complications of sepsis, device 
failure and thrombo-embolic events. 
Although these therapies ameliorate symptoms and improve survival, none are able to 
directly reverse the disease process itself. Therefore these treatment options all suffer 
from the same fundamental limitation that none can repair the damage that has already 
been done. 
If new myocardium could be grown in diseased hearts then the possibility that this 
disease process could be reversed may be realised and the dogma that the heart does not 
have regenerative ability could be challenged. 
1.2 Is the heart a terminally differentiated organ? 
There has been a commonly held view that the heart is a post mitotic organ without 
regenerative capacity especially since the usual pathophysiology after ischaemic injury is 
the loss of myocytes and replacement by connective tissue scar (Anversa and Kajstura, 
1998; Nadai-Ginard et al., 2003). It was postulated that myocytes could not enter into the 
proliferative phase of the cell cycle, but could only undergo cellular hypertrophy. The 
concept that myocytes cannot divide originated from both the difficulty of identifying 
mitotic figures in the cells and the absence of any substantive DNA synthesis in myocyte 
nuclei (Anversa and Kajstura, 1998). 
However, there has been a steady accumulation of evidence to challenge this view, 
beginning with studies in the 1960s when an increase in myocyte number in hypertrophic 
human left ventricles was observed (Linzbach, 1960). A few years later it was reported 
that some ventricular myocytes could pass through all phases of the cell cycle 
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(Rumyantsev, 1964). These observations have been confinned in recent years by Anversa 
and colleagues (Kajstura et al., 1998). 
There is additional evidence from instances of ischaemic heart disease. Kajstura et al 
examined myocyte proliferation in end stage cardiac failure in human hearts. They found 
a small number of mitotic figures in control hearts, but a I 0 fold increase in patients with 
end stage ischaemic heart disease, suggesting that cell division may occur at a low rate in 
normal myocardium, but play a role in response to cardiac damage (Kajstura et al., 1998). 
This was supported by further work by the same group (Beltrami et al., 2001 ). This study 
examined hearts of patients who had died after myocardial infarction (MI). Myocytes that 
had entered the cell cycle in preparation for cell division were measured using the nuclear 
labelling antigen Ki67, a marker which is associated with cell division. Ki67 was 
detected in 4% of myocyte nuclei in regions adjacent to the infarct area and in I% of 
those regions remote from the infarct. Events characteristic of cell division such as 
mitotic spindles, karyokinesis and cytokinesis were also observed. These results 
suggested that the adult myocytes were capable of re-entering the cell cycle, but only in 
those areas where oxygenation was maintained such as the peri-infarct zone. 
The question of the ongm of the mitotic cells could begin to be addressed by 
transplantation studies. Quani et al examined cases where a male patient had received a 
heart from a female donor (Quaini et al., 2002). The presence or absence of the Y 
chromosome was used to detect cells of recipient or donor origin. In the transplanted 
hearts, cells of the myocardium (9 ± 4%), atterioles (I 0 ± 3 %) and capillaries (7 ± I%) 
contained the Y chromosome. Of the myocytes which contained the Y chromosome 17.2 
± 4.2% were replicating (measured by Ki67 labelling). They also examined control hearts 
and transplanted hearts for cells expressing c-kit, MDR I and Sea-l. These are surface 
proteins characteristic of but not exclusive to stem cells (Demeule et al., 200 I; Jiang et 
al., 2000a; Thiebaut et al., 1987; Torrente et al., 200 I; Wu et al., 2000). Cells expressing 
these markers were found to be small and round with a large nucleus and a thin rim of 
cytoplasm. These cells were also negative for markers of haematopoietic cells, 
differentiated myocytes, smooth muscle cells, endothelial cells and fibroblasts. They 
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found that cells expressmg stem cell markers were found in control hearts but their 
numbers were up to 4 fold higher in the hearts which had been transplanted from the 
female donors into male recipients. 12 to 16% of these cells also expressed the Y 
chromosome indicating they had translocated from the host to the donor tissue. The 
authors speculate that the mechanical factors involved due to the implantation of the 
normal heart into a recipient where the heart will be subject to a changed haemodynamic 
load may trigger the translocation of primitive cells into the transplanted heart, and that 
these cells may be involved in contributing to optimizing cardiac mass and restoring 
function in the short term. 
The evidence for replicating myocytes and cells expressmg stem cell markers in 
transplants does not address whether there is a demand for such cells in nom1al 
physiological states. Such evidence could be gained by predicting normal cell turnover. 
An versa's group calculated that a rat left ventricle contains 23 x I 06 myocytes at 4 
months of age and 19 x I Oli myocytes at 29 months (An versa et al., 1990). Since the 
average rate of death was calculated as 1.34 x I Oli myocytes per month, it was estimated 
that all myocardial cells would have died within 17 months of life (Kajstura et al., 1996). 
Clearly this is not the case, giving weight to the argument that myocardial cells are 
replenished and that cardiac cell turnover is possible. 
From this data it could be postulated that cell turnover in the heart is not static, but 
dynamic in nature. The fact that there is evidence for cycling cells in the heart suggests 
that the heart may actually have the potential to repair and regenerate but that 
regeneration might be too inefficient to repair the extensive myocardial injllly after an 
ischaemic event. The question which one must ask is what is the source of these cells 
which may have this potential'? One source could be stem or progenitor cells. Hsieh et al 
explored the degree to which stem or progenitor cells may contribute to renewal of adult 
mammalian cardiomyocytes (Hsieh et al., 2007). A transgenic approach was used to map 
cell fate in the adult murine heart. Treatment with 4-0H-tamoxifen induced heart specific 
expressiOn of Cre recombinase (expressed under the tamoxifen-conditional 
transcriptional control of the a-myosin heavy chain (a-MHC) promoter), resulted in the 
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permanent marking of cells with green fluorescent protein (GFP). All of the progeny of 
these cells continue to express GFP, so allowing examination of the replicative potential 
of the marked cells. Cells which do not express the a-MHC gene at the time oftamoxifen 
treatment, such as uncommitted stem cells, would not be genetically labelled with G FP. 
Thus the hypothesis was that if the numbers of GFP marked myocardial cells diminished 
over time, this would be evidence for repopulation from a stem cell source. The authors 
found that during nonnal aging up to one year the percentage of GFP' cardiomyocytes 
did not change. However 3 months after myocardial infarction, the percentage of GFP'-
cardiomyocytes had decreased significantly not only in the peri-infarct area, but also in 
regions remote from the infarct. These results provided indirect evidence for the 
involvement of a non myocyte cell contribution in the response post infarct, and suppmts 
the argument that a stem cell population may play a role at least in response to 
myocardial infarction. 
Evidence for a regenerative response in the adult hemt can also be drawn from other 
animal models. 
1.3 Regeneration in urodele amphibians and zebrafish 
Selected non-mammalian vertebrates, including urodele amphibians and zebrafish show 
an elevated regenerative ability in comparison to their mammalian counterparts, reviewed 
in (Brockes and Kumar, 2002). An adult newt can regenerate its jaws, lens, retina, limbs 
and large sections of the heart in response to molecular signals which signal tissue 
damage. In the urodele amphibian it has been reported that adult cardiomyocytes re-enter 
the cell cycle and divide in the zone surrounding a blood clot. Zebrafish are also able to 
regenerate cardiac muscle after major injury. Pass et al showed that following resection 
of the apex of the ventricle, cardiomyocyte hyperplasia renews the myocardium and 
restricts scar fonnation (Pass et al., 2002). Transgenic repmter strains have in recent 
years been used to try to establish mechanisms involved in this process. Lepilina et al 
showed that an initial blastema is formed consisting of progenitor cells. These cells, 
expressing pre- cardiac markers such as Nkx2-5, can then undergo differentiation and 
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proliferation. Epicardial tissue surrounding both cardiac chambers then expands, creating 
a new epithelial cover for the exposed myocardium. A sub population of the epicardial 
cells localises to the wound. This subpopulation of cells which express the T -box 
transcription factor tbx 18 undergoes epithelial to mesenchymal transition (EMT), 
penetrates the regenerating tissue and provides new vasculature to the regenerating 
muscle. The epicardial cells have been found to express fibroblast growth factor receptors 
particularly fgf2 and fgf4. During regeneration fgfl7b was found to be induced in the 
myocardium. When fgf signalling was blocked, epicardial EMT and coronary 
neovascularisation was arrested (Lepilina et al., 2006). These findings demonstrated the 
importance of the epicardial tissues which together with fgf signalling were crucial to 
achieve cardiac regeneration in the zebrafish heart. 
These findings suggest that it is possible that the machinery to facilitate regeneration 
from progenitor cells may be present but lie dom1ant in adult mammals. However, 
cardiac tissue regeneration from precursor cells does occur at least once in their lifetime; 
during embryogenesis. In view of this it is important to briefly look at mammalian heart 
development to try to delineate sources of potential progenitors or stem cells during 
embryogenesis so as to help understand the cellular origin of cells which may have the 
potential to be able to contribute to repair and regeneration of the heart in the adult. 
1.4 Sources of resident cardiogenic precursors 
1.4.1 Cardiac progenitor cells during embryogenesis 
The heart is composed of many different tissues including myocytes, conduction system 
cells, smooth muscle, endothelial cells, interstitial cells and connective tissue. During 
development the differentiation of these multiple lineages is under tight spatial and 
temporal control resulting in the coordinated fonnation of the separate components of the 
heart as reviewed by Laugwitz et al (Laugwitz et al., 2008). In the embryo three main 
sources of hea1t cell precursors have been identified, the cardiogenic mesoderm, the 
cardiac neural crest and the proepicardial organ. Each one of these represents a separate 
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pool of progenitor cells which give rise to distinct cardiac structures in the embryo (figure 
1.1 ). Myocardial progenitor cells originate in the primitive streak which is a transitory 
embryonic structure, present as a strip of cells that align to the anterior-posterior axis of 
the embryo. The cells in the primitive streak involute (a process called gastrulation) 
resulting in the fonnation of the three cell regions that are the source for all subsequent 
cell types. The mesodenn gives rise to the musculoskeletal system, connective tissue, 
blood and internal organs such as the hea1t. The ectoderm develops into brain, skin, nails 
and epithelium of the nose, mouth, anal canal and nervous system and the endoderm 
forms the inner linings of the digestive tract and respiratory passages, the liver and 
pancreas. The mesodermal cells at the primitive streak migrate to the anterior pmt of the 
embryo at about embryonic day 6.5 and come to lie under the head folds and fonn the 
cardiac crescent, which is cardiogenic mesoderm (E7 .5). The cardiac crescent fuses in the 
midline to fom1 the early cardiac tube. It subsequently undergoes looping (E8.5) and then 
by E I 0.5 the hemt has well defined chambers. By E 14.5 septation has occuned 
separating the chambers, and the heart is connected to the pulmonary trunk and aorta. 
Cardiac neural crest migrates to the heart at a later stage of development, and gives rise to 
the vascular smooth muscle of the aortic arch, ductus arteriosus and the great vessels 
(Jiang et al., 2000b). The mesenchyme po1tion of the developing heart and the majority 
of the epicardial cells are derived from the proepicardium which is a cluster of 
mesothelial cells located in the caudal regions of the developing vertebrate heart. Lineage 
tracing studies have suggested this proepicardium, a distinct extra cardiac structure, is the 
source of many non-cardiomyocyte cardiac cell types including endothelium, smooth 
muscle and fibroblasts (Mikawa and Gourdie, 1996; Poelmann et al., 1993). Progenitors 
bud off from the proepicardium, traverse the pericardial cavity and re-attach to the 
surface of the heart forming the epicardium. These epicardially derived cells (EPDC) 
then invade the cardiomyocyte layer by a process called epithelial to mesenchymal 
transfonnation and differentiate into endothelial, smooth muscle and fibroblast cells. The 
epicardium also supplies growth factors including fibroblast growth factors 9116/20 
which are required for cardiomyocyte growth (Lavine et al., 2005). Disruption of 
epicardial specific genes has resulted in a phenotype of a thin myocardium (Moore et al., 
1999) and there are reports of contribution of proepicardially derived cells to 
A E7.5 EB.O EB.S E14.5 
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Figure 1.1 Cardiac development 
Contribution of the three populations of embryonic heart progenitors, cardiogenic 
mesoderm, cardiac neural crest and proepicardial organ to the different heatt 
compartments during cardiac morphogenesis. Progenitors of the cardiogenic mesoderm 
are first recognisable under the head folds (HF) of the embryo at E7 .5, then move to the 
midline (ML) and initially fom1 the heart tube and ultimately the four chambers of the 
heart. After the looping of the heatt tube (E8.5), cardiac neural crest progenitors migrate 
from the dorsal neural tube to engulf the aortic arch arteries and contribute to vascular 
smooth muscle cell s of the outflow tract (OFT) at E I 0.5). At the same time the 
proepicardial organ precursors mi grate to the heart and contribute to coronary 
vascu lature, fibroblasts and myocardium. Cranial (Cr)-cauda l (Ca), right (R) and Left 
(L), dorsal (D)-Ventral (V) axes are indicated . AA, aortic arch ;IVS interventricular 
septum; LA, left atrium; LV, left ventricle ; Ph pharyngeal arches ; PLA primitive left 
atrium; PRA, primitive right atrium; RA, right atrium; RV right ventricle. Reprinted 
with permission (Laugwilz et al , 2008) . 
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myocardium (Wessels and Perez-Pomares, 2004) in vitro hence suggesting a potential 
role for these cells in cardiomyogenesis. Interestingly recent data has corroborated the 
evidence for the contribution of epicardial cells to cardiomyocytes. Cai et al report the 
identification in mouse of a cardiac myocyte lineage that derives from the proepicardial 
organ (Cai et al., 2008). Using a Cre knock-in into the endogenous Tbx 18 locus, they 
crossed Tbx 18:Cre mice with the lineage reporter R26R1"cz. Early analysis of LacZ 
expression in embryos from this cross was consistent with that of endogenous Tbx 18. At 
E I 0.5 there was evidence of Thx derived lineages in the forming ventricles and atria and 
eo-staining with cardiac troponinT (cTnT), cardiac Troponinl (cTnl), and the 
transcription factors Nkx2-5 and GA TA4 showing that these Tbx derived cells were 
probably cardiomyocytes. Adult lineage analysis showed that Tbxl8 derivatives were 
seen in smooth muscle of the coronary vessels, ventricular and atrial myocytes and atrio-
ventricular valves. Tbx/8 lineage traced cells that eo-stained with cardiac Troponin T 
demonstrating their cardiomyocyte status. Tbx 18 lineages did not give rise to coronary 
endothelial cells, however approximately 30% of cardiac fibroblasts were shown to 
derive from Tbx 18 lineages. Further work on epicardial progenitors used the fact that 
Wilms Tumour protein I (Wt I) was found to be expressed in proepicardium and 
epicardium (Zhou et al., 2008). Similar lineage tracing experiments demonstrated that 
Wt I derived cells contribute to cardiomyocytes, endothelial and smooth muscle lineages 
during nonnal development. The Wt I derived cardiomyocytes were shown to express 
Gata4 and Nkx2-5. The above data demonstrate evidence for a potentially important 
progenitor cell or stem cell which could be involved in cardiac repair or regeneration, 
which is located in the proepicardial organ and epicardium of the developing heart. 
As explained above, three major sources of heart cell precursors have been identified in 
the embryo, the cardiogenic mesoderm, the cardiac neural crest and the proepicardial 
organ. The cardiac crescent which is part of the cardiogenic mesoderm is often referred to 
as the first hem1 field. It gives rise to the linear heart tube and ultimately the atrial 
chambers and ventricular region. No speci fie markers have been identified for this 
population. The second cardiogenic region, known as the second heart field lies dorsal to 
the linear heart tube and is derived from the pharyngeal mesodenn medial to the cardiac 
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crescent (Laugwitz et al., 2008). Cells from this second heart field are added to the 
developing heart tube and give rise to the outflow tract, the right ventricular region and 
the majority of the atrial tissue (reviewed by Buckingham et al (Buckingham et al., 
2005)). Recent studies have shown the expression of islet-! transcription factor (Is! I) as a 
marker of the second myocardial lineage during mammalian cardiogenesis (Cai et al., 
2003). Is// knockout mice were found to have an abnonnal cardiac phenotype. Mutant 
hearts were found to be misshapen and failed to undergo looping morphogenesis, with an 
absent right ventricle and outflow tract resulting in death by E I 0.5. Lineage tracing 
confirmed these findings, showing that cells which had previously expressed Isll 
contributed to the majority of the cells in the outflow tract, right ventricle, atria and parts 
of the left ventricle. It appeared that Is II was required for cell proliferation, migration and 
survival , its transcription being turned off as the precursor cells differentiated. After birth 
relatively few Isll' cells are detectable in the myocardium, the organ distribution 
matching the contributions of lsll' precursors suggesting that these cells are 
developmental remnants of the foetal progenitor population. Laugwitz et al and Moretti et 
al studied the contribution of I sir' precursors to cardiac cell lineages in the adult heart 
(Laugwitz et al., 2008; Laugwitz et al., 2005; Moretti et al., 2006). Cre mediated removal 
of a stop sequence in the cells that express Isll resulted in the expression of LacZ. In this 
way all cells that once expressed lsll during development were marked. This showed a 
high proportion of right ventricular myocardium and pat1s of both atria consisted of cells 
which expressed LacZ and the myocytic protein sarcomeric a-actinin. By analysing LacZ 
expression and acetylcholinesterase expression it was shown that lsll 1 progenitors 
contribute also to the conduction system, primarily to the sino-atrial node. Additionally 
LacZ expression was found in the proximal aorta and pulmonary outflow tract. eo-
expression of LacZ with endothelial and smooth muscle specific markers such as CD31 
and smooth muscle myosin heavy chain respectively showed that Is II 1 precursors could 
give rise to vascular lineages also. Therefore it appears that lsl defines a multipotent 
progenitor in the developing heart which contributes to distinct cell lineages within heat1 
compat1ments known to originate from the second heat1 field. The effect of in vivo 
transplantation of Is! I+ cells has not yet been detem1ined. 
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Hence it seems that Isll + cells and epicardially derived cells are integral to 
cardiomyogenesis and that remnants of these cells which remain in the adult could act as 
a putative stem or progenitor cell population. In addition , recent work from Prall et al 
(personal communication Or 0 Prall, Victor Chang Cardiac Research Institue, Sydney) 
has shown the presence of cells expressing platelet derived growth factor receptor alpha 
(PDGFRA) in the proepicardial organ at E9.0. These cells were found on the epicardial 
surface of the heart at E9.0 to EI0.5, and from El2.5 they appear in the myocardial 
interstitium. There is evidence of a cardiac developmental role for these cells also. 
1.4.2 Platelet Derived Growth Factor- its role in development and the adult 
Platelet-derived growth factor (PDGF) is a potent mitogen and chemotactic factor for a 
variety of mesenchymal cells, such as fibroblasts, vascular smooth muscle cells, 
glomerular mesangial cells and brain glial cells. Activation of its receptors Platelet 
derived growth factor receptor alpha (PDGFRA) and Platelet derived growth factor 
receptor beta (PDGFRB) stimulates fibroblast migration, proliferation and activation 
(Raines, 2004; Si mm et al., 1998; Yu et al., 200 I). In the mid 1970's several groups 
demonstrated that this growth factor in serum was derived from the alpha storage 
granules in platelets (Kohler and Lipton, 1974; Ross et al., 1974). 
The PDGFs are a family of dimeric disulphide-bound growth factors that can activate two 
structurally related tyrosine kinase receptors, PDGFRA and PDGFRB. These receptors 
are transmembrane proteins that have an extracellular ligand-binding domain, a 
transmembrane domain and a cytoplasmic tyrosine kinase domain (Fantl et al., 1993). 
The alpha and beta receptors have molecular sizes of approximately 170kd and 180kd 
respectively and are the products of 2 separate but highly homologous genes on 
chromosomes 7 and 22 respectively (Dalla-Favera et al., 1982). On ligand binding, PDGF 
receptors homodimerise or heterodimerise into PDGFAA, PDGFAB or PDGFBB 
initiating signal cascades (Heldin, 1996). Both receptors can activate similar signal 
transduction pathways including the phosphaticlylinositol 3-kinase (PI3K), Ras mitogen-
activated protein kinase (Ras-MAPK), and phospholipaseCy pathways. The PI3K 
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pathway is essential for PDGF-induced cell migration, actin reorganization and 
prevention of cell death (Vanhaesebroeck et al., 1997). Ras is important for the mitogenic 
effect of PDGF. 
The biologically active ligands are homodimers or heterodimers. The homodimers are 
PDGF-AA, PDGF-BB, PDGF-CC and PDGF-DD and the heterodimer is PDGFR-AB. 
All PDGF ligands, except PDGF-DD induce PDGFRA dimerisation. PDGF-BB and 
PDGF-DD activate PDGFRB dimerisation. PDGFRAB heterodimer is activated by all 
ligands except PDGF-AA. The predominant signaling appears to be PDGF-AA and 
PDGF-CC through PDGFRA homodimers, PDGFR-AB through PDGFRA homodimers 
and PDGFRAB heterodimers, and PDGFR-BB and PDGFR-DD through PDGFRB 
homodimers. PDGFR genes are receptor tyrosine kinases (RTKs) and are likely to have 
evolutionary origins in common with other RTKs whose expression has often defined 
stem/progenitor cell populations. Human PDGFRA is located within 0.9Mb of the 
haematopoietic stem cell marker c-kit (Yoshida et al., 1998). Levels of PDGFR 
expression on cells varies considerably, but of note PDGFRA and PDGFRB are 
expressed on vascular smooth muscle cells, vascular endothelial cells, fibroblasts, 
platelets, macrophages and keratinocytes (Heldin and Westennark, 1999). 
1.4.2.1 Developmental role of PDGF-B and PDGFRB 
Pdg(-b or Pdgfi·b negative m1ce die during late gestation from cardiovascular 
complications (Leveen et al., 1994; Soriano, 1994). The mutant mice look normal up 
until E 16-19 when there is dilatation of the heart and large blood vessels and dilatation 
and rupture of capillaries. Other findings include abnonnal kidney glomeruli, capillmy 
microaneurysms, arterial smooth muscle cell hyperplasia, cardiac muscle hypertrophy 
and widespread oedema and haemorrhage. The significance of biological signaling in 
vivo of PDGF-BB via PDGFRB is discussed below. PDGF-DD signaling via PDGFRB 
has not been fully clarified (Heldin and Westermark, 1999). In the mouse embryo PDGF-
B expression appears restricted to vascular endothelium and megakmyocytes (Heldin and 
Westermark, 1999; Lindahl et al., 1997). PDGFRB positive mesenchymal cells are found 
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in cells distinct from but tightly associated with endothelial cells. It is assumed that these 
cells may constitute vascular smooth muscle or pericyte progenitors (Heldin and 
Westermark, 1999; Hellstrom et al., 1999; Lindahl et al., 1997). The spatial and temporal 
expression patterns of PDGF-BB and PDGFRB suggest that PDGF-BB released from 
endothelial cells normally promote proliferation in adjacent vascular smooth muscle or 
pericyte progenitors. This hypothesis is confinned by the Pdg(r-b and Pdgfi·b null 
phenotypes. The embryonic null phenotypes show a reduced BrdU labeling index 
(indicating reduced cell turnover) and a reduction in the number of smooth muscle cell 
and pericyte progenitors. 
1.4.2.2 Developmental role of PDGF-A and PDGFRA 
Cardiac defects in Pdg(ra null embryos include aortic arch attery malformations, 
persistent truncus arteriosus (PT A), atrial and ventricular septal defects (ASD and YSD), 
myocardial wall thinning and abnorn1al atrio-ventricular valves and dilatation of the 
pericardium, leading to death between E8 and E 16 (personal communication, Or 0 Prall, 
Victor Chang Cardiac Research Institute). Other defects include spina bifida and cleft 
face (Soriano, 1997). Deletion of Pdgfi·a specifically in neural crest cells (NCCs) with 
Wnt 1-Cre produces aortic arch artery malfom1ations, PTA and VSD (Tallquist and 
Soriano, 2003). This may suggest a role for Pdgfi·a in NCC progenitors. Null mutations 
of Pdg(-a or Pdg(-c display subsets of the defects seen in Pdg(ra null embryos(Ding et 
al., 2004). Pdgf~al-c null animals completely phenocopy the loss of PDGFRA function 
suggesting that both PDGF-A and PDGF-C signal through PDGFRA during 
embryogenesis(Ding et al., 2004). 
1.4.2.3 Over expression of PDGF in the heart 
Ponten et al (Ponten et al., 2003) over expressed PDGF-CC in the heart using the a-
myosin heavy chain promotor. Initially these PDGF-CC transgenic mice appeared normal 
during embryonic development and bi1th as compared to WT littermates. At 2 weeks 
mild fibrosis but no hypertrophy was observed and the animals are reported to have 
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appeared normal. After I month heart:body weight ratios in aged matched animals were 
significantly higher in the females. Starting from 3 months female mice died due to hea1t 
failure. Male mice did not die spontaneously before sacrifice at 7 months. PDGF-CC 
transgenic hearts developed a progressive hypertrophy. There was an increased number 
of interstial tibroblasts leading to disorganized myocardial architecture in the transgenic 
hearts. Masson 's Trichrome stain showed progressive collagen deposition with age, 
suggesting these transgenic mice develop a progressive cardiac fibrosis. Transgenic 
heterozygote mice were normal and fettile. On examination of blood vessels it was 
shown that blood vessel density in transgenic hearts was generally lower after the age of 
3 months. In transgenic hearts the nom1al capillary network was gradually replaced by 
dilated capillaries. PDGFRA was also found to be up-regulated in transgenic hearts 
compared with the WT, and an increased number of proliferating fibroblasts were found 
suggesting that in these transgenic hearts with activation of PDGF-C, PDGFRA is 
activated. The up regulation of the PDGFRA mRNA was suggested in this study to 
reflect an increased number of interstitial fibroblasts. 
1.4.2.4 The role of Platelet derived growth factor in myocardial infarction 
Infarct healing is regulated by a well orchestrated inflammatory response that ultimately 
leads to scar formation (Frangogiannis et al., 2002). Myocardial necrosis results in an 
influx of inflammatory mediators. Activated neutrophils secrete proteolytic enzymes and 
help to debride the infarct area. After the inflammation, there is a proliferative phase of 
healing when fibroblasts accumulate in the infarct granulation tissue and deposit 
extracellular matrix proteins. The granulation tissue is eventually replaced by collagen-
rich scar. During the proliferative phase the wound is very vascular to provide oxygen 
and nutrients to the proliferating cells. This angiogenesis is eventually suppressed and 
many of the infarct neo-vessels acquire a muscular coat (Ren et al., 2002) while uncoated 
vessels regress. Resolution of this inflammatory response and maturation of the 
neovasculature are impottant to prevent uncontrolled angiogenesis and expansion of 
granulation tissue. PDGF signaling is important in directing the regulation of fibrous 
tissue deposition and angiogenesis. Activation of PDGFRA and PDGFRB stimulates 
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fibroblast migration, proliferation and activation (Raines, 2004; Simm et al., 1998; Yu et 
al., 2001). Endothelial cells form vascular tubes and direct the recruitment of mural cell 
precursors by secreting PDGF-BB. PDGFRB is expressed by pericytes and smooth 
muscle cells, hence recruitment of mural cells by infarct neovessels may be important in 
mediating suppression of the angiogenic process and resolution of the inflammat01y 
infiltrate during wound maturation (Hirschi et al., 1999). 
Zymeck and colleagues examined the effects of using systemic neutralizing antibodies to 
disrupt PDGFRA signaling (Zymek et al., 2006). They showed that both PDGF receptors 
have important actions in regulation of the cellular events associated with scar formation. 
Although PDGFRA inhibition did not affect vascular maturation, it significantly 
decreased collagen deposition in the infarcted myocardium. This is consistent with the 
established role of PDGFRA in the development of myocardial fibrosis. PDGF-AA 
potently stimulated cardiac fibroblast proliferation also (Li et al., 2000). 
Resolution of inflammation is critical for effective cardiac repatr after myocardial 
infarction. PDGFRB helps to stabilize the infarct vasculature, promoting resolution of 
inflammation, and then together with PDGFRA , promotes scar stability and collagen 
deposition. Defective scar formation may adversely affect cardiac function by having 
implications on remodeling post infarct. 
Hence it is clear there are well described mechanisms of contribution and involvement of 
specific cells and regions of the hemt in development. The existence of these embryonic 
multipotent cardiac progenitor cells has in parallel prompted a search for the prescence of 
such cells in the post natal heart. 
1.4.3 Cardiac progenitor cells in the adult 
As seen earlier, evidence of mitosis in the peri-infarct areas of the heatt suggested cell 
replication, but the origin of this activity was not identified (Beltrami et al., 200 I). Two 
separate groups then went on to describe the existence of resident stem cells as identified 
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by expression of the stem cell characteristic markers c-kit and Sea-l (Beltrami et al., 
2003; Oh et al., 2003). Beltrami et al concentrated on c-kit' cells primarily because they 
had previously demonstrated a potential role for bone marrow derived Lin-e-kit' cells in 
myocardial regeneration (Orlic et al., 200 I) and the fact that both heart and bone marrow 
have mesodennal origin and the use of c-kit as a haematopoietic stem cell marker 
(MotTison et al., 1997). One Lin-ckit' cell was found for every I x I 04 myocytes. These 
Lin-e-kit' cells were found in small clusters in the intersticia between myocytes (figure 
1.2). Some of the cells in these clusters expressed transcription factors associated with 
early cardiac development such as GAT A4 (Molkentin et al., 1997) and Nkx2-5 (Biben et 
al., 2000), providing evidence that they may have a cardiomyogenic fate. Lin-e-kit' cells 
were isolated by flow cytometry and found to be negative for myocyte markers (a-
sarcomeric actin, cardiac myosin, connexin 43), endothelial cell (von Willebrand factor, 
CD31) and smooth muscle cell (a-smooth muscle actin) cytoplasmic proteins. These cells 
were shown to be clonogenic, self renewing and in vitro gave rise to the three different 
cardiogenic lineages, cardiomyocytes, smooth muscle and endothelial cells. Beltrami et al 
also examined in vivo potential of the c-kit' cells by injecting cells which had been 
labelled with enhanced green fluorescent protein (EGFP) into hearts of syngeneic rodents 
five hours after surgical induction of Ml (Beltrami et al., 2003). On examination of these 
hearts at ten days post infarct, regenerating bands of EGFP positive myocytes, arterioles 
and capillaries were observed which were positive for BrDU indicating they had 
undergone recent cell division. 
The authors claimed these results were highly unlikely to be a result of fusion events 
because (I) The number of new myocytes was orders of magnitude higher than the 
injected cells, which in addition gave rise to smooth muscle and endothelial cells. (2) As 
the cells were injected five hours after the infarct was initiated, it would be unlikely that 
there would be viable myocytes available for the injected cells to fuse to. (3) No 
myocytes with biochemical tags of the injected cells (BrDU or EGFP) were found in the 
spared myocardium where there are many more fusion partners. ( 4) The size of the newly 
formed myocytes were much smaller than the spared myocytes. (5) If the new myocytes 
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Figure 1.2 Clusters of primitive and early committed ce lls located in the interstitial 
space between cardiac muscle fibres. 
These cells expressed early cardiac and progenitor cell markers. (A) Clusters of 
eleven ckit+ cells (green), with three cell s express ing c-kit only (arrows), seven cells 
expressing Nkx2-5 (whi te dots ; atTowheads) in the nuclei (blue, propidium iodide) , 
and one (asterisk and insett) expressing Nkx2-5 and a-sarcomeric actin (red) in the 
cytoplasm. (B) Cluster of fifteen c-kit+ cell s with five express ing c-kit on ly 
(arrows), eight cells expressing MEF2C (yellow dots; arrowheads), and one 
expressing MEF2C and a-sarcomeric actin (asterisk and insert). Bars= I O).lm. 
Reproduced with permission from (Beltrami et al, 2003). 
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were a result of fusion, they would have double the anticipated DNA content. In this case 
they did not. 
Challenging the prem1se that the c-kit1 cells described were resident in the heart as 
claimed by Anversa et a!, work from Faze! et al suggested that the c-kit1 cells in the heart 
originate from the bone marrow (Faze] et al., 2006). They rarely found c-kit1 cells in the 
heart prior to MI, however post infarct they found that c-kit1 cells could readily be 
detected with approximately 30% expressing CD45 and over 95% expressing VEGFR2 . 
The authors state it is not clear whether this represents a preferential proliferation of 
C04s- cells or a down regulation of CD45, if these cells really were haematopoietic 
origin . In order to address whether these c-kit1 cells were from the bone marrow, they 
engineered GFP bone marrow chimeric mice to track GFP expressing bone marrow cells. 
Control C57B6 mice were shown not to have any GFP expressing cells in the bone 
mmTow. Post infarct they found that 74% of the c-kit1 cells in the heart expressed GFP 
and that none of these were cardiomyocytes. Next, to assess the impmtance of c-kit 
expressing cells, MI was induced in c-kit mutant mice kitW!kitW-v_ These mice have 
defective haematopoietic stem cell (HSC) mobilisation but otherwise are phenotypically 
normal. In these mice there was a 2-fold increase in mortality post MI. This phenotype 
was reproduced in mice treated with Gleevec which is a tyrosine kinase inhibitor and 
therefore inhibits c-kit function. c-kit dysfunction appeared to increase apoptosis and 
decrease the number of cells in the heart undergoing mitosis. Faze! et a! did not actually 
show that the multipotent and clonogenic ckit1 cells isolated from the heart by Beltrami et 
a! were from bone marrow, however they raised the possibility that those putative cardiac 
c-kit 1 stem cells isolated by Beltrami et al (Beltrami et al., 2003)may not actually be from 
I I I d d I I k . W/kit\V-v · J d · · d · · t 1e 1eart. t was emonstrate t 1at t 1e mutant 1t m1ce 1a 1mpa1re angwgcnes1s 
which could be rescued by transplantation of c-kit 111 bone marrow cells . The authors 
postulated that because angiopoietin2 levels and VEGF levels arc reduced in the kitW/kitWv 
mice, the normal pro-angiogenic mileu post infarct is not established. Together with this 
they found a reduction in endothelial cells in the cell cycle in the mutant mice, hence 
concluding that c-kit cells recruited post infarct from the bone marrow are vital in 
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establishing a pro-ang10gemc milieu which IS critical 111 the fonnation of granulation 
repair tissue post infarct. 
Oh et al reported a resident population of cardiac progenitor cells which were 
characterised by the expression of Stem cell antigen (Sea-l) (Oh et al., 2003). Sea-l was 
first reported as one of the cell surface markers of haematopoietic stem cells (Okumoto et 
al., 2003). They isolated a myocyte depleted population from adult murine hearts and 
found approximately 14-17% of the cells expressed Sea-l. They found that cardiac Sea I+ 
cells were small interstitial cells, the majority eo-expressing PECAM I. These cardiac 
Sea 11 cells lacked blood cell lineage markers (CD4, CD8, 8220, Grl, Mac-! and 
TER 119), also they were negative for c-kit, von Willebrand factor, CD45 and CD34. 
Cardiac Sea 11 cells were found not to express the cardiac transcription factor Nkx2-5, 
however GATA-4 and MEF-2C were expressed in a proportion of cells. In vitro 
differentiation studies using 5-azacytidine induced a-sarcomeric actin, cardiac troponin I, 
a and p myosin heavy chain and Nkx2-5, indicating a potential role for these Sea I+ cells 
as a myocardial progenitor. Labelled Sea-l+ cells were also injected intravenously into 
mice post infarct to assess their ability to home to infarcted tissue and contribute to 
cardiomyogenesis. A Cre/Lox Donor/Reporter system was used where Sea-l+ cells from 
an aMHC-Cre mouse were injected into R26R reporter mice. In this system 
cardiomyocytic differentiation of donor cells would be reflected by induction of aMHC, a 
late but stringent criterion of cardiac differentiation, resulting in parallel expression of 
aMHC-Cre. Fusion was determined by expression of functional LacZ in the induced cell 
and all subsequent progeny. Freshly isolated Sea-l+ cells from aMHC-Cre mice did not 
express Cre. Although it was shown that Sea-l+ cells could home to the infarct area and 
differentiate into cells expressing a-sarcomeric actin, 50% of the cells appeared to have 
fused with recipient myocytes. No functional studies were unde11aken in this study and 
clonality or se If renewal were not determined. 
MDR I cells (Multi-drug resistance gene I), otherwise known as side population (SP) 
cells in the heart were described by Quani et al (Quaini et al., 2002). They were identified 
by having the ability to efflux Hoechst 33342 dye (Goodell et al., 1996; Martin et al., 
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2004). The ability of SP cells to efflux Hoechst 33342 dye is known to be dependent on 
the expression of Abcg2, a member of the family of A TP-binding cassette (ABC) 
transporters (Kim et al., 2002). SP cells were first isolated from bone marrow (Goodell et 
al., 1996)and were shown to be enriched for long term repopulating haematopoietic stem 
cells (Pannar et al., 2003). Pfister et al demonstrated a cardiac SP which were 
immunophenotypically different from bone marrow SP cells (Pfister et al., 2005) 
(Jackson et al., 200 I). Pfister et al showed that CD31-/Sca 11 cardiac side population cells 
represented a specific cardiac progenitor cell population capable of self renewal and 
biochemical and functional cardiomyogenic differentiation into mature contracting 
cardiomyocytes. Cardiac side population cells were largely negative for CD45 and CD34, 
the majority do express Sea-l but were negative for c-kit (however the authors do state a 
caveat that the low expression of c-kit may have been due to enzymatic cleavage during 
digestion of the heart). Bone marrow SP cells stain positively for CD45 and CD34 as well 
as c-kit, Sea-l and CD31. Sea 1 1 cardiac side population cells which had been freshly 
isolated showed expression of GAT A4 and Nkx2-5 which have both been shown to play 
a crucial role in cardiomyogenesis(Biben et al., 2000; Brown et al., 2004; Srivastava and 
Olson, 2000). Contractile proteins associated with later cardiac development including a-
sarcomeric actin in and a-myosin heavy chain were not observed in freshly isolated Sea I 1 
cardiac side population cells. The CD311/Sca I+ cardiac side population cells comprised 
the majority of total cardiac side population cells , only I 0% were CD31-/Sca I+. When 
eo-cultured with adult cardiomyocytes, CD31-/Sca I+ cardiac side population cells 
showed evidence of electromechanical coupling with the adult cardiomyocytes and 
expression of the gap junction protein connexin 43. I 0% showed evidence of sarcomeric 
organisation together with spontaneous contraction and calcium transients, providing 
further support for a cardiomyocyte phenotype. In contrast CD31 1/Sca 11 cardiac side 
population cells and also bone marrow side population cells did not show these features. 
As yet clonality and self renewal of these cells has not been detennined and in vivo 
transplantation work is also awaited. 
One approach to identifying putative stem cells is to examine their ability to fom1 three-
dimensional aggregates containing both self renewing cells and differentiated progeny. 
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This approach has proved particularly useful in the study of neural stem cells, where 
'neurospheres' have been produced (Reynolds and Rietze, 2005). Using this approach in 
respect of putative cardiac stem cells, several groups have described the production of 
'cardiospheres' from mixed populations of cells called 'cardiosphere cells' (CSs) isolated 
from adult heart (Messina et al., 2004; Smith et al., 2007). Hem1 specimen biopsies were 
digested and cardiospheres were cultured. These consisted of spherical multicellular 
clusters which consisted of many proliferative cells expressing stem cell antigens, and 
other cells towards the periphery of the sphere undergoing spontaneous cardiac 
differentiation. Cardiosphere cells were found to be composed of clonally derived cells 
which had the ability to self renew. Both human and mouse cardiosphere cells were 
found to express c-kit, Sea-l and CD34 with few expressing CD31. They were negative 
for CD45. Some cells in the cardiosphere were found to express markers of cardiac 
differentiation including cardiac troponin I and myosin heavy chain. When dissociated 
into single cells and cultured on collagen coated dishes cardiosphere derived cells from 
mouse hemt assumed a cardiomyocyte morphology and began to spontaneously contract. 
In vivo injection of these cells into infarcted myocardium showed no subsequent change 
in infarct size, however it was repo11ed that bands of regenerating myocardium were 
present in those hearts which received the cardiospheres. Hence cardiospheres appear to 
be a mixture of cardiac stem and progenitor cells and although they demonstrated some 
regenerative potential in vivo, it is difficult to asce1tain exactly which cell type was 
responsible for this. The authors postulate that the cardiosphere could in effect act as a 
stem cell niche providing support for the progenitor cells. An important point shown 
however was the potential to isolate cells from small fragments of cardiac tissue which 
could then be expanded in vitro without losing their differentiation potential. 
Taken collectively this data provides an argument that there may be cell populations in 
the heart that could be putative stem cells or progenitor cells. It is not ce1tain whether 
these cells contribute to either normal cardiac homeostasis or response to injury, however 
in the model used by Hsieh et al the suggestion is that their contribution would primarily 
be the latter (Hsieh et al., 2007). In summary the hea11 does appear not to be static , but a 
very dynamic organ. Although the heart has a poor ability to regenerate in normal 
23 
circumstances post infarct, the magnitude of this specific pathological insult may exceed 
any endogenous repair capacity. Certainly there is evidence from other tissues, such as 
intestine, which are rich in endogenous tissue specific stem cells, showing a poor 
response to such a severe insult as infarction and therefore failure to regenerate after such 
an injury should not be equated with the absence of stem cells (Muny et al., 2006). This 
outcome of ischemic injury could well be because resident stem and progenitor cells 
within the infarct die, and other local stem cells may be inhibited by the acute 
inflammatory processes at the time of a myocardial infarct or may be unable to mobilise 
to the damaged area (Santini et al., 2007; Segers and Lee, 2008). Although myocardial 
infarcts do not appear to regenerate effectively spontaneously, it appears that the 
endogenous repair and regenerative mechanisms may be manipulated and exploited to 
achieve this objective. Local growth factor activation of cardiac stem cells within the 
myocardium have been shown to rescue hearts subject to ischaemic injury and help to 
reconstitute myocardium and function of the heatt as described below (Linke et al., 2005; 
Santini et al., 2007; Urbanek et al., 2005). 
1.5 Studies using proregenerative models 
From the evidence cited above it is suggestive that primitive cells with regenerative 
abilities may reside in the hemt and under favourable conditions may have the ability to 
influence repair and regeneration. However it is clear that they fail to respond under 
nom1al circumstances to prevent the extent of damage which ensues following an acute 
ischaemic insult. The reason for this is not clear. Urbanek et al aimed to explore the 
concept that if properly activated, cardiac stem cells may be able to contribute to cardiac 
regeneration in these circumstances by using insulin-like growth factor (IGF -I) and 
hepatocyte growth factor (HGF) to recruit and activate primitive cells in the hea1t 
(Urbanek et al., 2005) . IGF-1 is a cytokine which has been reported to be mitogenic, 
anti-apoptotie and necessary for neural stem cell growth (Arsenijevic et al., 200 I). It has 
also been found to promote myocyte formation and reduce death after infarction (Li et al., 
1999). HGF stimulates cell migration by expression of metalloproteinases which breaks 
down extracellular matrix and enables cell migration (Powell et al., 2001). If cardiac stem 
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cells express receptors to these growth factors then HGF and IGF-1 may have 
complementary functions in the translocation and proliferation of putative stem and 
progenitor cells in the heart. Urbanek et al defined cardiac stem cells (CSCs) in this study 
as those cells found in the heart which expressed c-kit, M DR I or Sea-l. They found that 
CSCs possess the receptor for HGF, and IGF-1. In vitro studies showed that HGF had a 
chemoattractant effect on CSCs and both HGF and IGF-1 decreased apoptosis of CSCs in 
vitro (Urbanek et al., 2005). 
CSCs were shown to be responsive to treatment with HGF and IGF-1 in vivo. After 
induction of myocardial infarction and direct intra-myocardial injection of HGF and IGF-
1 into the peri-infarct area CSCs which had been labelled with EGFP were found to 
translocate to the infarct area and differentiate into cardiomyocytes together with 
mterioles and capillaries which would help to support the newly forming myocardium. 
84% of myocytes and vessels in the regenerating area were positive for BrDU at 16 clays 
post infarct indicating they had undergone recent cell division, and treated hearts showed 
improved haemodynamics and reduced mortality (Urbanek et al., 2005). Combined with 
the in vitro studies described above, this in vivo data suggested that at least in mice, HGF 
and IGF-1 may play a role in regeneration in the heart, potentially employing CSCs. 
These observations were extended to larger mammals. Linke and colleagues tested the 
effects of HGF and IGF-1 in dogs after myocardial infarction (Linke et al., 2005). It was 
found that activation of the CSCs by intramyocardial injection of HGF and IGF-1 
resulted in fonnation of myocytes (expressing a-sarcomeric actin, cardiac myosin heavy 
chain, troponin I and a-actinin) and coronary vessels within the infarct area. Connexin 43 
was also present showing evidence for electrical coupling. The number of CSCs 
significantly increased in the area adjacent to the infarct and in remote areas, as well as 
the number of cells which were actually in the cell cycle. Treated hearts showed 
improved haemodynamic function. These studies employed direct injection of cytokines. 
In order to regulate expression of these cytokines in a tissue-specific manner, several 
studies have adopted a transgenic approach. 
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a-MHC/miGF-1 transgenic mice, which carry a cardiac restricted expression of muscle 
specific IGF-1 transgene (miGF-1) were shown to restore cardiac function in infarcted 
hearts by blocking scar formation and enabling myocardial reconstruction (Santini et al., 
2007). This transgenic mouse had a rat miGF-1 cDNA driven by the mouse a-myosin 
heavy chain promoter to restrict expression of miGF-1 to the mouse myocardium. 
Restorative capacity of miGF-1 transgenic hearts was analysed by ligation of the left 
coronary artery. In wild type mice, infarcts were characterised by progressive fonnation 
of fibrous tissue accompanied by functional impairment when measured at I month and 
worsening at 2 months. In contrast, infarcted miGF-1 transgenic hearts showed a 
moderate but significant reduction in function after I month, with no significant changes 
after 2 months compared with wild type ligated mice. The miGF-1 mice also showed a 
significantly smaller infarct size and reduced scar formation compared with control hearts 
at 2 months post surgery (figure 1.3). There may be a number of mechanisms for these 
differences, including the role of inflammation. After myocardial injury there is a 
cascade of inflammatory events including activation of complement, chemokine 
upregulation and activation of cytokine cascades (Frangogiannis et al., 2002). Twenty 
four hours after induction of injury wild type hearts showed a significant increase in the 
pro inflammatory cytokines I L-6 and ILl p, however in the miGF-1 transgenic hearts 
levels were unchanged. Also, anti-inflammatory cytokines IL-4 and I L-1 0 were found to 
be down regulated in wild type hearts after injury compared to the miGF-1 transgenic 
heatts. IL-l 0 normally suppresses injury and blocks scar fonnation (Liechty et al., 2000). 
It is known that many of the cellular growth responses attributable to IGF-1 are mediated 
by activation of the PI3K/ Akt/mTOR phosphorylation cascade, leading to prosurvival 
signalling in vivo (Matsui et al., 200 I). Akt is known to act as a protective agent in 
cardiomyocyte survival and function (Chao et al., 2003). Phosphoprotein profiling 
showed that Akt phosphorylation was not activated in miGF-1 transgenic hearts and 
phosphorylation levels of downstream mTOR (mammalian target of rapamycin) and 
p70S6K intennediates were unaffected. However in miGF-1 transgenic mice there was 
phophorylation of S6 ribosomal protein at 2, 4 and 6 months compared to wild type 
hearts. This relative activation of S6 appeared to be independent of Akt signalling which 
decreased postnatally in wild type and miGF-1 transgenic hearts. 
Trichrome 
staining 
~ ~ 
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Figure 1.3 Enhanced cardiac repair m miGF-1 transgenic mice after myocardial 
infarction. 
Wholemount histological analys is of sham operated control (WT) heart (left) and 
infarcted hearts of WT and transgenic (TG) (right) 2 months after myocardial 
infarction. An-ows indicate fibrotic tissue. LA (left atrium); LV (left ventricle); RA 
(right atrium); RV right ventric le. Histological analys is by tr ichrome sta ini ng for 
collagen is shown for each treatment. Adapted by pem1ission from (Santin i et al, 
2007) . 
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PI3K (3-Phosphoinositide dependent protein kinase- I) also signals through PDK I 
(pyruvate dehydrogenase kinase). This can directly phosphorylate p70S6K independently 
of Akt (Pullen et al., 1998) and promote survival through other intermediates such as 
SGKI (serum and glucocorticoid regulated kinase), a PI3K dependant kinase that is 
expressed in the heart and promotes survival in cardiomyocytes (Aoyama et al., 2005). 
Note that increased levels of phosphorylated PDK I were found in miGF-1 transgenic 
hearts and it was shown to complex with SGK I in miGF-1 transgenic hearts but not in 
wild type hem1s. Also, no interaction between PDK I and any of the Akt isofom1s was 
detected in miGF-1 transgenic hearts , indicating that the cardiac signalling cascade 
induced by m!GF-1 was independent of Akt and p70S6K and preferentially used the 
PDKI/SGK1 pathway to increase protein synthesis and growth. This intracellular 
signalling cascade postulated by Santini et al could be the basis for the improved healing 
capacity conferred on the transgenic hearts (figure 1.4). Following on from this a TUNEL 
assay was used to show decreased apoptosis in the area surrounding injury in the m!GF-1 
transgenic hearts in comparison to wild type. Increased levels of mitochondrial 
uncoupling protein UCP1 (uncoupling protein I) in transgenic heat1s was also found post 
cardiac injury indicating some degree of protection from ischaemic injury possibly by 
limiting damage which may be caused by oxygen free radical release (Hoet1er et al., 
2004). 
BrDU was used to assess cell turnover in the peri-infarct area in the miGF-1 transgenic 
hearts. At I month post infarct, the number of proliferating cells in the infarct border 
zone was significantly higher in miGF-1 transgenic hearts compared to wild type. 
Although they found incorporation of BrDU in cardiomyocyte nuclei there was also 
abundant staining in cells which were not muscle. The origin and fate of these cells were 
not investigated however it was thought they may contribute to the miGF-1 mediated 
recovery. There was no evidence of hypertrophy in miGF-1 transgenic or wild type 
cardiomyocytes. 
Hence it was postulated that the miGF-1 transgenic mtce were able to resolve 
inflammation more rapidly and also promoted prosurvival signals which enabled a more 
c 
Post-infarct 
(1 week) 
Figure 1.4 Mechanisms ofmJGF-1 i11duced recovery in injured hearts. 
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(A) Transgenic mlGF-1 induces protein synthesis and cell survival pathways in 
cardiac tissue through a PDK l/SGK 1 phosphorylation cascade, bypassing Akt, 
mTOR and p70S6K intem1mediates. (B) After myocardial infarction (Ml) pathways 
induced by miGF-1 result in rapid repression of pro inflammatory cytokines such as 
IL6 that promote fibrosis and cardiac decompensation while activating cytokines 
such as IL4 and IL I 0 that resolve inflammation . (C) This permissive tissue 
environment enables efficient cardiac wall replacement, as shown by increased 
proliferation of cells at I month after injury, and functional repair in mJGF-1 
transgenic hearts. Adapted with pennission from (Santin i et al, 2007). 
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substantial repair to take place in comparison to wild type controls. Although there was 
no direct evidence that reduction of inflammation facilitated stem or progenitor cell 
mediated repair, one mechanism for the poor response of the putative stem and progenitor 
cells in the heatt to engage in regeneration may have been due to the inhibitory effect of 
the intense inflammatory response at the time of infarct. Modulation of the inflammatory 
response in ischaemic injury has been shown to be a potentially useful target to reduce 
injury at the time of ischaemia and possibly promote repair. 
1.6 The inflammatory response in myocardial ischaemia and its 
modulation 
Inflammation plays a major role in the myocardial necrosis resulting from occlusion of a 
coronary artery during myocardial infarction. In order to look at strategies of how to 
reduce damage or promote repair post infarct one must examine the pathophysiology of 
this process. Ischaemia results in an intense inflammatory reaction as reviewed by 
Frangogiannis (Frangogiannis et al., 2002). This inflammat01y reaction is known to be 
augmented if the infarcted tissue is then reperfused. Initial attempts to target 
inflammation were not particularly speci fie. Corticosteroids were used in animal models 
of myocardial ischaemia to try to ameliorate the inflammation (Libby et al., 1973). This 
initial work in dogs was shown to actually decrease the infarct size. Due to these 
promising results clinical studies were undertaken using methylprednisolone in humans 
post MI (Roberts et al., 1976). Unfottunately this appeared to inhibit the number of 
infiltrating leukocytes and delayed collagen deposition which is a vital part of the 
immediate healing process, resulting in a negative outcome. Hence if the inflammatory 
response is to be targeted it would be important to attempt to ameliorate the inflammatory 
response without interfering with myocardial healing. 
Neutrophils have been shown to be instrumental in the myocardial injury sustained at the 
time of an ischaemic insult. Neutrophils become trapped in microvasculature 
exacerbating ischaemic damage due to capillary plugging (Engler et al., 1986), as well as 
mediating damage by the release of toxic products including proteolytic enzymes and 
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reactive oxygen species (Frangogiannis et al., 2002). Once ischaemic damage ensues, 
neutrophils eventually adhere to endothelium, by initially rolling along the surface and 
eventually slowing until they change shape and extravasate into extravascular tissue 
(Adams and Shaw, 1994). This is mediated by a family of adhesion molecules called the 
selectins, E-selectin, P-Selectin and L-Selectin (McEver et al., 1995). Once the 
neutrophils are rolling along the endothelium in response to the selectins, another set of 
adhesion molecules called the p2 lntegrins are necessary for adhesion and migration of 
the leukocytes. P2 integrins are heterodimeric glycoproteins constitutively expressed on 
the surface of neutrophils. Adherence of neutrophils to endothelium is mediated by 
interaction with its counter ligand ICAM-1 on endothelium (Jordan et al., 1999). Once 
neutrophils have adhered to the endothelium, the neutrophils can then migrate into the 
inflamed tissue. Chemokines at the site of inflammation are vital to facilitate neutrophil 
chemotaxis. IL-8 and C5a are both increased at sites of inflammation (lvey et al., 1995). 
Also, activated neutrophils release Leukotriene 84 (L TB4), a potent chemotactic agent 
and Platelet Actvating Factor (PAF) is produced from endothelial cells in response to 
thrombin, promoting neutrophil adhesion to endothelial cells (Montrucchio et al., 1993). 
Inhibition studies of PAF have shown a reduction in neutrophil infiltration in a rabbit 
model of infarction (Morgan et al., 1999). In addition, monoclonal antibodies against L-
selectin and P-selectin have been shown to reduce myocardial necrosis and reduce 
neutrophil accumulation in a feline model of ischaemia (Ma et al., 1993; Weyrich et al., 
1993). 
Nitric oxide (NO) has also been shown to be able to modulate the neutrophil mediated 
damage post infarct. NO is formed from vascular endothelium and can directly affect the 
endothelium and neutrophils so as to reduce the extent of injury post infarct. NO is 
known to inhibit superoxide production, degranulation and adherence to endothelium of 
neutrophils (Kubes et al., 1991; Sato et al., 1996). At the level of the endothelium nitric 
oxide attenuates up regulation of P-Selectin, E-Selectin and !CAM-I (De Caterina et al., 
1995; Ohashi et al., 1997). Hence NO has been reported to be able to provide some 
cardioprotection from neutrophil mediated ischaemic injury. 
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As well as showing the importance of the role of neutrophils in mediating myocardial 
injury these studies also suggest a therapeutic role in manipulating this neutrophil 
response m an ischaemic environment. Superoxide amons are generated from the 
neutrophil membrane associated NADPH oxidase (Jordan et al., 1999) which can be 
activated by soluble pro-inflammatory cytokines including C5a. C5a is a complement 
product which is fonned as part of the complement cascade which is activated at the time 
of myocardial ischaemia.and is a potent chemoattractant for neutrophil recruitment (Guo 
and Ward, 2005). 
1. 7 Complement activation 
The activation of the complement cascade in myocardial infarction was first 
demonstrated by Hill and Ward (Hill and Ward, 1971 ). Traditionally the complement 
system has been seen as a central part of the innate immune system in host defence 
against invading pathogens and in clearing cell debris, however complement activation is 
now known to be involved in the pathogenesis of many inflammatory disorders including 
the injury sustained in myocardial ischaemia and ischaemia reperfusion. 
The complement system refers to a senes of proteins circulating in the blood. The 
proteins circulate in an inactive fonn but once triggered they become sequentially 
activated as shown in figure 1.5. Three pathways of complement activation have been 
recognized, the classical, alternative and lectin-binding pathways. The classical pathway 
is activated by antigen-antibody complexes. The altemative pathway is directly initiated 
by surface molecules containing carbohydrates or lipids and the lectin binding pathway is 
triggered by binding of either mannose-binding lectin protein or ficolin to 
bacterial/fungal carbohydrate structures (Guo and Ward, 2005). All complement 
pathways appear to be involved in ischaemic injuty (Guo and Ward, 2005) and all 
eventually have the same functions: 
Figure 1.5 The complement pathway. 
I Alternative Pathway 
C3 (H,P) 
I C3(fi10)B I 
l 
Terminal Membrane Attack 
Complex (MAC, CSI>9) 
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Tllustration of the complement activation products C3a , C4a , C5a and the membrane 
attack complex (C5b-9). C3a, C4a and C5a are all anaphylotoxins. C5b-9 can cause 
direct cellular injury and lysis of bacteria. Figure adapted from (Guo and Ward, 2005) . 
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1. Trigger Inflammation 
2. Chemoattraction for phagocytes 
3. Opsonisation (promote attachment of antigens to phagocytes) 
4. Cause lysis of gram negative bacteria 
5. Activate B cells 
6. Remove harmful immune complexes from the body 
The activation of the complement pathway is central to the body's defence against 
infection. Unfortunately the complement system cannot distinguish self from non-self 
and therefore activation of this cascade can result in local tissue injury (Wang, 2006)., as 
occurs during myocardial ischaemia. 
All of the complement pathways converge at the complement proteins C3 and C5 (Wang, 
2006). The C3 and C5 proteins are cleaved by multisubunit convertases. C5a is a potent 
anaphylatoxin for neutrophils, monocytes and macrophages, whereas C5b goes on to 
form the C5b-9 membrane attack complex (MAC) which can cause lysis of cells and 
bacteria. C3a is much less potent than C5a. C3b is very important in opsonisation of 
immune complexes and invading organisms. C5a increases expression of CD 18 on 
neutrophils and increases P-Selectin expression on endothelium (Foreman et al., 1996; 
Foreman et al., 1994), contributing to neutrophil accumulation. 
Early studies showed that the complement components C 1 q, C3, C4 and C5 have been 
identified in infarcted tissue (Pinckard et al., 1980). Early work recognizing the 
complement cascade as a target for reducing the extent of injury after coronary artery 
occlusion used cobra venom factor (CVF) to inhibit fonnation of C3. Mm·oko and 
colleagues found that CVF given within 30 minutes of coronary occlusion resulted in a 
decreased infiltration of neutrophils and a reduction in the size of the infarct as evaluated 
by measuring Creatine Kinase (CK), (Maroko et al., 1978). Since this study there has 
been numerous other work attempting to reduce the level of inflammation and damage 
after myocardial ischaemia by attempting to inhibit parts of the complement cascade. One 
complement inhibitor which has been used in many organ systems in ischaemia and 
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reperfusion injury is recombinant sCR I, which inhibits activation of C3, a complement 
protein common to all pathways of complement activation. This therefore blocks the 
generation of C3a , C5a and the MAC. sCR I has been shown to reduce infarct size and 
reduce accumulation of neutrophils within the infarct area (Zacharowski et al., 1999). 
This cardioprotective role has been demonstrated by other investigators also in models of 
myocardial ischaemia (Shandelya et al., 1993a; Weisman et al., 1990). An inhibitor of C I 
blocks the classical pathway of complement activation and has been shown to reduce 
tissue injury in liver, brain and myocardial ischaemia reperfusion injury (Bergamaschini 
et al., 200 I; De Simoni et al., 2003; Hors tick et al., 200 I). C I inhibitor has also been used 
in human post thrombolytic therapy after myocardial ischaemia reperfusion, showing a 
significant reduction in troponin T cardiac enzyme release in the treated group(de Zwaan 
et al., 2002). 
1. 7.1 C5/C5a as a potential target for therapy 
C5 and its cleavage product C5a have been extensively studied in experimental models of 
ischaemia and ischaemia reperfusion. C5a is a potent anaphylatoxin and works in concert 
with neutrophils. C5 is the final step prior to fonnation of the tenninal MAC complex 
(which has its own ability to cause direct myocardial injury (Yakeva et al., 1998)) 
Complement inhibition can be advantageous and disadvantageous as it does have an 
impottant role in host defence, patticularly C3b in opsonisation of foreign organisms and 
debris. Hence the C5/C5a axis is a particularly attractive target for anti-inflammatory 
therapy because of its central role in neutrophil chemotaxis, its role in fom1ation of the 
terminal MAC complex and because it is downstream of C3, therefore any inhibitor 
acting at this level would avoid the inhibition of C3 cleavage and formation of the 
important opsonic fragment C3b. 
As reviewed by Gerard (Gerard et al 1994), the receptor for C5a is widely expressed on 
inflammatory cells, particularly neutrophils with I 00000 to 200000 C5a receptors per 
human neutrophil. C5a reversibly binds to C5a receptor by interaction ofthe positively 
charged N-terminal disulphide linked core of C5a and the negative charged N terminal 
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domain of its receptor and also by the positively charged C-tenninal tail of C5a with the 
interhelical region of its receptor. 
1.7.2 Targetting the C5a receptor using small molecules 
Kidney 
Renal ischaemia/reperfusion is a significant complication of vascular surgery of the aorta 
and kidney. In this study a peptide antagonist against C5aR was used in rats subject to 
renal ischaemia for 60 minutes followed by reperfusion for 60 minutes. Effects were 
measured by measuring tissue levels of myeloperoxidase (MPO) (a measure of neutrophil 
infiltration), serum creatinine levels (a measure of renal dysfunction) and renal 
histopathology. The C5aR antagonist was given 15 minutes prior to occlusion of the renal 
blood vessels IV or by oral gavage 60 minutes prior to occlusion. The antagonist was 
effective when given orally and IV. Treated animals had a reduced incidence of 
haematuria, tissue levels of MPO and reduced serum creatinine and less severe ischaemic 
changes on histopathology (Arumugam et al., 2003). 
Small Intestine 
The same small molecule antagonist has also been used in ischaemia reperfusion injury in 
the rat small intestine. Intravenous and oral dosing was used in an ischaemia (30 minutes) 
reperfusion (120 minutes) model for small intestine. Histological analysis showed 
markedly reduced mucosal layer damage in treated animals compared to untreated 
animals. Levels of haptoglobin, an acute phase response protein was significantly 
reduced in treated animals compared to control and also levels of aspartate 
aminotransferase (AST), which reflects liver parenchyma( cell integrity was reduced in 
the treated group. Histopathology confirmed the findings of reduced injury in the treated 
group by demonstrating a reduction in mucosal injllly. This demonstrated the imp01tance 
of C5a in the ensuing injury post ischaemia reperfusion in the small intestine (Arumugam 
et al., 2002) 
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Small molecule peptide C5aR antagonist has also been used in a model of hepatic 
ischaemia reperfusion. The C5aR antagonist was either given systemically 15 minutes 
prior to occlusion of the hepatic vessels or orally 60 minutes prior to occlusion. 60 
minutes of occlusion was followed by 4 or 24 hours of reperfusion. The levels of liver 
enzymes AST, AL T and LDH, and also MPO were significantly reduced in the treatment 
group in comparison to the vehicle treated group. In keeping with this the numbers of 
circulating neutrophils was significantly reduced in treated animals with evidence of 
reduced histopathological changes indicating liver necrosis and improved survival 
(Arumugam et al., 2004) 
1.7.3 Targetting C5a using antibody 
An antibody against the complement component C5a has been used in the setting of 
myocardial ischaemia reperfusion in a porcine model (Amsterdam et al., 1995). 
Ischaemia was induced by a 50 minute occlusion of the left anterior descending coronary 
a11ery (LAD) followed by 3 hours of reperfusion (Amsterdam et al., 1995). The antibody 
used was shown in vitro to block porcine C5a-induced neutrophil chemotaxis and 
degranulation. lt was administered intravenously I 0 minutes prior to occlusion of the 
LAD. The infarct proportion was calculated by calculating the percent weight of infarcted 
myocardium as a percentage of the whole heart using triphenyl tetrazolium chloride to 
identify the infarcted area. Also MPO activity and neutrophil accumulation were used as 
a measure of neutrophil infiltration. Results from this study showed that although the 
treated group had a significant reduction of myocardial infarct size, this was not 
associated with a reduction in neutrophil infiltration. The authors postulate that the fact 
that the neutrophils were not affected may be due to operation of other pathways such as 
PAF (platelet activating factor). Note that there is evidence from a study which used an 
isolated ischaemic heart preparation that neutrophils can accumulate in the myocardium 
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during reperfusion without causmg lllJury (Shandelya et al., 1993b). In this study, if 
complement was present or if C5a was provided then there was marked neutrophil 
mediated damage, indicating the importance of complement in ensuing injury. 
1.7.4 Targetting CSaR using a specific CSaR antagonist 
Kidney 
In this study a specific C5aR antagonist was used in the setting of renal ischaemia 
reperfusion in a mouse model. Ischaemia was induced for 45 minutes and then the kidney 
was allowed to reperfuse for 24 hours. Renal dysfunction (assessed by measuring serum 
creatinine) was significantly improved in the group that received the C5aR antagonist. 
Infiltration of neutrophils was significantly reduced also in the treatment group. In 
addition the experiment was repeated in neutrophil depleted mice. Neutrophil depletion 
did not protect the kidney against ischaemia reperfusion injury, with similar renal 
function being maintained in neutrophil depleted animals and control treated animals, 
thus suggesting that neutrophils were not essential for renal dysfunction in the course of 
renal ischaemia reperfusion injury. However application of the C5aR antagonist protected 
neutrophil depleted mice from renal failure, indicating that infiltration of neutrophils 
alone is not sufficient to mediate renal ischaemia reperfusion injury. The results do 
however give evidence that activation of the complement system and in particular the 
C5aR pathway is instrumental in induction of renal dysfunction in ischaemia reperfusion 
injury (de Vries et al., 2003). 
1.7.5 Targetting CS using antibody 
Anti-CS therapy in the setting of myocardial ischaemia reperfusion in rats resulted in 
decreased infarct size and reduced neutrophil infiltration. Ischaemia was induced for 30 
minutes and reperfusion for 4 hours. Neutrophil analysis was done by measuring MPO, 
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showing a significant reduction in the group treated with antibody. Creatine Kinase (CK) 
was used as a biochemical marker of myocardial injury. The group treated with antibody 
showed a reduction in CK levels indicating attenuation of myocardial damage. Treatment 
with the anti-CS antibody 60 minutes prior to occlusion of the left coronary artery 
showed a significantly reduced infarct size. In addition a group of hearts which were 
subject to 4 hours of ischaemia and no reperfusion was analysed. This demonstrated also 
a significant reduction in infarct size. Another group which were reperfused for 7 days 
showed again a reduced infarct size after I bolus injection of the antibody prior to 
reperfusion (Vakeva et al., 1998). 
1.7.6 Clinical studies targeting CS 
The first human clinical trial of an antibody specific for the C5 complement product was 
undertaken in the setting of patients who were being subject to cardiopulmonary bypass 
as pa11 of a surgical revascularization procedure (Fitch et al., 1999). Cardiopulmonary 
bypass elicits a systemic inflammatory response that can cause tissue injury and lead to 
long term clinical eo-morbidity (Wan et al., 1997). It is known that exposure of blood to 
bioincompatible surfaces of the extracorporeal circuit as well as tissue ischaemia and 
reperfusion associated with the procedure results in activation of humoral pathways of 
inflammation including complement (Hall et al., 1997). The antibody was delivered prior 
to initiation of bypass. Serum levels of C3a were no different between treatment and 
control group, however serum levels of C5b-9 were significantly reduced in the antibody 
treatment am1. CD 11 b expression on neutrophils was significantly reduced as was the 
total CK-MB , an enzyme normally used as a marker of myocardial injury, demonstrating 
that this C5 specific antibody against C5 was a safe and effective inhibitor of pathological 
complement activation in patients undergoing cardiopulmonary bypass. 
This study was followed by the COMPLY (Mahaffey et al., 2003) and COMMA 
(Granger et al., 2003) studies which examined the effect of a monoclonal antibody 
against the complement component C5. A single chain fragment of monoclonal antibody 
against C5 called Pexelizumab was used. This antibody specifically binds to C5 with high 
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affinity and prevents cleavage and generation of activated C5a and C5b-9. In this study 
complement inhibition with pexelizumab as an adjunct to fibrinolysis had no measurable 
effect on the primary end point infarct size as measured with CK-MB up to 72 hours or 
on the 90 day clinical endpoint reporting death, congestive heart failure, shock or stroke 
despite the fact that pexelizumab completely inhibited complement activity for 24 hours 
by using an infusion . In parallel to the COMPLY study, the COMMA study was carried 
out (Granger et al., 2003). Pexelizumab was used in the setting of patients with acute MI 
undergoing primary percutaneous intervention. Infarct size measured by CK-MB was not 
significantly different between the 2 groups however 90 day mortality was significantly 
reduced in the group which had received the anti CS antibody bolus and infusion, 
suggesting that pexelizumab may benefit patients through alternative mechanisms. 
Subsequently a randomized control trial companng placebo with Pexelizumab in the 
setting of CABG surgery did not show a significant risk reduction in the enclpoints of 
death or MI, but Pexelizumab was associated with a significant risk reduction 30 days 
after the procedure (Verrier et al., 2004). 
More recently a randomizecl double blind placebo controlled trial was uncle11aken using 
Pexelizumab in patients undergoing primary PCI post Ml, which did not show any 
difference in the composite endpoints of death, shock or heart failure (Annstrong et al., 
2007) 
In chapter 4 of this thesis the effect of a human C5aR mAb on inflammation and infarct 
size is tested in the setting of myocardial infarction. 
1.8 Overall conclusions and aims 
As evidenced by the literature reviewed in this chapter, an ever increasing number of 
publications have emerged relating to cells in the heart which may be able to contribute 
to cardiac repair and regeneration. Despite the fact that a number of different cells have 
been isolated from mammalian heart using different phenotypic strategies which have 
40 
shown potential in this respect, there is no consensus as to which cell may be most useful. 
There is a recent body of evidence however which has documented the involvement of 
epicardial-derived cells in the regeneration process in zebra fish, and together with the 
findings that cells expressing PDGFRA are found in the epicardial layer of the 
mammalian embtyo and in the interstitium of adult heart, these cells are an interesting 
candidate population to investigate in terms of their potential to contribute to cardiac 
repair and regeneration. 
Although putative stem cell populations have been isolated from adult heart, the 
regenerative ability of the heart has been shown to be poor under circumstances of 
ischaemic injury. One reason for this could be the harsh inflammatory environment at the 
time of an acute infarct. It has been shown that targeting this inflammat01y response, 
particularly at the C5/C5a axis, has had mixed results in improving outcomes after 
myocardial infarction. Hence an antibody against the C5aR which has not been used 
before in the setting of myocardial infarction was an attractive agent to use. 
To tackle these issues a robust model of myocardial infarction was necessary in the 
mouse particularly as an increasing variety of transgenic models are becoming available, 
which have proved invaluable in this area of research. Although rodent models of 
myocardial infarction have been used before, they have been associated with significant 
levels of death and variability in size of infarct induced (section 3.8) 
Aims of this thesis: 
I. Develop and characterise a more reproducible, consistent munne model of 
myocardial infarction with low mortality. 
2. Use this to investigate the role of a human C5aR mAb in inflammation as a route 
to possible therapy. 
3. Investigate stem cell activity in the adult heart using a transgenic approach. 
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Chapter 2 
Materials and Methods 
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2.1 Resin casts to demonstrate coronary vasculature 
Mice were anaesthetized and ventilated as described in section 2.2. The left femoral vein 
was injected with 2001U heparin (BBL HK08264). A thoracotomy was performed as 
described in section 2.2 and the great vessels to the head and neck were ligated. A total of 
5ml methyl methacrylate casting compound (Dow Coming, USA) was then injected into 
the left atrium. The heart was excised and placed on ice. The heart was then left in 30% 
potassium hydroxide overnight to digest the tissue, washed in water and air dried for 
examination under microscopy (Leica MZ6) 
2.2 Mouse model of Myocardial Infarction 
2.2.1 Anaesthesia 
I. Anaesthesia was induced usmg ketamine (I OOmg/kg) (Parnell Laboratories, 
Australia) and xylazine (20mg/kg) (Troy Laboratories, Australia) vta 
intraperitoneal injection. If further anaesthesia was necessary during the 
procedure, halothane 2% was used. 
2. Once fully anaesthetised the left anterior chest wall was shaved. 
3. The mouse was intubated using a 20G cannula (Insyte BD) (figure 2.1 ). 
4. Ventilation was set at 110 breaths per minute, with a tidal volume of 0.1-0.2 ml 
(0.008ml/g) (Harvard Minivent 079232). 
5. Oxygen flow was adjusted prior to the procedure to give an inspiratory pressure 
of approximately 15cm water. 
6. The mouse was positioned on a heating pad supine with a slight rotation to its 
right side (figure 2.2) 
7. Moisturising gel (Delvet Pty Ltd, Australia) was applied to the eyes to avoid 
dehydration. 
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Figure 2.1 Intubation technique. 
a) The larynx of the mouse was illuminated from an external light source prior to 
intubation. (b) A 0.64mm diameter guidewire was used to guide insertion of the 
20G cannula. Scale shown in cm. 
Figure 2.2 Operative set up showing mouse position and thoracotomy. 
Scale bar = I cm. 
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2.2.2 Surgery 
I. The initial transverse incision was made 0.8mm below the left axilla 
approximately 1.5 cm long 
2. Any obvious superficial vessels were coagulated at this stage. 
3. A thoracotomy incision I cm long was made in the 4'" intercostal space, and a 
mini-retractor was used to expose the heart. (figure 2.2) At this stage an 
intraperitoneal injection of atropine (0.12mg/1 Og) (Pfizer) was given to counteract 
the bradycardia induced due to anaesthesia. 
4. At all stages meticulous haemostasis was essential due to the small blood volume 
in the mice. 
5. The left coronary artery usually emerges from under the tip of the left atrium and 
courses towards the apex. The pericardium and associated fat was stripped and 
stretched over the retractor to suspend the hem1 in a 'cradle'. 
6. A 7/0 prolene suture (Ethicon 8735H) was carefully used to pass around the left 
coronary artery. The major pitfall to avoid here was intraventricular puncture 
which would be easy to do especially as the heart beats at between 400-600 beats 
per minute. 
7. This suture was then tied using a 4/0 silk buttress against the myocardial wall, to 
occlude the left coronary artery (figure 2.3). 
8. The chest was then closed in layers. 6/0 prolene (Ethicon 8711 H) was used to 
close the thoracotomy and also the skin. 
9. When the thoracotomy was closed positive airway pressure was applied to the 
lungs to displace air and fluid from the chest cavity to reduce the risk of 
pneumothorax and haemothorax. 
I 0. Antisedan (atipamezole hydrochloride) (0.05mg/20g) (Novartis Animal Health 
Pty Ltd)) was given subcutaneously (Se) to reverse effects of anaesthesia. 
11. In addition 0.075mg/kg of buprenorphine (Pfizer) was given Se for analgesia and 
0.1 mg/20g frusemide (Aventis 40N276) Se. 
12. The mouse was then observed until it had enough respiratory effort to be detached 
from the ventilator and extubated. 
(a) (b) 
Figure 2.3 Schematic illustration of transverse section tlu·ough the left ventricle 
(a) This demonstrates the relations between the left coronary artery and the 
prolene suture. 
(b) The 4/0 silk buttress suture was used to reduce the chance of the 7/0 prolene 
cutting through the myocardium. The blue arrow demonstrates the direction the 
suture is tied to compress the left coronary a11ery (LCA). 
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13. Mice were recovered in a wann cage placed on a heating pad with food and water 
ad libatum. 
14. During the procedure monitoring was via continuous observation of limb reflexes, 
colour of mucous membranes, heart rate and any evidence of spontaneous 
respiratory effort. 
15. On day I post surgery a fllliher dose of buprenorphine and frusemide was 
administered as above. 
16. Mice were observed and weighed daily and given daily injections of frusemide for 
the first 7 days. 
2.3 Haematoxylin and Eosin staining 
Sections stained had been snap frozen using Optimal Cutting Temperature Compound 
(OCT) (TissueTek 4583). Sections were initially fixed in 4% para formaldehyde (PF A) 
(Sigma P6148) for 5 minutes and then stained for I 0 minutes in Haematoxylin stain 
(Sigma MHS 16) followed by a 10 minute wash in running water. Sections were then 
immersed in Eosin solution for 2 minutes and then washed in running tap water before 
being taken through ascending alcohol solutions for 2 minutes each of 80%, 95% and 
I 00% ethanol. The sections were briefly dipped in xylene and air dryed. Sections were 
mounted with Eukitt mounting solution (Calibrated Instruments Inc. USA) and cover 
slips added prior to viewing. Nuclei structures stained blue and cytoplasm stained light to 
dark red. 
2.4 Tetrazolium method to demonstrate infarcted tissue 
Tetrazolium staining was used to demonstrate infarcted tissue (figure 2.4). Triphenyl 
tetrazolium chloride (TTC} (Merck 1.08380.0 I 00) is water soluble and colourless. It 
reacts with dehydrogenase enzymes in actively respiring tissue to fom1 the pigment 
fonnazen. Fonnazen is deposited in healthy tissue and stains it brick red. Infarcted tissue 
is not actively respiring therefore the tetrazolium salt is deposited, staining the tissue 
a) 
b) Base 
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Figure 2.4 Demonstration of tetrazolium staining of the heart post MI. 
Apex 
4 
(a) Schematic showing who le heart prior to sectioning. (b) Series shows serial 
sections of the heart 7 days post MI. It clearly demonstrates the white infa rcted area 
below the level of the black silk suture which can be seen in panel 2. Scale bar = 
5mm. 
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white (Gao et al., 2000; Michael et al., 1995). The tetrazolium staining method IS an 
adaptation of the method described by Michael et al. (Michael et al., 1995). 
I. After harvesting the heart, the atria were excised and the ventricles were wrapped 
in clear food wrap and placed in a -20°C freezer for I hour. The tissues were 
wrapped to avoid freeze diying. The tissue is easier to cut when it is semi frozen 
and it also puts the tissue into rigor. If fresh slices are put into TTC the tissue 
becomes contracted and distorted. Freeze dried tissue will be tetrazolium 
negative. 
2. Specimens were wrapped in Whatman y I filter paper and placed in a bowl. 
3. I .5% TTC made in 0.1 M phosphate buffer pH 7.4 was poured into the bowl and 
covered with aluminium foil. 
4. These bowls were then incubated for 30 minutes at 3 7°. The specimens were 
turned once at 15 minutes. 
5. Infarcted and non infarcted areas of the left ventricle were weighed separately. 
6. Infarct size was expressed as a percentage of the left ventricle taking into account 
the weight of each specimen. 
2.5 Myeloperoxidase assay 
Myeloperoxidase (MPO) is an enzyme contained in the azurophillic granules in 
neutrophils and in the lysosomes of monocytes. It is released when the cells are activated. 
Monocytes contain only one third of the MPO contained in neutrophils (Askari et al., 
2003). Activity of MPO was measured by an adaptation of the method described by 
Bradley et al and Zhao et a! (Bradley et al., I 982; Zhao et al., 1997). 
At all times except the final analysis, solutions and tissue were kept at 4°C. 
I. Heai1 tissue samples which had been stained were homogenised ( 4 x I 0 seconds) 
(Polytron Homogeniser) in 0.1 M potassium phosphate buffer pH 6 containing 
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5mM EDTA (I O%w/v). The volume of buffer used (m I) was the tissue weight in 
grams multiplied by 7. 
2. The homogenised sample was then centrifuged at 40000g for 15 minutes at 4°C 
(Beckman Optimax TLX Centrifuge). 
3. The supernatant was discarded and the pellets resuspended in the same potassium 
phosphate buffer with the addition of 0.5% hexadecyltrimethylammonium 
bromide to dissolve the myeloperoxidase. 
4. The sample was homogenised (4 xiO seconds) and then sonicated (3 x 10 
seconds) (Branson Ultrasonic Sonifier 250). 
5. The sample was centrifuged again at 40000g for 15 minutes at 4°C. 
6. The final supernatant was collected and kept at 4°C for MPO activity analysis as 
below. 
7. An aliquot of SO~tl of supernatant was mixed with 14500~tl of 50mM phosphate 
buffer pH 6 containing 0.167mg/ml of 0-dianisidine dihydrochloride and 
0.0005% hydrogen peroxide. This phosphate buffer and the aliquot were kept at 
room temperature. 
8. The change in absorbance at 460nm was measured using a spectrophotometer for 
5 minutes at l 0 second intervals. 
9. For each specimen the units of MPO were calculated in the well assuming that I 
J.lmole hydrogen peroxide results in a change in absorbance of 1.13 X 10-2 
(Bradley et al., 1982). 
I 0. The final calculation was made per I OOOg of tissue so the result for each sample 
could be compared. 
2.6 Gr-1 Immunohistochemistry 
Gr-1 antibody reacts with the epitope Gr-1 which is expressed on granulocytes 
(neutrophils and eosinophils) and monocytes. Sections were cut at 6~m1 and fixed in 
acetone for 4 minutes. They were then air dried and washed in 0.05% Tween (Sigma 
P 1379) made up with PBS (Sigma P4417). A I% bovine serum albumin (BSA) (Sigma 
A2153), I% goat serum (Sigma G9023) blocking solution made up in PBS was then 
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applied to each slide and incubated for one hour at room temperature. Primary Gr-1 
antibody (BD Pharmingen 550291) was then applied to each slide (I :200) made in the 
blocking solution. For the control sections an isotype control antibody (BD Pharmingen 
559478) was used at the same dilution. Primary antibody was applied and left overnight 
in a humidified chamber. Slides were then washed three times for 5 minutes in 0.05% 
Tween made up in PBS. Secondary antibody (lnvitrogen A 11006 goat anti-rat) was 
applied to all si ides (I : 500) and incubated for 30 minutes in the dark at room temperature. 
Slides were washed again 3 times in Tween (0.05%) and mounted with immunotluore 
mounting medium containing Hoechst (I: I 00) (Sigma D9564 ). 
2.7 Fluorescence microscopy of PdgfraGFPI+ hearts 
Hearts were embedded in OCT by snap-freezing using isopentane. 6 J.lm sections were 
cut and mounted on slides at -20C. Specimens were fixed in 4% parafonnaldehyde 
(Sigma P6148) for 2 minutes at 4°C and then washed 3 times in PBS (Sigma P4417). A 
pap pen was used to encircle each specimen and Hoescht staining was applied to each 
section for I 0 minutes. The Hoescht staining (I: I 00) was made up in I %BSA (w/v) 
(Sigma A2153) in which was 3% goat serum (w/v) (Sigma G9023) and 0.3% triton (w/v) 
(Sigma 234729). Specimens were then examined using a ZeissM I Axio fluorescent 
1111CrOSCOpe. 
2.8 Preparation of heart for Flow cytometry 
Mice were killed by cervical dislocation and the hem1 was carefully dissected out and 
washed in cold PBS (Sigma P4417). The heart was minced using a scalpel in I ml 2% 
foetal calf serum (FCS) (w/v) (Gibco I 0082170) before being transferred into a specimen 
pot with 5ml of pre-tiltered (0.2~tm) 0.1% collagenase type 2 (Gibco 1710 I 0 15) (w/v) in 
PBS (Sigma P4417). The pot was then placed in a shaking water bath at 3 7°C. At I 0 
minutes the supematant was taken and inactivated by pipelting into neat FCS at 4°C. The 
remaining heart tissue was re-suspended in 5ml fresh I% collagenase type 2 and digested 
again for I 0 minutes. The supernatant was collected as before and the process repeated 
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one more time. The supematant was tittered with a 40~tm filter then centrifuged for 10 
minutes at 300g. The supematant was then discarded and the pellet re-suspended in 2% 
FCS . This was centrifuged for I 0 minutes at 300g, the supernatant was discarded and the 
pellet re-suspended in red cell lysis buffer. After standing for I minute at room 
temperature, it was centrifuged and re-suspended in 2% FCS. The specimen was then 
washed again by centrifuging at 300g for I 0 minutes. The specimen was then subject to 
MACS@ dead cell removal as per manufacturers instructions (MACS'ID Miltenyi Biotech 
Gladbach, Gennany) which negatively selects for the viable cells. The cell suspension 
was then centrifuged and re-suspended in I 00~1 2% FCS. This was then centrifuged at 
300g for I 0 minutes and re-suspended in I OO~tl 2% FCS in preparation for addition of 
antibodies. Antibodies were now added according to the specific experiment (see table 
2.1 for antibodies used) and incubated at 4°C for 30 minutes. Specimens were then 
centrifuged and re-suspended in 2% FCS two more times to wash. 5~1 7 Amino-
Actinomycin D (7AAD) (eBioscience 006993) (which was used to gate out any 
remaining dead cells) were added to the specimens prior to analysis by flow cytometry. 
Flow cytometry enabled separation of populations according to size and surface epitopes. 
Prior to loading samples to be analysed, compensation samples were taken using 
fluorochromes being used in each experiment. lsotype control samples were used in each 
experiment to enable accurate gating. Cell sorting was used to obtain cell preparations of 
high purity which had been sorted based on the desired surface markers. Cells were 
sorted using the BD FACS Aria™ Cell Sorter (BD Biosciences) and FACS DiVA SE™ 
software (BD Biosciences). FlowJo software (TreeStar, Oregon, USA) was used for flow 
cytometry data analysis. 
2.9 Preparation of bone marrow for Flow cytometry 
Mice were killed by cervical dislocation and tibia and femur were carefully dissected out 
and washed in cold PBS (sigma P4417). The bone marrow was then flushed out using 2% 
FCS (w/v) (Gibco I 0082170) before being centrifuged at 0.3rcf for I 0 minutes and re-
suspended in I ml 2% FCS. The sample was then centrifuged again at 0.3rcf for I 0 
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Antibody and Cat. number Company I so type Cat. number Company 
Fluorochrome 
Sea PE 553108 BD PE IgG2a 553930 BD 
bisoscience bioscience 
PECAM APC 551262 BD APC IgG2a 553932 BD 
bioscience bioscience 
PECAM 25031182 ebioscience PECy7 254321 ebioscience 
APCCy7 IgG2a 
ckit APC 553356 BD APC IgG2b 55391 BD 
bioscience bioscience 
CD45 557659 BD APCCy7 552773 BD 
APCCy7 bioscience IgG2b bioscience 
CD90 PE ab24904 abeam PE IgG2c ab37368 abeam 
CD44 APC 559250 BD APC IgG2b 553991 BD 
bioscience bioscience 
Table 2.1 Antibodies used in flow cytometry (all were used at a dilution of I: I 00) 
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minutes. Supernatant was discarded and cells were resuspended in red cell lysis buffer. 
Preparation of samples were now identical to that of heart described above. 
2.10 Primary CFU-F assay 
Once cells had been isolated using flow cytometry, 5000 cells were plated into separate 
tissue culture plates in 2ml of 20% Foetal calf serum (v/v) (Valley Biomedical BS3038) 
made up with minimum essential medium (MEM) (lnvitrogen 12571 063) containing 
penicillin (I OO~tg/ml)/streptomysin (250ng/ml) and incubated in an incubator in humid 
air at 37°C with 5% C02. Media was changed the next day then every 3 days. At media 
change the plates were initially washed twice using sterile PBS (Sigma Australia P4417) 
before replenishing media. At day 12 the plates were stained with crystal violet (section 
2.12) so that colonies could be counted. For the serial dilution assay, cells were plated 
into separate plates in an incremental dilution. 
2.11 Secondary and tertiary CFU-F assay 
Primary micro colonies, small colonies and large colonies were isolated using an 0-ring 
at day 12 in culture and cells were re-plated after trypsinisation into individual plates (I 
cell/well) with 20% foetal calf serum (v/v) made up with MEM as above (section 2.1 0), 
to assess the ability to form secondary and tertiary colonies. Counts were done at 12 days 
after plating. Continual passaging was also done by taking a secondary colony from a 
primary colony of each size and plating these cells into a 75cm flask. Before con fluency 
was achieved the cells were trypsinised and 20000 cells were re-plated into another flask. 
This process was repeated for as long as the cells continued to passage. 
2.12 Crystal Violet staining 
Old media was discarded and plates were washed twice with PBS (Sigma P4417), then 
once with 50% ethanol (v/v) and left in ethanol for 15 minutes. The ethanol was then 
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aspirated and plates were left to air dry. Crystal violet (0.5% in 50% ethanol (v/w)) 
(Sigma Australia C6158) was then added and left to stain for 30 minutes. Dishes were 
washed with disti lied water and colonies counted. Colonies were scored as being a micro 
colony, small colony or a large colony. Micro colonies contained 5-25 cells, small and 
large colonies were made up of >25 cells with small colonies being <2mm diameter and 
large colonies being>2mm diameter. A Zeiss Axiovett 25 microscope was used to view 
the cells. 
2.13 Differentiation assays 
Cells were initially allowed to attach to the tissue culture plates and start to form 
colonies, and after 5 days were then subject to specific tissue culture conditions detailed 
below. The control groups continued to have the usual M EM media described above. 
2.13.1 Cardiomyocyte differentiation 
At day 5 post plating, after aspiration of media and washing, the media used was changed 
to I 0% FCS (v/v) (Valley Biomedical BS3038) made up with Dulbecco's Minimum 
Essential Medium high glucose (lnvitrogen Australia 10938025) containing penicillin 
(I OO~tg/ml) /streptomycin (250ng/ml). Added to this was I O~mol/1 5-azacytidine (Sigma 
A2385), I O~tg/1 fibroblast growth factor (RND Systems 3139FB025), 0.25mg/l 
amphotericin (Sigma A9528). After 24 hours the media was changed to one without 
amphotericin and thereafter every 4 days (Makino et al., 1999). At 14 days the cells were 
stained for a-sarcomeric actinin. 
2.13.2 Smooth muscle differentiation 
At day 5 post plating, after aspiration of media and washing, the media was changed to 
2% FCS (v/v) (Valley Biomedical BS3038) made up with Dulbecco's Minimal Essential 
Medium high glucose (DMEM HG) (lnvitrogen I 0938025) containing penicillin 
(I OO~g/ml)/streptomycin (250ng/ml). Added to this was 50ng/ml Platelet derived growth 
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factor BB (PDGF-BB) (lnvitrogen PMG0044) (Yamashita et al., 2000; Yoon et al., 
2005). Media was changed every 4 days. At 14 days cells were stained for smooth muscle 
myosin heavy chain. 
2.13.3 Endothelial differentiation 
At day 5 post plating, after aspiration of media and washing, the media was changed to 
I% FCS (v/v) (Valley Biomedical BS3038) made up with Iscove's modified Dulbecco's 
Medium (lnvitrogen 12440046) containing penicillin (I OO~tg/ml)/streptomycin 
(250ng/ml). Added to this was I Ong/ml vascular endothelial growth factor (VEGF) 
(Yoon et al., 2005). Media was changed every 4 days. At 14 days cells were stained for 
PECAM I (CD31 ). 
2.13.4 Adipogenic differentiation 
At day 5 post plating, after aspiration of media and washing, the media was changed to 
adipogenic differentiation media which consisted of I 0% FCS (v/v) (Valley Biomedical 
BS3038) made up with Dulbecco's Minimal Essential Medium high glucose (DMEM 
HG) (lnvitrogen I 0938025) containing penicillin (I OO~g/ml)/streptomysin (250ng/ml) 
and 0.5~tM isobutylmethylxantine (Sigma), I ~M dexamethasone (sigma 04902), I 0 ~M 
insulin (sigma 10516), 200~tM indomethacin (Sigma 17378) (Romanov et al., 2003). 
Media was changed every 4 days and cells were examined at 14 days, staining with oil 
red 0 for adipocytes (Romanov et al., 2003). Oil red 0 stock was made with 0. 7g oil red 
0 (sigma 00625) and 200ml isopropanolol. I 0% formalin (v/v) was added to the cells for 
5 minutes, then plates were washed with 60% isopropanolol (v/v). A 60% oil red 0 
solution (v/v) was made up from the oil red stock, using distilled water and this was used 
to stain the cells for I 0 minutes. The plates were then washed with distilled water. Lipid 
droplets were visible inside cells stained red with the oil red 0 solution. 
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2.13.5 Osteogenic differentiation 
At day 5 post plating, after aspiration of media and washing, the media was changed to 
osteogenic differentiation media which consisted of 10% FCS (v/v) (Valley Biomedical 
BS3038) made up with Dulbecco's Minimum Essential Medium low glucose (lnvitrogen 
11885) containing penicillin (I OO~tg/ml)/streptomysin (250ng/ml) and O.lj..tM 
dexamethasone (Sigma 04902), 50~tM PGiycerol (Sigma 50020), 50~tM ascorbic acid 
(Biochemika 49752) (Romanov et al., 2003). Media was changed every 4 days and cells 
were examined at 14 days for staining with alizarin red which complexes with calcium 
(Aikawa et al., 2007; Lee et al., 2003). 2g of alizarin red (Sigma A5533) was added to 
I OOml distilled water. The pH was adjusted to 4.1-4.3 using OS% ammonium hydroxide. 
The culture plates were incubated in this solution for I 0 minutes and then washed with 
distilled water. Any calcium deposits complex with the alizarin red, visible as an 
orange/red stain. 
2.14 lmmunostaining 
Media was aspirated from tissue culture plates and washed 3 times in PBS (Sigma P4417) 
with I% Bovine albumin (BSA)(w/v) (Sigma A2153) washing solution. The cells were 
then fixed with 2% PFA (w/v) (Sigma P6148) with 0.1% Tween-20 (v/v) (Sigma P 1379) 
for I 0 minutes at room temperature. The plates were washed again 3 times in the washing 
solution. Blocking solution PBS with I% BSA (w/v)(Sigma A2153), 3% goat serum 
(Sigma G9023) (w/v), 0.1% tween-20 was added for I hour. Cells were then stained with 
the primary antibody made up to the required concentration (table 2.2) in PBS, I %BSA 
(w/v), 0.1% Tween-20 (v/v) ovemight at 4°C. Next the plates were washed with the 
washing solution 3 times and stained with the appropriate secondmy antibody made up to 
the required concentration (table 2.2) in PBS, I %BSA(w/v) 0.1% Tween-20 (v/v) for 30 
minutes at room temperature. 1-loechst (invitrogen H3569) was used to stain nuclei 
(IOmg/ml) 1% (v/v) made up in blocking solution . Cells were mounted with 
immunofluore mounting medium (ICN, Aurora USA). 
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Primary antibody Secondary antibody 
Manufacturer/ Cat number/ Manufacturer/ Catalogue/ 
Host (dilution) Host (dilution) 
Alpha sarcomeric actinin Sigma/ A 7811/ mouse Goat anti-mouse 555 
(I :500) lnvitrogen A21424 
(I :300) 
Smooth muscle myosin Santa Cruz/ SC6956/ mouse Goat anti-mouse 555 
heavy chain (I :300) Initrogen A21424 
(I :300) 
PECAMI BD/ 550274/ rat (I :50) Goat anti-rat 555 
lnvitrogen A21434 (1:300) 
Table 2.2 Antibodies used in differentiation assays and the dilutions 
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2.15 Analysis 
Analysis of results from flow cytometry used FlowJo software (TreeStar, Oregon, USA). 
Comparison of means was analysed using t-test, and standard error was used as the 
measure of spread unless indicated otherwise. GraphPad Prism version 4 was used for 
statistical analysis. 
2.16 Buffers 
Potassium Phospate Buffer 0.1 M 
mill 
I M Dipotassium hydrogen orthophosphate 132 
174.18g/l 
I M Potassium Dihydrogen Orthophosphate 868 
136.09g/l 
Phosphate Buffer 0.1 M 
mill 
O.IM Disodium hydrogen orthophosphate 774 
14.2g/l 
0.1 M Sodium dihydrogen orthophosphate 226 
12.0g/l 
EthyleneDiamine Tetra Acetic Acid (EDTA) 0.5M 
g/1 
EDTA 186.12 
I OM Sodium Hydroxide 60ml 
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Make up to volume with MilliQ water. Add Sodium Hydroxide and heat. The EDTA 
dissolves at pH 8.0. 
Chapter 3 
Establishing a mouse model of 
Myocardial Infarction 
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3.1 Introduction 
Animal models of myocardial infarction (MI) have proved to be very valuable in 
determining the complex pathophysiology of ischaemic hemt disease (Hasenfuss, 1998). 
Experimental models of MI in rats have been used for a long time to provide infonnation 
conceming structural, biochemical and haemodynamic changes aller coronary artery 
occlusion and the effect of therapies. Surgical coronary ligation is a useful experimental 
technique to induce reproducible myocardial infarction. It has been shown that the vessel 
ligated and the coronary anatomy of the given animal model determines the extent of the 
resulting Ml and its functional impact (Liu et al., 1997). Coronary artery ligation in 
Lewis in-bred rats has been shown to produce large infarcts, with progressive left 
ventricular (LV) dysfunction (Liu et al., 1997). Despite the technical advantages of 
operating on larger animals and the potential for chronic instrumentation, the mouse has 
started to emerge as an important animal to base disease models in especially due to the 
wide variety of transgcnic models available, short gestation times, breeding capabilities 
and case of housing due to their size, and especially with the accelerated interest in 
regenerative medicine over the last ten years it has become apparent that this model is an 
essential tool to facilitate investigation into this field (Bcltrami et al., 2003). As 
documented in Chapters 4 and 5 the intention in this thesis was to investigate the role of a 
monoclonal antibody against C5a receptor and examine its effects on Ml, and also to 
explore putative stem cell and progenitor populations in nom1al hearts and hearts post 
infarct, therefore it was essential to set up a model of Ml in the mouse, which was 
consistent, reproducible and did not result in excessive mortality. 
3.2 Pathophysiology of acute Ml 
Ischaemic heart disease is characterised by coronary atherosclerosis. An atherosclerotic 
plaque is composed mainly of fibrous tissue and lipid laden foam cells. Acute Ml is 
associated with plaque rupture. This results in platelet aggregation and activation, 
thrombin generation and thrombus formation. The resulting thrombus interrupts the 
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myocardial blood supply. If this persists there is an imbalance between supply and 
demand of oxygen which results in myocardial necrosis (Braunwald, 200 I). 
Acute Ml can be divided into transmural infarcts (myocardial necrosis involves the full 
thickness of the ventricular wall) and subendocardial (where the necrosis just involves the 
subendocardium, the intramural myocardium or both without extending all the way 
through to the epicardium). 
Gross pathological changes can be seen 6-12 hours after the onset of necrosis in humans. 
Initially the myocardium in the affected area looks pale. Approximately 18 to 36 hours 
after the onset of the infarct the myocardium looks reddish purple due to trapped 
erythrocytes. During the first few days the myocardial wall in the region of the infarct 
thins as necrotic tissue is removed by inflammatory cells. Eventually in humans fibrous 
tissue is layed down over the course of the next 8 to 12 weeks. 
If reperfusion is not instituted irreversible changes can be seen in some cells between 20 
minutes and 2 hours after the onset of ischaemia. Under electron microscopy, cells 
irreversibly damaged by ischaemia are usually swollen with an enlarged sarcoplasmic 
space. The sarcolemma can peel off the cells and the mitochondria become fragmented. 
On light microscopy, a pattem of wavy myocardial fibres can sometimes be seen I to 3 
hours after onset of myocardial infarction. By 8 hours there is interstitial oedema and 
infiltration of neutrophils. Muscle cell nuclei undergo karyolysis and small blood vessels 
undergo necrosis. Neutrophils continue to accumulate and by day 4 post infarct there is 
an infiltration of macrophages which remove necrotic debris. Over the next few weeks 
there is continued accumulation of fibroblasts and the infarcted area becomes converted 
into a firm connective tissue scar with some interspersed intact muscle fibres (Fishbein et 
al., 1978). 
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3.3 Ventricular remodelling 
Initially after myocardial infarction there is an acute reduction in the ejection fraction in 
propmtion to the size of the myocardial infarct. To compensate, there is an acute 
distension of the viable myocardium and operation of the Frank-Starling mechanism, as 
well as augmentation of chronotropic and inotropic activity through adrenergic receptor 
stimulation. All of these changes help to maintain pump function despite the loss of 
contractile tissue (Pfeffer and Braunwald, 1990). 
After the acute phase described above, there are architectural changes in the wall of the 
myocardium which were initially described as 'infarct expansion' (Hutchins and Bulkley, 
1978). This is defined as 'dilatation and thinning of the area of infarction not explained 
by additional myocardial necrosis'. Histology shows that this thinning of the infarcted 
region is due to slippage between muscle bundles. As previously explained, during the 
course of healing there is an accumulation of fibroblasts. The laying down of connective 
tissue scar connects the disrupted myocyte fibres and provides resistance to further 
stretching (Pfeffer and Braunwald, 1990). Infarct expansion is observed most frequently 
after large transmural infarcts and results in an increased likelihood of left ventricular 
aneurysm formation, congestive heart failure and myocardial rupture. 
3.4 Differences in mouse and human coronary anatomy 
The mouse and human both have a right and left coronary mtery, however the mouse left 
coronary artery does not divide proximally into the left anterior descending coronary 
artery (LAD) and circumflex. [t courses obliquely across the left ventricular free wall and 
branches in a variable fashion. The septal mtety arises either from a separate ostia from 
the right sinus of valsalva or as a proximal branch of the right coronary artery (Kumar et 
al., 2005). The mouse coronary arteries are intramyocardial as opposed to epicardial 
(figure 3.1 ), therefore are more difficult to visualise than in the human and the right 
coronary artery is invariably small and non-dominant (Gan et al., 2004). 
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(a) (b) 
Figure 3.1 Mouse coronary anatomy 
(a) This shows the intramyocardial course of the left coronary artery (arrows) and 
demonstrates how difficult it is to visualise, particularly when the heart is beating at 
400-600bpm. (b) Post Iigation there is blanching of the area distal to the ligation 
(arrow). Left atrium (LA). Left ventricle (LV). Scale bar = 5mm. 
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Immediate mortality in the left coronary ligation procedure has been quoted as high as 
50% in the rat (Muders and Elsner, 2000}, the main difficulties being the small size of 
rodents and the technical difficulties associated with this and other physiologic 
parameters. Some physiologic differences between mice and humans are outlined in table 
3.1 (Barbee et al., 1992). In mice the procedure is inherently difficult, not only due to the 
small size of the heart and thoracic cavity, but also because physiologic parameters such 
as its very small blood volume and heart rate of 600 beats per minute, combined with a 
ventricular wall thickness of less than I mm, and intramyocardial coronary arteries 
provide no margin for error in this technically demanding procedure. 
Although myocardial infarction in mice has been used as a platform in the investigation 
of cardiac biology (Hsieh et al., 2007; Wang et al., 2006), no complete protocol is 
documented for this procedure, therefore it was established from basic principles as 
detailed in the Methods section. The first step in this process was to determine the 
vascular structure of the coronary tree. 
3.5 Visualisation of the coronary tree 
Due to the fact that the coronary arteries in the mouse are intramyocardial and therefore 
difficult to visualise, 5 mice were initially used to make acrylic resin casts to assess the 
coronary tree and its variability in the C57B6 mouse strain. An example of one of the 
casts is shown in figure 3.2. This illustrates how the mouse coronary arterial tree does 
not have a well developed collateral circulation. Due to this, the infarct produced after 
ligation of the left coronary artery in the mouse typically provided a sharply delineated 
and reproducible area of ischaemic damage (figure 3.3). Unfortunately for the same 
reason, as discussed below, if the left coronaty at1ery is ligated close to its origin the 
infarct produced is extensive due to the fact there is no collateral protection, commonly 
resulting in early mortality. 
67 
Human (70kg) Mouse (20g) 
Heart rate (bpm) 80 600 
Blood volume (ml) 5000 1.6 
Cardiac Output (1/min) 5 0.016 
Tidal volume (ml) 500 0.15 
Respiratory rate 12 110 
(breaths/m in) 
Table 3.1 Comparison of haemodynamic variables in mice and humans 
In pat1icular note the small blood volume and tidal volume in the mouse 
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RCA 
Figure 3.2 Acry lic resin cast of mouse coronary arterial tree. 
Anterior vtew of the heart demonstrates the right (RCA) and left (LCA) 
coronary arteries. The right coronary artery was always less dominant than the 
left. The left coronary artery traversed over the left ventricle with multiple 
small branches and bifurcated towards the apex of the hemt. 
Figure 3.3 . Whole heart at 5 days post infarct stained with triphenyl tetrazolium 
chlotide. 
Healthy tissue is stained red and infarcted tissue is stained white. This is typical 
of the sharply de lineated and reproducible area of ischaemic damage resulting 
from thi s technique. The atria have been removed. Scale bar = 5mm. 
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3.6 Initial mortality and other complications 
Initially the procedure was set up as detailed in the Methods section. Although this 
procedure resulted in myocardial infarction, it was associated with complications of 
mot1ality due to technical errors, left ventricular rupture and heat1 failure. Figures 3.4 and 
3.5 demonstrate the appearance post M! of the infarcted area of the myocardium at 
different time points. Early technical errors were part of the leaming curve and involved 
misplacement of the suture either too superficial causing damage to the left coronary 
artery , or too deep so it pierced the left ventricle. Both of these resulted in excessive 
blood loss and death. The other common technical enor in the early stages was 
misplacement of the endotracheal tube resulting in inadequate ventilation. Once these 
technical errors were overcome with practice, the mortality for the procedure was 46% at 
day 7 post infarct (figure 3.6). Sham operated controls were used as a comparison. In the 
control mice a needle was passed through the myocardium without ligating the left 
coronary artery. No difference was found between female and male mice. Sub analysis of 
the mortality data showed the trend in figure 3.7. There was an initial peak at day I and 2 
followed by another peak between day 3 and 5 post infarct. Post mortems on those mice 
which died at day I and day 2 post infarct showed evidence of acute heart failure. Prior to 
death these mice showed respiratory distress and on careful examination were found to 
have an increased lung weight/body weight ratio as evidence of pulmonary congestion 
(tigure 3.8). There was no difference in heart weight/body weight ratios between sham 
and those with infarct which reached the 7 day endpoint. The mice which died at day 3 to 
day 5 post surgery were invariably found to have left ventricular rupture, a known 
complication of M! (figure 3.9). Left ventricular rupture is known to be a consequence of 
large transmural myocardial infarction and is associated with left ventricular aneurysm 
formation (Pfeffer and Braunwald, 1990). 
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(a) 
(b) 
100 microns 
Figure 3.4 Histo logical demonstration of appearance of infarct area with time. 
(a) H and E stained transverse section through the infarct area at 24 hours post 
infarct demonstrating loss of normal myocyte architecture in the infarct region 
(arrow) and replacement by inflammatory cells. (b) H and E stained transverse 
section through the infarct area 6 weeks post infarct demonstrating loss of 
normal myocyte architecture and replacement by fibrotic scar (anow). 
Figure 3.5 Transverse section through the ventricle below the level of the 
atrioventricular valves at 5 days post infarct. 
This demonstrates the pale thi11 infarcted LV wall (arrow) associated with 
dilatation of the left ventricu lar cavity. Scale bar = 5mm. 
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Figure 3.6 Mortality with in the first 7 days after surgical ligation of the left 
coronary artery 
Mm1ality was 45% at this stage of development of the model of MI. Th is is 
similar to that quoted for rat models of myocardial infarction. There was no 
mortality in the sham operated group. N = 50 in each group. 
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Figure 3. 7 Sub analysis of morta lity data over time 
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This showed 2 peaks of morta lity, one within the first two days post MI and another 
significant increase at day four post M I. N= 50 . 
Cl 
0 
0 
..... 
-Cl 
E 
-
- Ml (inadvertant death) 
- MI 
- Sham 
Figure 3.8 Comparison of lung weight/body weight (mg/ lOOg) 
Lung weight/body weight ratios of those mice wh ich had an inadvertant death 
within the first 2 days of surgery are shown compared with mice which had MI 
and no inadvertant death within the first 2 days, and also sham operated mice at 
equ ivalent time points. *signifies p<0.05. 
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(a) 
(b) 
Figure 3.9 Diagnosis of left ventricu lar rupture 
This was identified at post mortem by identification of haemopericardium and 
haemothorax (the pleura was often opened at the time of surgery). Figure 3.9(a) 
shows the heart within the thoracic cavity post rupture. Figure 3.9(b) 
demonstrates localisation of the point of rupture (aiTow). Left ventric le (LV). 
Sca le bar= 2mm. 
76 
77 
3.7 Optimisation of the model 
3. 7.1 Reduction of early mortality 
There were a very small proportion of mice which died at day 0. Some of these were 
initially due to bleeding or misplacement of the endotracheal tube. However it was 
noticed that there were some deaths without either of these 2 occurrences. On 
examination of these mice which had died on the day of surgery, post mortem revealed 
very small petechial haemorrhages in the lungs and occasionally tears at the bifurcation 
of the bronchi were found. This was thought to be due to barotrauma as a result of over 
ventilation . At the time the only ventilator available was one normally used for rats 
which could deliver a minimum of 0.8ml tidal volume. For this reason another ventilator 
with the ability to deliver small tidal volumes of O.l-0.3ml was acquired (Harvard 
Minivent 079232). Mot1ality associated with these petechial haemon·hages was not seen 
once the ventilatory strategy was changed. 
In order to address the deaths due to pulmonary congestion noted above, frusemide 
(0.1 mg/20g) was given on a daily basis from the day of surgery. Two groups of 50 mice 
were each subject to surgery. One group received frusemide (0.1 mg/20g intraperitoneal) 
daily, the other group received instead a daily intraperitoneal injection of the equivalent 
volume of saline. For each group there was an equivalent sham group which either 
received a daily injection of intraperitoneal frusemide or saline. This resulted in an 
overall reduction in 7 day mortality from 40% in the group which had an infarct and 
saline to 32% in the group which had an infarct and frusemide. This was not significant 
using the chi squared test. There were no deaths in sham operated animals in the 
frusemide or saline group. The actual numbers of deaths each day is shown in figure 
3.10. Note that the proportion of early deaths (within 2 days) was reduced when 
frusemide was used (p<0.05). Late deaths at day 4 post infarct were similar and all of 
these were found to have rupture of the left ventricle. 
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Figure 3.10 Effect of intraperitoneal frusemide inj ection on early mortality post MI 
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(a) Daily intraperitoneal frusemide inj ection resulted in a decrease in overall mortality 
from 40% to 32% (p = 0.05)) (Ch i squared test) . Primarily early death (D0-02) was 
reduced as illustrated (p<0.05), which has been previously attributed to acute 
pulmonary congest ion post MI. (b) Control group received an equivalent volu me of 
sal ine. N=50 in each group. 
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3.7.2 Reduction of late mortality 
Although use of frusemide and change of ventilation strategy reduced early inadvertent 
death, overall mot1ality was still found to be 32%, with most of the deaths resulting from 
LV rupture. In the experiments described above, the mean infarct size was 45% (± 1.44). 
As infarct size is related to risk of ruptue (Pfeffer and Braunwald, 1990), it was important 
to attempt to decrease infarct size so as to further improve survival in this model of M!. 
Originally the left coronary at1ery was ligated just proximal to where it emerges from the 
tip of the left atrium. lt was thought this may be resulting in the large infarct, which led 
to high mortality from LV rupture. Therefore the strategy was changed and 2 groups of 
50 mice were again subject to surgery, one group having ligation of the left coronary 
artery as above, and the second group subject to ligation 2mm distal to the point at which 
the left coronary artery emerges from under the tip of the left atrium as shown in figure 
3.1 (b) . Sham operated controls consisted of mice which were subject to thoracotomy 
without ligation of the left coronary artery. The results in infarct size produced can be 
seen in figure 3.11. Re-positioning of the ligation point of the left coronary artery resulted 
in a significant decrease in infarct size from 42% ± 1.98 to 31% ± 1.70 (p<0.05). The 
impact of this on overall mot1ality is demonstrated in figure 3.12. Seven day mortality 
was reduced in this experiment from 34% in the group which had proximal ligation of the 
left coronary artery to 18% with the new more distal level of ligation of the left coronary 
artery ((p<0.05) using chi squared test). There was a concomitant drop in LV rupture 
from 24% to 14% ((p<0.05) using chi squared test). Note that all groups received 
frusemide daily in this experiment. There were no deaths or evidence of infarct in the 
sham group. 
Although the risk of death from pulmonary congestion and LV rupture was now 
decreased within the first seven days, there was still evidence of the usual post infarct 
pathophysiology of thinning of the myocardial wall and LV aneurysm formation as 
shown in figure 3.13, however as the infarct size was smaller this evidently resulted in 
decreased risk of large aneurysm formation which could lead to death from LV rupture. 
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Figure 3.11 Change in infarct size with level of li gation. 
Infarct size with the new more distal ligation of the left coronary attery resulted 
in a significant reduction in infarct size from 42% (.± 1.98) to 31% (± 1.70) 
p<0.05. N=50 in each Ml group. N=20 in sham group. * signifies p<0.05. 
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Figure 3.12 Reduction of mottality by changing level of ligation of the left 
coronary aiieiy 
(a) A more distal ligation strategy of the left coronary artery resulted in smaller 
infarct size (p<0.05) and also impacted on the overall mortality as shown 
compared to a proximal li gation strategy (b). Overall mortality decreased from 
24% to 14% ((p<0.05) using chi squared test) . All groups received frusemide dai ly 
(0 .1 mg/20g) . There was no m01tality in the sham operated group. N=50 in each Ml 
group. 
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Figure 3.13 Apical LV anelllysm in the heart. 
This smal l aneurysm at seven days post infarct is delineated by the blue line at 
the inferior aspect of the heati. Scale bar = 2mm. 
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3.8 Discussion 
Models of myocardial infarction have been used for some time to provide infom1ation on 
pathophysiologic and haemodynamic changes post infarct (Hasenfuss, 1998). Much of 
the small animal work in this field has been based on rats. Rep011s of surgical induction 
of MI in rats have shown mortality rates of up to 50% in the initial 24 hours post 
procedure and infarct size varying between 4-59% of the left ventricle(Gu et al., 1998; 
Pfeffer et al., 1979). However, with the expansion of interest in regenerative medicine it 
is apparent that a mouse model of infarct is essential in this field of study, pattly because 
of their ease of housing and breeding capabilities but more importantly due to the fact 
there is an increasing variety of transgenic models becoming available together with 
technology allowing conditional expression of transgenes (Hsieh et al., 2007), which 
would help to facilitate the understanding of the endogenous biology surrounding events 
post infarction (Santini et al., 2007; Zhou et al., 2008), and also the isolation of putative 
stem and progenitor cells and tracing their derivatives. Additionally, unlike larger rodents 
and other animals, murine electrophysiology dictates that they have a lesser likelihood to 
develop fatal ventricular arrythmias, hence improving their chance of survival after 
ischaemic events (lames et al., 1998). This thesis aims to explore events surrounding 
myocardial infarction, including inflammation (Chapter 4) and also aims to explore a 
putative stem and progenitor cell population (Chapter 5), hence a robust and efficient 
murine model was vital to set up. Although mouse models of MI are being used, it is 
apparent that they are technically very difficult to establish (Kajstura et al., 2005; Li et 
al., 1997a; Santini et al., 2007) and there are limited guidelines or protocols to safely, and 
efficiently achieve this goal with consistent results. Although cryoinjury has been used as 
a means of inducing myocardial injury (Leferovich et al., 200 I) and is technically much 
simpler, it may not mechanistically be comparable to clinical occlusion of the coronary 
artery as occurs in human disease and hence physiologic mechanisms which follow may 
not be an accurate representation of what may occur after ligation of the coronary artery. 
This discrepancy was noted by Abdullah and colleagues (Abdullah et al., 2005) who used 
a coronary occlusion model in the MRL mouse strain, and Lefevorich et al (Leferovich et 
al., 200 I )who used ctyoinjury in the same mouse strain. The MRL mouse strain has been 
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reported to be able to have a unique capacity for wound healing after ear punch injury 
(Ciark et al., 1998), reminiscent of that shown in amphibian regeneration, however in 
rcpect to the heart, this regenerative ability was shown to be the case only after 
c1yoinjury. After coronary occlusion, this regenerative response was not found (Abdullah 
et al., 2005). 
Guidelines to establish a model of murine myocardial infarction were pursued in this 
chapter to achieve a model which resulted in a reproducible, consistent infarct with a 
relatively low mortality. This study has demonstrated some important differences 
between the human and mouse coronary tree in a similar way to work by Kumar et al 
(Kumar et al., 2005), particularly the limited collateral circulation and reliance primarily 
on the dominant left coronmy m1ery, which helps to explain the consistency of infarct 
achievable, but also the concomitant high mortality in this procedure, reported to be as 
high as 40-50% (Kumar et al., 2005; Muders and Elsner, 2000). Mortality associated with 
coronary ligation in mice have been reported at 50-60% at 24 hours (Li et al., 1997a; Li 
et al., 1997b) and 57-70% at 7 days post infarct (Li et al., 1997b). Ruptue of the LV has 
not been described in the literature in other species, however analysis of post infarct 
rupture by Gao and colleagues found the incidence to be 27%, which is similar to the 
24% found in the present study prior to changing the point of ligation (Gao et al., 2005). 
Gao and colleagues showed a 24 hour mortality of 8% with a range in infarct size of I 0-
62% in comparison to the consistent infarct size generated in the present study of 31% ± 
1.70. 
In summary a step wise approach to limiting the degree of physiologic insult has been 
developed in this study so as to reduce 7 day mortality to 18% by limiting pulmonary 
congestion, lung barotrauma, making the procedure as simple as possible to reduce 
anaesthesia time and limitation of death from ventricular rupture. A robust model was 
now available to continue the study of inflammation and stem cells in cardiac ischaemic 
111JLIIY. 
85 
Chapter 4 
Use of a C5a receptor antibody in Acute 
Myocardial Infarction 
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4.1 Introduction 
As previously described in Chapter I, the CS/CSa ax1s IS a key mediator of the 
inflammatory process involved in myocardial ischaemia and is an important candidate for 
anti-inflammatory based therapy. Many different approaches have been used to target the 
inflammatory pathway but due to its pivotal role in ischaemic injury the CS/CSa axis has 
been a popular target using small molecules and speci fie antibodies. 
The complement system is central to defence against harmful stimuli, however because it 
cannot discriminate between self and non-self, inappropriate complement activation can 
cause tissue inflammation in many circumstances such as rheumatoid arthritis, sepsis, 
inflammatory bowel disease and ischaemia .. The complement cascade, activated via 
classical, alternative and lectin pathways converge at complement proteins C3 and CS 
(Wang, 2006). This is illustrated in the schematic figure 4.1. 
C3 and CS are cleaved by multi-subunit convertases. Once CS is cleaved, this generates 
CSa, a potent anaphylatoxin and chemotactic mediator for neutrophils, monocytes and 
macrophages, and CSb which initiates assembly of the CSb-9 membrane attack complex 
which can cause direct cellular injury. C3 is cleaved to C3a and C3b. C3a has similar 
properties to CSa but is less potent, C3b is critical for innate defence against infection and 
immune complexes due to its role in opsonisation prior to phagocytosis (Wang, 2006). 
There is in addition another pathway through the coagulation system (specifically 
thrombin) which acts on CS but not C3 (Huber-Lang et al., 2006). 
Recent work from Rosenthal et al has postulated that in a transgenic mouse line where 
miGF-1 is over expressed in the heart, the early resolution of inflammation at the site of 
injury may allow processes to occur which facilitate tissue repair (Santini et al., 2007), 
making the inflammatory response and its resolution a very attractive target for repair 
post cardiac injury. 
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Figure 4.1 The central role of C3 and CS in the complement activation cascade. 
Schematic figure of the complement activation cascade showing that C3 and CS are 
critical convergence points of four activation pathways and indicates potential targets 
of anti-inflammatory drugs. Inhibitors targetting CS may impact activation of all four 
pathways and offer advantages over C3b inhibitors, most notably the generation of 
C3b, a key component of the innate immune response. Reprinted by permission from 
(Wang, 2006). 
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Hence a collaboration with Mackay et al (Lee et al., 2006) enabled the testing of a 
monoclonal antibody against human C5a receptor (hC5aR) in the setting of myocardial 
ischaemia to assess the effect of this antibody on its potential role in limiting myocardial 
injury and possibly to observe the effects of enhanced repair. Prior to this a specific 
monoclonal antibody against the human C5aR had not been tested in this environment. 
As previously documented, small molecules and antibodies have been used at the C5/C5a 
axis however with varying results (see Chapter I). 
When considering the optimal site for complement blockade, it seemed appropriate to 
focus on products which are common to each of the activation pathways. C5/C5a has in 
recent years been the target of choice so as to avoid blocking C3b which is a critical 
player in opsonisation and therefore innate immunity. Monoclonal antibodies are a 
rapidly growing class of therapeutics due to their predictable pharmacokinetic properties, 
high success rate in the clinic and their ability to inhibit interactions between large 
proteins such as a receptor and its protein ligand (Reichert et al., 2005). However poor 
cross-reactivity of certain monoclonal antibodies between humans and rodents often 
complicates the use of the same drug in pre-clinical studies, in animals as well as for 
human trials due to interspecies differences in receptors. To overcome this Mackay et al 
generated mice in which the native C5a receptor had been replaced by its human 
counterpmt (Human C5aR mice), hence not only having a model for use at the benchside 
but also one where the same reagents could be translated into use in human clinical trials. 
As well as this, human C5aR mice could be used to produce high affinity monoclonal 
antibodies which were able to target the C5a receptor and reverse inflammation (Lee et 
al., 2006). Mice homozygous for the human C5aR transgene (hC5aR1' 1 '") had neutrophils 
with high expression of human C5aR as shown by flow cytometry (Lee et al., 2006). 
Mouse and human C5a bound to human C5aR with similar affinities. Also human C5aR 
was functional in mice, in that neutrophils from hC5aR 1'-1+ mice migrated in response to 
both human and mouse C5a in vitro in a similar fashion (Lee et al., 2006). Human C5aR 
was shown to be expressed at high levels on neutrophils, eosinophils, basophils and 
monocytes, but was absent from memory, effector T cells and B cells. At this time the 
antibody available was named 7F3 mAb. Mackay et al went on to test this antibody in a 
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mouse model of rheumatoid arthritis. Transfer of serum containing autoantibodies from 
m1hritic K!BxN mice to healthy mice induces a joint specific inflammatory reaction that 
mimics the disease which develops spontaneously in K!BxN mice (Reichert et al., 200S). 
After serum was transferred from K!Bx N mice the hC5aR r•·l+ mice pretreated with 
control antibody or saline showed typical clinical arthritis with joint swelling and 
inflammatory infiltrates consisting of primarily neutrophils whereas mice which were 
pre-treated with 7F3 mAb were completely free of inflammation clinically and 
histologically (Lee et al., 2006). Also when the antibody was given S days after induction 
of the disease there was complete reversal of the inflammation (figure 4.2). 7F3 mAb 
showed only a modest effect on neutrophil depletion. Anti-CS mAb has been used to 
inhibit arthritis in mice before, however the doses which were required were much 
greater than that required for 7F3 mAb. One reason that could be postulated that much 
greater concentrations were needed for anti-CS antibody is because of the high 
concentration of CS present in blood. In addition 7F3 mAb was shown not to recognize 
CSL2 (Lee et al., 2006) which is a second CSa binding receptor that provides inhibitory 
signals on CSa binding(Gerard et al., 200S). 
4.2 Efficacy of the 7F3 mAb on neutrophil infiltration and effect 
on infarct size 
In v1ew of the efficacy of 7F3 mAb in combating inflammation associated with 
rheumatoid arthritis, this antibody was then assessed in the setting of acute myocardial 
infarction. Chapter 3 illustrates the development of a mouse model of myocardial 
infarction by surgical ligation of the left coronary m1ery. Initially hC5aR 1' 11 mice were 
used to establish that infarct size induced using the methods established were consistent 
with that established using the CS7B6 mice initially used to establish this model. 
hC5aR1'1+ are on a background of CS7B6 therefore although no anatomical differences 
were expected it was important to establish the consistency of the technique in this 
mouse. No significant difference in infarct size was found between CS7B6 and 
hC5aR I+/+ (figure 4.8). 
Swollen 
paw 
Synovial 
infiltration 
Cartilage 
erosion 
Control 7F3 pre-treated 7F3 post-treated 
Figure 4.2 Anti-C5aR antibody can suppress inflammation m a model of 
rheumatoid arthritis. 
Representative photographs and sections of hind paws from hC5aRJ +I+ mice 
treated with I Omg/kg isotype contro l antibody (left) or 7F3 mAb (centre) in a 
regime where the antibody was given prior to development of arthritis. The 
figure on the right shows the result of g iving 3mg/kg 7F3 mAb after at1hritis 
had developed. Haematoxylin and Eosin staining shows cellular infiltration to 
the joint and severity of histological a11hritis. Safranin 0 staining shows 
ca1 ilage structure. Original magnification x I 00. Reprinted with permission 
(Lee et al , 2006). 
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The hC5aRI' 1 ' m1ce were used for all studies. A schematic representation of the 
experimental outline is shown in figure 4.3. Groups were divided into an antibody 
treatment arm and a control ann. The 7F3 mAb was used by Mackay et al at lmg/kg, 
3mg/kg and I Omg/kg. Effective outcomes were achieved with intraperitoneal delivery. 
Both 3mg/kg and I Omg/kg were found to be highly effective in reducing the clinical 
signs of innammation of the joints (lee et al., 2006). When 3mg/kg was used the mice 
were injected twice per week to keep the signs of joint swelling quiescent. (personal 
communication Dr P Whitfield, Garvan Research Institute, Sydney). In this present study 
an initial dose of I Omg/kg intraperitoneal injection was used 20 minutes prior to surgery 
in an attempt to achieve an adequate systemic load before manipulation of the heart. 
After surgery 3mg/kg were given as a daily intraperitoneal injection until the 3"1 day post 
surgery when the hearts were harvested and analysed. The rationale behind giving a 
greater dose than that used in the rheumatoid arthritis model was because the intention 
was that any effect of the antibody on innammation would be manifest at this dose and 
there was an increased likelihood of the anti-inflammatory effects of the 7F3 mAb to be 
clinically effective as had been shown in the rheumatoid arthritis model. The intention 
was to perfonn dose titrations in later experiments. Hearts were harvested at 3 days post 
surgery as previous studies have rep011ed a peak in neutrophil infiltration post infarct in 
rodent models at day 3 post MI (Smith et al., 1988). The Control arm used an IgG2a 
isotype control. 
4.2.1 Pre-operative characteristics 
As shown in table 4.1 there were no significant demographic differences between the 
treatment group and the control group. 
4.2.2 Neutrophil infiltration analysis 
In initial pilot studies Haematoxylin and Eosin stained sections were used to estimate the 
neutrophi I infiltration, however neutrophi Is were difficult to distinguish from other 
granulocytes (figure 4.4), also this technique did not incorporate the whole of the heart to 
Daily injection of 
7F3 mAb or lsotype 
control Ab 
Days post Ml 
Figure 4.3 Schematic representation of the experimental outline. 
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Mice were given a 1 Omg/kg intraperitoneal injection of 7F3 mAb or isotype control 
Ab 20 minutes prior to surgery, and then 3mg/kg daily until hearts were harvested on 
day 3 post MI. 
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7F3 mAb lsotype Control 
N = 25 N = 25 
Mean± SE Mean± SE 
Age (weeks) 10.4 ± 0.5 10.2 ± 0.5 
Weight (g) 21.9 ± 0.6 21.2 ± 0.6 
%male 16 20 
Table 4.1 Populations of mice employed in this study. 
The experimental and isotype control groups showed no significant difference m 
respect of age, mass or sex ratio prior to protocol start. 
(a) 
(b) 
Figure 4.4 Haematoxylin and Eosin stained transverse sections of mouse left 
ventricle 3 days post infarct. 
This demonstrates influx of neutroph ils. (a) Anows indicate infiltration into the 
infarct and peri- infarct area post MT. (b) AtTow indicates characteristic muliti-
lobed nucleus of neutrophils. (a) and (b) are low and high magnification images 
respectively. Scale bar = 20J.!m. 
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be examined or permit measurement of infarct size in the same specimen. Due to this, 
myeloperoxidase (MPO) activity was used as the measure of neutrophil infiltration. 
Briefly, any myeloperoxidase present in the tissue reacts with hydrogen peroxide, 
releasing a free radical. This free radical oxidizes a substrate 0-dianisidine 
dihydrochloride resulting in a change in colour of the specimen. This change in colour is 
detected by a spectrophotometer. From changes in the spectrophotometer reading, the 
units of MPO per specimen are calculated. Results of initial experiments to show low 
level of interassay variance are shown in figure 4.5. Photomicrographs of myocardial 
sections stained with Gr-1 antibody (recognizes neutrophils, eosinophils and monocytes) 
are shown in figure 4.6 together with images of the spectrophotometer wells illustrating 
the change in colour. As can be seen from the immunohistochemistry, in an uninjured 
heart there were very few neutrophils seen after sectioning and staining. This was also 
reflected in the MPO assay. In each experiment an uninjured heart was used as a negative 
control and the spleen was used as a positive control for neutrophils. Using this technique 
to detect neutrophil prescence in tissue pennits measurement of infarct size using the 
triphenyl terazolium chloride technique described in Chapter 2. Smith et al have shown a 
concordance between tissue MPO activity and histologic determination of neutrophils in 
infarcted myocardium (Smith et al., 1988). Having detem1ined that MPO was an 
appropriate tool to examine neutrophil infiltration, the MPO activity in the infarcted 
hearts from 7F3 mAb treated or isotype control treated animals was examined. As can be 
seen in figure 4. 7 the 7F3 mAb treated animals had a significantly reduced neutrophil 
infiltrate 3 days post Ml compared with control treated animals ( 416.8 ± 52.6U 
MP0/1 OOOg and 590.3 ± 55.6 U M PO/I OOOg respectively). As discussed earlier, 
infiltrating neutrophils associated with inflammation are associated with poorer outcomes 
post M I. Hence the size of infarct after 7F3 mAb and control Ab was also examined. 
4.2.3 Infarct size analysis. 
This was done on day 3 post Ml prior to analysis for MPO activity in the same manner as 
described in Chapter 3 using triphenyl tetrazolium chloride to mark the infarcted area. 
Initially C57B6 mice and hC5aR1111 mice were infarcted in parallel to ensure the infarct 
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Heart Control 
- Heart Day 3 post Ml 
- Spleen 
Figure 4.5 Use of MPO assay to monitor neutrophil infiltrate into the infarcted 
heart. 
The MPO assay was ab le to detect neutrophi l prescence in hearts at 3 days post 
MI. Note comparatively low level of inter-assay variance in these samples. Spleen 
was used as a positive control. Coefficient of variation calcu lated to be 24.5% and 
8.4% for heart post MI and spleen respectively. N = 10 per group. 
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(a) (b) (c) 
B N MI s 
Figure 4.6 Detection of infi ltrating neutrophils by immunofluorescence.and MPO assay 
(a) - (c) show staining of transverse sections of the heart using Gr-1 antibody to detect 
infiltration of neutrophils post MI. (a) Normal heart. No Gr-1 staining indicating 
normally there are few, if any, neutrophils residing in the interstium of the hea1 . (b) 3 
days post MI the Gr- 1 stained neutrophils can be seen primarily in the peri-infarct area 
recognisable by the junction between nmmal architecture of myocardium and infarct 
area (arrow ind icates infarct area). (c) Sp leen tissue used as a positive control due to the 
abundance of neutrophils . Gr-1 is stained green. Nuclei are stained blue with Hoechst. 
(d) Demonstrates the change in colour in the myeloperoxidase assay in relation to the 
neutrophil content of the specimen, illustrating that the MPO assay shows broad 
concordance with numbers of neutrophils determined by immuofluorescence. Blank 
specimen contained no tissue. B =B lank, N =Normal hem1, MI = 3 days post MI, S = 
Spleen. Scale bar = 50Jlm. 
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Figure 4.7 MPO assay of neutrophil accumulation in 7F3 mAb and isotype control 
Ab hemts post MI 
Neutrophil accumulation was assessed by MPO activity. Those animals treated 
with 7F3 mAb had a significantly reduced level of MPO activity compared with 
control treated animals (p<0.05). N=23 and 24 for 7F3 mAb and control groups 
respectively. 
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technique resulted in consistently unifom1 infarcts in both types of mice and to ensure the 
transgenic mouse did not have any inherent differences which would affect the outcome 
of coronary ligation .. Infarct size was similar in both groups with the technique used, as 
shown in figure 4.8. Once establishing that the infarct technique gave a consistent result, 
the 7F3 mAb was tested in comparison to the isotype control. These results are shown in 
figure 4.9, demonstrating that there was no significant difference in infarct size between 
the treated (32.6% ± 2.98) and control Ab (34.3% ± 2.61) groups (p<O.OS). 
To ensure differences observed between infarct size and MPO were not due to changes in 
total heart mass, each heart was weighed at the time of harvest. No significant difference 
was found between the 7F3 mAb treated and control groups. The mean weight of the 
hearts which had received 7F3 mAb and control were 0.1 I ± 0.02g and 0.11 ± 0.02g 
respectively. 
Although there was no significant difference in infarct size, this does not measure all of 
the physiological effects of 7F3 mAb treatment. In order to assess this, m1ce were 
observed and weighed during the period leading up to the 3 day endpoint. 
4.2.4 Physiological observations 
Mice were checked and weighed daily. Surgical induction of myocardial infarction has a 
significant physiologic impact on the mouse and this is usually reflected in some weight 
loss in the first week post procedure. The weight loss documented at day 3 post infarct 
was not significantly different in the 7F3 m Ab treated group and the control group 
( 13.6% ± 1.42 and I 0.7% ± 1.63 respectively) as illustrated in figure 4.1 0. 
Although there were no peri-operative deaths the cause of all deaths which occuned prior 
to elective harvesting of the hearts were investigated at post mortem. All deaths prior to 
harvest were found to be due to rupture of the left ventricle. Each group started with 25 
mice in each group. 23 mice reached the 3 day end point in the group which received 7F3 
mAb and 24 hea11s reached the end point in the control group. All deaths were due to left 
Figure 4.8 Comparison of infarct size induced 111 C57B6 and hC5aRJ +/+ 
mice. 
There was no significant difference in the size of infarcts induced in the 
hC5aR+I+ mice compared with C57B6 mice. No antibody treatment was used 
in either group (p = ns ). N= l 0 in each group. 
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Figure 4.9 Effect of hC5aR m Ab on infarct size at day 3 post MI. 
lOL 
There was no significant difference in the size of infarct in tbe 7F3 mAb treated 
group compared with the control (p = ns). N=23 and 24 for 7F3 mAb and control 
groups respectively. 
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Figure 4.10 Weight loss in mice post Ml as percentage of original weight. 
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There was no significant difference in weight loss post Ml in the 7F3 mAb treated 
group and control animals (p = ns). N=23 and 24 for 7F3 mAb and control groups 
respectively. 
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ventricular rupture. Incidence of left ventricular rupture was very low in both groups, 
being 8% in the 7F3 mAb group and 4% in the control mAb group. This difference was 
not significant, using the chi squared test (p = ns). There were no complications of local 
infection or sepsis. 
4.3 Discussion 
This study examined the effect of complement inhibition in a murine model of acute 
myocardial infarction. The complement pathway was inhibited using a monoclonal 
antibody against human C5aR (7F3 mAb) in a transgenic mouse in which human C5aR 
had been knocked in (hC5aR / 111 ) (Lee et al., 2006). 
Inflammation is known to contribute to cell damage during ischaemia (Frangogiannis et 
al., 2002). Initial attempts to inhibit inflammation with corticosteroids (Hammerman et 
al., 1983a)or non steroidal anti-inflammat01y drugs (Hammerman et al., 1983b) have not 
shown to improve outcome after MI. Neutrophil depletion or inhibition of function has 
been shown to limit infarct size underlying their importance in myocyte injury after an 
ischaemic event (Amsterdam et al., 1993; Mullane et al., 1984), however it would be 
useful to specifically reduce neutrophil mediated damage at the site of inflammation. 
Hence antibodies or antagonists targeted at C5/C5a/C5aR have been an attractive 
candidate for reduction of ischaemic damage due to the impo11ance of this pa11 of the 
complement pathway in neutrophil chemotaxis and also in generation of the C5b-9 
membrane attack complex. Additionally targeting this part of the complement pathway 
does not affect C3b which is a critical for opsonisation in its role in innate immunity. A 
number of animal studies and human studies in this regard have already been described in 
Chapter I, which have shown varying efficacy. This is the first time the 7F3 mAb has 
been used in the setting of myocardial infarction. 
In the present study in a munne model of infarction, 7F3 mAb was given pnor to 
infarction and the hearts were analysed after 3 days. In contrast, the majority of previous 
studies have used antagonists or antibodies at the C5/C5a axis in models of ischaemia 
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reperfusion and have usually been analysed within hours. A number of different methods 
have been used previously to assess outcomes including assessment of neutrophil 
infiltration by MPO assay and measurement of myocardial injury by measuring infarct 
size using triphenyl tetrazolium chloride, biomarkers such as CK-MB, functional studies 
including echocardiography and long term survival data. 
In this study on the effect on myocardial infarction, neutrophil infiltration was assessed 
by MPO activity in the heart at 3 days post infarct. This time point was chosen as the 
most appropriate point for assessment as it has been shown to correlate with the peak of 
neutrophil infiltration after coronary artery occlusion (Smith et al., 1988). Assessment of 
MPO activity demonstrated that treatment with the 7F3 mAb resulted in a significant 
reduction in the MPO activity in the heart. M PO activity has previously been shown to 
correlate well with neutrophil infiltration after ischaemia. (Smith et al., 1988). Despite 
this reduction in neutrophil infiltration, surprisingly there was no significant change in 
infarct size after using the 7F3 mAb despite the outstanding clinical results demonstrated 
when using this antibody in a murine model of rheumatoid arthritis (Lee et al., 2006) .. 
Despite the encouraging results of other studies in using an inhibitor or antibody at the 
C5/C5a axis, one reason a significant change in infarct size was not demonstrated here 
could be the mechanism of ischaemia employed. No reperfusion was instituted here, 
whereas in the majority of previous studies reperfusion was instituted after a much 
shorter time of ischaemia (Amsterdam et al., 1995; Yakeva et al., 1998). Although this 
reperfusion time will be involved in contributing to myocardial injury in response to 
complement activation and cytokine release, it also may allow enough blood to perfuse to 
salvage some of the damage resulting from the initial ischaemic insult, thereby affecting 
the final outcome. The results in the present study retlect those in the COMPLY and 
COMMA trials where no change in infarct size was observed (Granger et al., 2003; 
Mahaffey et al., 2003). There is a possibility that modulating the intlammatory pathway 
by using the 7F3 mAb in the setting of myocardial infarction might enhance outcomes in 
a manner which is not detectable from measuring infarct size at such an early time point 
of 3 days post M I. The COMMA trial showed that despite the fact that myocardial injury 
(measured using CK-MB) was no different in the treated and control group, there was a 
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beneficial effect in the treatment group evident at 90 days with a reduction of mortality. 
Hence even thought no difference using the antibody has been noted in the present study 
there is a possibility that its anti-inflammatory effect may affect ventricular remodeling 
and affect long term survival in this manner. 
In summary, the findings from this study demonstrated the use of a human C5aR mAb 
(7F3 mAb) in a human C5aR knock in mouse in the setting of acute myocardial 
infarction. Use of 7F3 mAb resulted in a significant reduction in neutrophil infiltration at 
3 days post infarct, but no difference in infarct size at that time point. There were no 
infective complications or differences in ventricular rupture between the two groups. This 
data supports an imp01tant role for 7F3 mAb in reducing inflammation when 
administered prior to onset of myocardial infarction, however it also suggests other 
mechanisms of potential regenerative and repair strategies must be studied to try to 
elucidate mechanisms which may be available in cardiac repair. Hence an investigation 
was carried out into the phenotype of a putative stem cell population found in the adult 
heart. 
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CHAPTER 5 
In vitro characterization of a putative 
stem cell population in the adult heart 
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5.1 Introduction 
A disease model of myocardial infarction in mice was initially established in order to 
have an in vivo model for investigating regenerative activity in the heart (Chapter 3). This 
model was used to assess the efficacy of reduction in the inflammatory response after an 
ischaemic insult, by using an antibody directed against the C5a receptor (Chapter 4). It 
was suggested that cells extrinsic to the hea11, such as inflammatory cells may not play a 
complete role in infarct recovery. Recent studies have highlighted the potential role of 
cardiac resident cells that may be capable of regenerating the heart (Chapter!) however 
their nature, role and phenotype is as yet not completely understood. One approach to 
finding a cardiac resident stem cell population is to look for those cell types present 
within the developing embryo which may also be present in the adult. One such candidate 
cell population is that expressing platelet derived growth factor receptor alpha 
(PDGFRA). PDGFRA expressing cells have been found in the developing mouse embryo 
in the region of the proepicardial organ at E9.0. These cells are also found on the 
epicardial surface of the heart at E9.0 to E I 0.5. From E 12.5 they appear in the 
interstitium of the myocardium. PDGFRA also eo-localises with Wilms tumour protein 
(Wt I) which has been reported as being an expression marker for the epicardium of the 
heart (Perez-Pomares et al., 1998) (personal communication, Owen Prall, Victor Chang 
Cardiac Research Institute, Sydney). Epicardial derived cells are known to invade the 
cardiomyocyte layer by a process called epithelial to mesenchymal transfom1ation (EMT) 
and contribute to endothelium, smooth muscle and fibroblasts of the developing coronary 
vasculature. Soriano et al generated a mouse with a targeted null mutation of the Pdgfra 
locus using a histone H2B-eGFP fusion repm1er protein construct knock in (Soriano, 
1997). Heterozygous mice show that GFP reproduced the PDGFRA expression pattern 
(On-U11reger et al., 1992; Takakura et al., 1997). Fu11her, Hamilton et al showed by 
flow cytomctry analysis of cells from PdgfraGFPI+ mice that H2BGFP and the wild type 
PDGFRA are expressed in the same population of cells, further suppmting the idea that 
Pdgfi·ac;,.-, faithfully reproduces the native wild-type PDGFRA expression pattern 
(Hamilton et al., 2003). Homozygous Pdgfi·a-nu/1 mice die by E I 0.5 showing multiple 
defects which include cardiac defects such as aortic arch malfonnations, persistent 
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truncus arteriosus, atrial and ventricular septal defects, myocardial wall thinning and 
abnonnal atrio-ventricular valves and dilatation of the pericardium (personal 
communication, Dr 0 Prall, Victor Chang Cardiac Research Institute, Sydney). 
The anatomical location of the PDGFRA expressing cells in the heart, coupled with the 
phenotypic changes in the Pdgfi·a-nu/1 mice, suggest that this population may exhibit 
stem cell activity in the adult. In order to address this an assay for stem cell activity was 
needed. In vivo reconstitution is arguably the strongest and most robust assessment 
(Seaberg and van der Kooy, 2003), however in vivo models are very time consuming and 
demand very large numbers of animals. An alternative initial approach is to characterise 
the stem cell properties of a candidate population in vitro, assessing self renewal, 
proliferation and differentiation (Potten and Loeffler, 1990). An assay needed to be 
chosen which may isolate a stem/progenitor cell population, to show in vitro self renewal 
and proliferation potential. The assay chosen was a Colony Forming Unit Fibroblast 
(CFU-F) assay. This was initially demonstrated by Friedenstein and colleagues 
(Friedenstein et al., 1970) where they plated whole bone marrow in plastic culture dishes, 
discarding the non-adherent (typically haematopoietic) cells after 4 hours. The remaining 
adherent cells were found to form colonies and fUither work established that these cells 
were also multi-potent being capable of differentiating into osteoblasts, chondrocytes and 
adipocytes (Digirolamo et al., 1999). Due to their self renewal ability, proliferative 
capacity and ability to differentiate into multiple mesenchymal lineages they were known 
as Mesenchymal Stem Cells (MSCs). Amongst all the stem cell assays described it 
seemed appropriate to choose a simple robust assay which not only is capable of 
revealing key in vitro features of self renewal and proliferation but also one which has 
been shown to allow isolation or enrichment of stem cells. 
This chapter (Chapter 5) will assess mononuclear cell populations in the murine adult 
heart for expression of PDGFRA and examine their stem cell status using a CFU-F assay 
in vitro. 
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5.2 Initial characterization of PdgfraGFPI+ mice 
The reporter mice, carrying a Pdgji·aGFf' knock-in/knockout allele, were maintained as 
heterozygotes (PdgfraGFf'l' >. There were no detectable differences in development, 
growth or fertility between WT littennates and heterozygous PdgfraGFPI+ knock-in 
mice, an observation confirmed by others (personal communication, Dr 0 Prall, Victor 
Chang Cardiac Research Institute, Australia; Professor P Soriano, Fred Hutchinson 
Cancer Research Centre, Seattle). In order to confirm that GFP expression in these 
Pdgfi·aGFf'l+ mice faithfully renected endogenous PDGFRA expression, cells from the 
hearts of these mice were subjected to now cytometry. As can be seen in figure 5.1, 
expression of native PDGFRA was coincident with GFP expression. Having confirmed 
the validity of the model, the relationship of these GFP' cells with expression of other 
stem cell markers and their stem cell status was investigated using a CFU-F assay. 
5.3 CFU-F in the heart and enrichment of Sca1+/PECAM1-
/PDGFRA GFP+ population 
Initial experiments demonstrated that the prop01tion of GFP positive mononuclear cells 
in the Pdgji·aGFf'l+ adult heatt was approximately 14% (figure 5.1 ). In order to refine this 
comparatively large population prior to CFU-F analysis, additional surface markers 
characteristic of stem cells needed to be employed. As outlined in chapter I there are a 
number of candidate surface antigen markers. Sea-l was selected as there are a number of 
independent reports indicating its expression on candidate stem cells (Matsuura et al., 
2004; Oh et al., 2003; Pfister et al., 2005), and unlike other markers (for example c-kit), it 
is less sensitive to enzymatic degradation (Li et al., 2008; Pfister et al., 2005). 
Mononuclear cell fractions from the heatt were therefore subjected to sequential 
cytometry and sorting based on the expression of surface antigen markers and/or GFP. A 
schematic diagram showing organization of the gating by the now cytometry used in 
these series of experiments is shown in figure 5.2. All specific nuorescent antibody 
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Figure 5.1 Flow cytometry plot demonstrating eo-expression of PDGFRA GFPHIGH 
and PDGFRA Ab in adult Pd.fgraGFP!+ heart. 
Expression of native PDGFRA was coincident w ith GFP expressiOn m the 
PdgfraGFPI+ heart 
~ 
u 
w 
a. 
11 I 
(i) (i i) (i ii) 
1000 . 1000 
BOO 800 
l: 600 .. eoo 
0 u .. ~ .. 
400 400 
~00 200 
0 
~00 400 500 800 100 200 400 1000 
FSC·A FSC-A 
(vi) (v) (iv) ~ 
103 103 10
3 Dead cells 
... 
10~ >. 102 101 .. 
., 
1 o1 101 10
1 
10° 10° 
10° 101 102 1 o3 lOO 400 600 800 1000 
0 lOO 400 600 800 1000 
GFP FSC·A FSC·A 
Figure 5.2 Schematic diagram showing the gating strategy used in flow cytometry. 
i) The hear1 was initially digested.(ii) Forward Scatter Height/ Forward Scatter Area gate 
shown aims to reduce aggregates (iii) Side Scatter/Forward Scatter demonstrates isolation 
of cells excl uding cell fragments . (iv) 7 AAD was used to gate out dead cells. (v) Sea-l + 
cells were isolated using Ab. (vi) Finally PECAM I Ab and GFP were used to isolate the 
PECAMUPDGFRAGFPI fraction from Sea- l+ cell fraction in PdgfraGFP/ I hearts. 
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labeling was confirmed by isotype matched negative control antibodies. The sorted 
populations were then assessed for colony forming activity. 
Although the present study concentrated on a PDGFRA GFP+ population, the numbers of 
colony forming cells in whole unfractionated heart was first addressed, and then in order 
to enrich for this population the mononuclear cell population was fractionated on the 
basis of expression markers which have been found to be associated with stem cells. 
Hearts from adult mice aged between 8 to 12 weeks were digested and the unfractionated 
mononuclear fraction plated out in a CFU -F assay. In three independent experiments 
0.39% ± 0.014 of the unfractionated heart mononuclear cells demonstrated colony 
forming ability (figure 5.3). 
Primary CFU-F assays demonstrated a heterogeneity in the size of colonies formed. This 
is consistent with other reports of similar assays (Louis et al., 2008). Louis et al found in 
a neural colony forming assay that different size colonies had different re-plating abilities 
enabling the authors to make conclusions as to the putative progenitor or stem cell status 
of a selection of cells. The progenitor cells which formed the smaller colonies were found 
to have limited self-renewal potential and also a restricted differentiation potential 
compared to the cells which formed the larger colonies (putative stem cells) which had a 
greater potential for self renewal and differentiation. In a similar way in the present study 
colonies formed could be scored into different size categories, micro (<2mm diameter 
with 5-25 cells), small ( <2mm diameter with > 25 cells), large (> 2mm diameter with >25 
cells). In initial experiments only small (<2mm) and large (>2mm) colonies were 
quantitated but once the PDGFRA GFPI fraction was subject to CFU-F assay, micro 
colonies were also quantitated. When assessed by size, the numbers of colonies fonned 
from the whole heart were broadly equivalent, 0.20% ± 0.015 and 0.19% ± 0.020 for 
small and large colonies respectively (figure 5.4). 
Having established that CFU-F could be detected, the association of this activity with 
surface antigen expression was investigated. The mononuclear cell fraction from adult 
mouse hearts was F ACS sorted into Sea-l positive and negative fractions in ten 
Figure 5.3 Photograph of a typical large primary colony. 
Stained with crystal violet. Sca le Bar= 2mm. 
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Figure 5.4 Whole heart percentage colony formation after selection for live cells 
Numbers of colonies formed from the whole heart were broadly equivalent, 
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independent experiments, and the isolated cells plated out in a CFU-F assay. 52.3% ± 
3.03 of live mononuclear cells expressed high levels of Sea-l (Figure 5.5a). When plated 
out in a CFU-F assay, this Sea-l' fraction contained all of the detectable colony forming 
activity (figure 5.5b), a result which was statistically signiticant (p<0.05). However the 
propmtion of cells giving rise to colonies was still comparatively low, 0.33 1% ± 0.016 for 
small colonies and 0.30% ±_0.037 for large colonies. In order to enrich this population 
further the expression of PECAM I (CD31) was investigated, as this has been used 
previously by Pfister et al to enrich the yield of putative stem cell populations in the 
heart. Pfister and colleagues showed that from a side population (SP) group of cells 
isolated from the heart, only those Sca-l'/CD31- cells showed any cardiomyogenic 
potential (Pfister et al., 2005). The digested heart specimens were therefore subject to 
Sea-l and PECAM I dual staining and analysed by flow cytometry. 25.1% ± 3.2 of the 
Sea-l' cells were PECAM I negative (ligure 5.6), and in three independent experiments it 
was found that all of the detectable CFU-F activity was found in this Sca-l'PECAM ]-
sub-population (data not shown). 
Having established that 100% of detectable CFU-F activity in the heart segregated with 
the Sea-l' PECAM I" population the expression of Sca-11-/PECAM 1"/PDGFRA GFr was 
examined. Figure 5. 7a shows the flow cytometry contour plot for PECAM I and 
PDGFRA c;rr from the Sea-l' fraction of cells. As can be seen, there was a distinct 
PDGFRA GFPIIIGH population that was PECAM I negative. Note that from now on it can be 
assumed that PDGFRA GFP population refers to the Sca-1'/PECAM 1- /PDGFRA GFP+ 
subfraction. There was a small shoulder of PECAM I' cells which appeared to 
demonstrate a GFP fluorescence greater than that seen in the negative control. Gates were 
set up to identify all of these populations as shown in figure 5.7b. All of the seven 
populations were assessed for CFU-F activity, however only the PDGFRA GFPHIGH 
fraction possessed any detectable colony forming ability. In this experiment which 
incorporated data from 8 hearts, colony forming ability was 0.18% ± 0.022 for small 
colonies and 0. 7% ± 0.036 for large colonies. This represented an enrichment of small 
and large colony forming efficiency from using just the whole heart. Figure 5.8 
summarises the CFU-F proportions for the small and large colonies and also micro 
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Figure 5.5 (a) Flow cytometry plot showing gating strategy for Sea-l r cells. 
52.3% ± 3.03 of live mononuclear cells expressed high levels of Sea-l +. N=20. 
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Figure 5.5 (b) Percentage colony formation in the heart according to Sea- l status. 
All the detectable CFU-F acti vity m the heart was shown to be m the Sea 11 
fraction. N= l 0 in each group 
(.) 
0.. 
<( 
i 
<( 
(.) 
w 
0.. 
I 17 
lsotype control Ab PECAM1 Ab 
1 o3 1 o3 
(.) 
0.. 
<( 
1 o2 i 1 o2 <( 
(.) 
w 
0.. 
1 o1 1 o1 
1 o0 1 o
0 
0 200 400 600 BOO 1000 0 200 400 600 BOO 1000 
FS C-A FSC-A 
Figure 5.6 Flow cytometry plot demonstrating the PECAM I gate. 
25 .1% ± 3.20 of the Sea-l + fract ion were negative for PECAMl and when plated 
out in the CFU-F assay, this negative fraction contained all of the detectable 
co lony fom1ing activity. 
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Figure 5.7(a) Flow cytometry plot of examination of GFP expression 
(i) WT heart demonstrating gating strategy (ii) PdgfraGFPI+ heart. I 0.2% ± 1.37 of 
the Sea-l + population was found to be PECAM-/GFPHIGH in PdgfraGFPI+ hearts. All 
of the CFU-F activity was contained in this population. This plot was divided into 
the gates shown in figure 5. 7b and the same strategy was used in further analyses. 
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Figure 5.7(b) Gating strategy used in flow cytometty prior to CFU-F assay 
Each of these seven populations (A-G) were assessed for colony forming activity. 
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Figure 5.8 Primary colony fonnation from PDGFRA GFPHJGJJ cells. 
Colonies were divided into micro, small and large sizes . The percentage colony 
formation of each of these was significantly different from each of the others 
(p<O.OS). N = 8 hearts. 5 plates counted for each colony type per heart. 
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colonies . In addition to analyzing colony formation in a cell population it was impmtant 
to examine colony formation at the single cell level to assess whether there was any 
effect of cell -cell interaction on colony formation. Figure 5.9 demonstrates the results 
from a serial dilution assay showing consistency of colony formation at the single cell 
level of PDGFRA GFPIIIGII cells. 
Now that it had been established that CFU-F activity was present in the adult heatt and 
that this CFU-F activity was exclusively associated with the PDGFRA GFPHIGII fraction of 
cells, it was important to establish any changes in these populations in diseased states and 
also characterize further their self renewal capacity. 
5.4 Quantification of PdgfraGFP+ cells in a diseased heart-
Myocardial Infarction 
As shown in Chapter 3 a murine model of myocardial infarction had been established for 
the purpose of investigating the diseased heart. In this experiment, sham operated mice 
were used as controls, where the mice were anaesthetized and thoracotomy perfonned, 
but there was no manipulation of the hea11. Figure 5.10 depicts an annotated outline of 
the experimental events. 
Murine hearts, 5 days and 12 days after surgical ligation of the left coronaty attery were 
digested and subject to flow cytometry to delineate the cell fractions on the basis of 
expression of Sea-l, PECAM I and PDGFRA c;rr. Figure 5.11 demonstrates the contour 
plots of PECAM I and PDGFRA c;rr for the Sea-l positive fraction of both sham operated 
and those subject to MI. The gates used were those already established (figure 5.7b). 
Compared with the sham operated mice the mice subject to MI demonstrated the 
appearance of an increased number of cells in fractions F and G, a result consistently seen 
across 18 experiments. In order to examine the CFU-F activity of each of these 
populations the cells from all fractions shown in figure 5.11 from both sham operated and 
MI mice were plated out in a CFU-F assay. Only cells from fractions F and G (Sca-
11/PECAM 1-PDGFRA GFPIIIGII and Sca-1 1/PECAM 1-/PDGFRA GFPMEDIUM) contained cells 
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Figure 5.9 Seria l dilution assay using PDGFRA GFPHIGH cells from PdgfraGFP!I 
heart. 
Total colony fonnation percentage is shown demonstrating consistency of total 
colony fom1ation down to the single cell level. N = 3 hearts. 
Assay perfom1ed by Dr V Chandrakanthan (Victor Chang Cardiac Research 
Institute, Australia) 
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Figure 5.10 Experimental outline of events prior to analysis 
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Figure 5.11 Flow cytometry plot of PdgfraGFPlt heart comparing sham and M!. 
This demonstrates the change in proportions of the co lony fom1ing fract ions in (a) 
sham and (b) 5 days post MI. Note that post MI, cells could be isolated from Gate F, a 
PDGFRA GFPMEDI UM population which formed co lonies. Only cell frac tions F and G 
formed colonies. 
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which fom1ed colonies. There were very few PDFGFRA GFPMEDIUM cells isolated from the 
sham operated mouse therefore it was only after MI that enough of these cells could be 
obtained for plating. Change 111 the propmtion of PDGFRA GFPMEDIUM and 
PDGFRAGFPHIGH cells after Ml 1s illustrated in figures 5.12a and 5.12b. The 
PDGFRA GFPIIIGH fraction post Ml was significantly increased (17.40% ± 1.08) compared 
to the same population in the sham operated control (8.10% ± 1.37) (p<0.05). The 
PDGFRA GrPMEDIUM population also changed post infarct increasing from a mean of 
1.50% ± 0.09 to 4.70% ± 0.51 (p<0.05). Note also from figure 5.11 b there was an 
increase in the proportion of cells in gate D post MI (p<0.05). There was a similar pattern 
as that just described found in hemts at day 12 post infarct. The PDGFRA GrPHIGH fraction 
increased significantly from a mean of9.47% ± 0.38 in the sham to 13.3% ± 0.58 post Ml 
(p<0.05). The PDGFRA GFPMEDIUM population increased nearly 5 fold from a mean of 
1.45% ± 0.37 to 6.91% ± 0.12 (p<0.05) (figure 5.12a,b). 
These changes in proportion of PDGFRA GrPHIGII and PDGFRA GFPMEDIUM populations 
could be due not to an increase in absolute number, but a diminution of the other 
populations. In order to address this, the absolute numbers were assessed (figure 5.13). In 
correlation to the increase in proportions, actual cell number for these 2 populations 
increased post Ml . Indeed, the absolute increase was even greater than that suggested 
by the proportional analysis. The proportions calculated by flow cytometry showed an 
increase at 5 days post Ml in PDGFRA GFPIIIGH population by a factor of 2.1 and an 
increase in the PDG FRA GrPMEDIUM population by a factor of 3 .I, whereas when cell 
numbers were analysed the increase for PDGFRA GFPIIIGII population was 2.5 and for the 
PDGFRA GFI'MEDIUM population was 4.8. This may be because the increase in proportion 
calculated on flow cytometry may be 'diluted' by an influx of inflammatory cells post Ml 
(this may account for the increase in gate D). Indeed, the PECAM-PDGFRA Grr- fraction 
(labeled as D in figure 5.11) was shown to stain positive for CD45, a marker of 
haematopoietic cell types (figure 5.14b ), which would be consistent with this expanded 
population reflecting an influx of extra-cardiac inflammatory cells, such as neutrophils, 
part of the post infarct inflammatory response (Frangogiannis et al., 2002). However, this 
raised the question of whether the increased populations of PDGFRA GFPI-IIGH and 
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Figure 5.12 Histogram demonstrating the change in (a) PDGFRA GFPMEDIUM and (b) 
PDGFRA GFPHIGII populations at Day 5 and 12 post MI in comparison to sham. 
Note the significant increase in percentage of PDGFRA GFPMEDIUM and 
PDFGRA GFPHIGH populations post MI. * denotes p<0.05. N = 18 in each Day 5 (D5) 
post surgery group. N = 3 in each Day 12 (D 12) post surgery group . 
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Figure 5.13 Comparison of actual cell numbers per hem1 isolated by flow 
cytometry for PDGFRA GFPMEDIUM and PDGFRA GFPI-IIGH cells in sham hem1s and 
day 5 post MI (MI 05); PdgfraGFPI+ hearts. 
Numbers of PDGFRA GF PI-IIGH and PDGFRA GFPMEDIUM cells increased significantly 
post MI (p<0.05). A lso shown is the increase in PECAM-;POGFRA GFP- fraction 
(labelled as D in figure 5.11) (p<0.05) . The increase in this PECAM-PDGFRA GFP-
fraction could be represented by an influx of cells from the bone marrow post 
infarct- see section 5.5 on CD45 status.* denotes p<0.05. N = 8 hearts. 
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Figure 5.14 (b) Interrogation of the Sea-l ~ populat ion in Pdgfra GFPI+ hearts for CD45 
express ton. 
The PDGFRA GFPHtGtt and PDGFRA GFPMEDI UM populations were negative for CD45 . The 
PDGFRA GFP- fraction however was shown to contain CD45+ cells in sham operated 
hearts and post MI. See main body of text section 5.5 for interpretation of isotype. 
control. 
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PDGFRA c;rrMr:oluM 11 . -1 1 fl 1 · fii · f 1 · · · ce s sum ar y re · ectec an m 1 trat1on o exogenous 1aematopo1etic 
cells. In order to address this, the CD45 status of these populations was assessed. 
5.5 CD45 status 
In an eff011 to assess whether the increase in the candidate cell populations which fonned 
colonies (PDGFRA GrrMEDIUM and PDGFRA GFI'IIIGII) may have been due to an influx of 
haematopoietic cells, the cells were interrogated with antibody against CD45. The results 
of this are shown in figure 5.14b. The PDGFRA GFPIIIGH and PDGFRA GFPMEDIUM cells 
were negative for CD45 reducing the possibility that there had been any influx of 
haematopoietic cells into these populations. The initial gating was performed using the 
lgG2b isotype for CD45 in the sham. The positivity for the isotype control in the Ml is 
likely to be due to activation of and influx of inflammatory cells in the heart. It is known 
that Fey receptors are found on most effector cells of the immune system, notably 
monocytes, macrophages, natural killer cells, mast cells, eosinophils and neutrophils. 
FcyR I is expressed on the surface of neutrophils, monocytes, granulocytes and 
macrophages and binds the Fe portion of lgG with high affinity (Raghavan and 
Bjorkman, 1996). All of these cells are activated as pa11 of the post infarct inflammatory 
response and hence are likely to bind to the IgG isotype control as shown in figure 5.14b. 
Having detem1ined that the PDGFRA GFPHIGII and PDGFRA GFPMEDIUM populations were 
unlikely to be haematopoietic, the nature of the colonies that these cell types could 
produce was examined. 
5.6 Primary colony formation from PdgfraGFPI+ mice post Ml 
In a manner similar to non-infarcted mice, there was heterogeneity in the size of the 
primary colonies fonned by PDGFRA GFP+ cells isolated 5 days after either Ml or sham 
operation. However, although there was no significant difference in the frequencies of the 
different sizes of colony formed from un-operated mice compared to the sham operated 
130 
controls, there were substantial changes in the colony forming ability post Ml, as shown 
in figure 5.15. PDGFRA GFPMEDIUM cells formed very few small and large colonies, 
however they formed significantly greater numbers of micro colonies compared to the 
PDGFRA GFPIIIGII population (p<0.05). Also interestingly, post Ml there was a 
significantly greater colony forming ability of the PDGFRA GFPIIIGII cells for micro, small 
and large colonies (p<0.05). These differences in colony size could reflect a different 
potential of the initiating cell. In order to address this, the ability of cells from these 
different populations to form secondary and tertiary colonies was assessed. 
5. 7 Secondary and tertiary colony formation from PdgfraGFPI+ 
mice 
Individual pnmary colonies were disaggregated and re-plated in a secondary CFU-F 
assay and numbers and size of new colonies assessed. Micro colonies did not 
demonstrate any ability to form secondary colonies of any size. Similarly, colonies 
formed by PDGFRA GFP MEDIUM cell population from either the sham or post MI mice did 
not produce secondary colonies. However colonies did form from small colonies and 
large colonies from the PDGFRA GFPIIIGH cell population as illustrated in figure 5.16a and 
5.16b. The small and large primary colonies gave rise to all sizes of secondmy colony, 
however large colonies predominated. There were no significant differences between the 
groups which were sham operated or five days post Ml in the percentage colony forming 
ability from any one patticular primary colony size. The large primaty colonies from the 
PDGFRA GFPHIGII cell population generated a greater percentage of large secondary 
colonies in comparison to that from small primary colonies (p<0.05). Small primaty 
colonies gave 12% ± 1.84 large colonies in the sham and 12% ± 1.18 large colonies post 
MI. Large primary colonies gave 16% ± 1.00 large colonies in the sham and 13% ± 1.67 
post MI. These data suggested that the numbers of CFU-F present in the different 
PDGFRA GFP+ populations within the sham and MI mouse differed, the phenotype of 
individual CFU-F groups appeared broadly similar for sham and post M I, with secondary 
colony formation of large colonies being greatest from large primary colonies. Production 
of secondary colonies is evidence for self-renewal of a CFU-F initiating cell, but this 
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Figure 5.15 Primary colony formation in Pdgfi·aGFP/I hearts in sham and 5 days 
post MI. 
PDGFRA GFPMEDI UM cells formed very few small and large colonies, however they 
formed significantly greater numbers of micro colonies compared to the 
PDGFRA GFPHIGH population (p<0.05). Post MI there was a significantly greater 
colony fonning ability of the PDGFRA GFPIIIGII cells for micro, small and large 
colonies (p<0.05). * denotes p<0.05. Tota l of 16 hearts used in this analysis for 
Sham and MI and 5 plates counted per population per heart. 
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Figure 5.16 (a) Secondary colony fonnation from small pnmary colonies 111 
PdgfraGFPI+ hea11s. 
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Figure 5.16 (b) Secondary colony fonnation from large pnmary colonies m 
PdgfraGFPI+ hearts . 
Small and large primary colonies gave rise to all sizes of secondary co lony, however 
large co lonies predominated. There were no significant differences between the 
groups which were sham operated or five days post MI in the percentage colony 
forming ability from any one pat1icu lar primary colony size. The large primary 
colonies from the PDGFRA GFPII IGH cell population generated a greater percentage of 
large secondaty co lon ies in comparison to that from small primary colonies in the 
sham heat1 (p<0.05). Total of 12 heat1s were used in this analysis for Sham and MI 
and 30 colonies counted for each colony type per heart. 
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does not address whether such self renewal is maintained. In order to examme this 
individual secondary colonies were disaggregated and assessed for the fom1ation of 
tertiary colonies. 
Te1tiary colonies were not formed from micro colonies. Tertiary micro, small and large 
colonies were produced from small and large secondmy colonies, the predominant colony 
type being large. Small secondary colonies gave rise to 8.7% .±: 1.80 large colonies in the 
sham and 9.5% .±: 1.68 large colonies post Ml (p = ns). Large secondary colonies 
generated 16% .±: 1.4 7 large colonies in the sham and 14%.:!:: 1.68 large colonies post MI 
(p = ns). Note that the percentage of large tertimy colonies was greater from large 
secondary colonies compared to small secondary colonies in sham and post Ml (p<0.05). 
This data is brought together in figure 5. 17 so that direct comparisons can be made. There 
was a significantly greater percentage of tertiary small and micro colonies from small 
secondary colonies post MI (P<0.05) compared to the percentage from small seconda1y 
colonies in a sham heart. These data suggested that the size of the initial colony was a 
strong predictor of both proliferative capacity (size of secondary/tertiary colonies) and 
self-renewal ability (numbers of colonies formed). lfthis was the case, then the ability of 
the different sized colonies to support extended culture in vitro should show a similar 
correlation. In separate experiments, the clonal passagability of the small and large 
colonies were assessed, showing that the small primary colonies did not passage beyond 
passage 4. At this end-stage they were predominantly non-adherent and although 
occasional cells were seen , no further colonies fonned (data not shown). Cultures 
established from large colonies however showed no such limit, and have been cultured 
out to passage 15 with no phenotypic change, suggesting that their growth may extend 
beyond this. One possibility is that rather than showing a different proliferative/self 
renewal capacity, cells from large colonies may show a greater sensitivity to cellular 
transformation and/or tissue culture adaptation, which might also extend their in vitro life 
span. However, such transformation is normally associated with marked changes in cell 
cycle time. As can be seen from figure 5.18, the population dynamics of cultures from 
large colonies remained essentially constant through the entire period. That the 
population doubling time at the very oldest passage was the same as that at passage I 
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Figure 5.17 Tertiary colony fonnation from small and large secondary colonies derived 
from PDGFRA GFPHIGH cells 5 days post sham surgery and post MT. 
Tertiary colonies were not formed from micro colonies. Tertiary micro, small and large 
colonies were produced from small and large secondary colonies, the predominant 
colony type being large. Small secondary co lonies gave rise to 8.7% ± 1.80 large 
co lonies in the sham and 9.5% ± 1.68 large colonies post MI (p = ns). Large secondary 
colonies generated 16% ± 1.471arge colonies in the sham and 14% ± 1.681arge colonies 
post MI (p = ns). Note that the percentage of large tertiary colonies was greater from 
large secondaty colonies compared to small secondary colonies in sham and post MI 
(p<0.05), indicated by *. Total of 6 hearts were used in this analysis for sham and Ml 
and 30 colonies counted for each colony type per heart. 
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Figure 5.18 Serial passage growth curve for PDGFRA GFPIIIGII cells from a 
primary large colony (Pdgfi·aGFPI+ hem1). 
Population dynamics of cultures from large colonies remained essentially 
constant through the entire period suggesting that substantial cellular 
transfom1ation was unlikely. 
(Reproduced with permission from Or V Chandrakanthan, Victor Chang 
Cardiac Research Institute, Sydney) 
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suggests that substantial cellular transfonnation was very unlikely, and that the 
phenotypic differences between small and large colonies were indeed likely to be a 
function of their self renewal/proliferative capacity. Ml is an acute, degenerative event, 
which promotes a number of responses, including inflammatory (see section 1.6). One 
hypothesis is that the PDGFRA GFP+ populations with CFU-F activity are changing as a 
component of a potential repair/regenerative response . If that is the case, these numbers 
should also be altered in mouse models which show a propensity for cardiac 
repair/regeneration. One such model is the a-MHC/miGF-1 transgenic mouse. 
5.8 Quantification of PdgfraGFP+ cells in a proregenerative model 
aMHC/miGF-1 transgenic mice have been engineered to express an isofonn of IGF-1 
(Insulin like growth factorl) under the control of the aMHC promotor (Santini et al., 
2007). Injury ofmammalian tissues induces a transient production oflocally acting IGF-1 
isofonns that control growth, survival and differentiation (Goldspink, 2002). Tissues 
which over express IGF-1 could be predicted to show enhanced regenerative abilities. 
Indeed, a recent study has shown that the aMHC/miGF-1 transgenic mice have an 
enhanced ability to recover heart functionality after cardiac injury, as outlined in chapter 
I (Santini et al., 2007). In order to examine whether this enhanced ability reflected 
changes in the Sea-l +/PECAM t·PDGFRA Grr+ population, the aMHC/miGF-1 transgene 
was crossed onto the Pdgfi·aGFPI+ background and the resulting double transgenics 
maintained as heterozygotes (Pdgfi·aGFPI-I-;mlGFtg). These mice will be refered to as 
Pdgfi·aGFP;,nJGF. 
The hearts of PdgfraGFP/m!GF mice were assessed by flow cytometry for the expression 
of Sea-l, PECAM I and PDGFRA GFr, using the same gating strategy as described in 
section 5.3. There were no detectable differences in the profiles of the sham and un-
operated mice (data not shown), a result identical to that seen in the Pdgfi·aGFPI+ mouse, 
suggesting that over expression of IGF-1 had no direct effect on numbers of PDGFRA Gr:r 
cells. However, induction of Ml changed this profile (figure 5.19). As in the PdgfraGFPI+ 
mice, there was an increase in the proportion of cells in the PDGFRA Gr:PMEDIUM gate (gate 
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Figure 5.19 demonstrating the change in proportions of the colony forming 
fractions in (a) sham and (b) 5 days post MI in the Pdfi·aGFP/miGFmouse. 
Most notably post MI, cells could be isolated from Gate F aswell as gate G. Gate F 
was a PDGFRA GFPM EDI UM population which fonned primary colonies . Only cells 
from gates F and G showed colony fom1ing ability. 
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F) and the PDGFRA GFPIIIGII gate (gate G) post MI (figure 5.19b ), however this increase in 
PDGFRA GFPMEDIUM cells was significantly greater (p<0.05) than for the PdgfraGFPI+ mice 
post MI (figure 5.20). Having demonstrated that the proportions of PDGFRA GFP+ cells 
increased in the proregenerative model, absolute numbers of cells isolated at 5 days post 
infarct were also quantitated as for Pdgfi·aGFP/I hearts (section 5.4.1) (figure 5.21). As in 
the Pfgfi·aGFPII mice the PDGFRA GFI'IIIGH and PDGFRA GFI'MEDIUM cell population in 
Pdgfi·aGFP/m!GF mice was CD45 negative (data not shown). The phenotype of the 
colonies present within the PDGFRA GFPHIGII and PDGFRA GFPMEDIUM populations were 
GrP then addressed for the Pdgfi·a · /m!GF mouse. 
5.9 Primary colony formation from PdgfraGFP/m/GF hearts post 
MI 
Data from the Pdgfi·aGFPII mouse demonstrated that the PDGFRA GFPHIGII and 
PDGFRA GFPMEDIUM populations showed quantitative and qualitative differences in the 
respective CFU-F. Thus these two populations were sorted from the hearts of 
PdgfraGFP/m!GF heatts and assessed for CFU-F activity. First the PDGFRA GFPHIGH 
population will be considered. Although there was an increase in colony forming ability 
post infarct for Pdgfi·a.GFP/m!GF hearts as previously described for Pdgfi·aGFPll, the 
increase was only significant for small colonies (increasing from 0.18% ±. 0.004 to 0.34% 
± 0.005, p<0.05) and large colonies (increasing from 0. 76% ± 0.007 to 1.02% ± 0.0 I 0, 
p<0.05). The increase in colony forming activity from large colonies post Ml in the 
Pdgfi·aGFP/m/GF hearts was particularly pronounced (figure 5.22) and was significantly 
greater than in the equivalent population from Pdgfi"(/GJ.-Pit· (p<0.05). The results for the 
PDGFRA GFPMEDIUM population are shown in figure 5.23 . As for the Pdgfi·aGFPII hea1ts, 
PDGFRA GFPMEDIUM cells from Pdgfi·cFFP/m!GF hearts formed primarily micro colonies, 
with few small and large. However the percentage colony formation in Pdgfi·aGFP/m!GF 
hearts was significantly higher for small and large colonies (p<0.05). The self-renewal 
and proliferative capacity of these colonies was then assessed by secondary and tertiary 
re-plating studies. 
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Figure 5.20 Change 111 PDGFRA GFPIIIGH and PDGFRA GFPMEDI UM populations m 
PdgfraGFPI+ and PdgfraGFP/mJGF hearts at day 5 and day 12 post MI. 
There was an increase in percentage of cells in all populations post MI, however the 
increase in PDGFRA GF PM EDIUM frac tion was significantly greater at day 5 post MI and 
day 12 post MI in the PdgfraGFP/m!GF heat1 (p<0.05) than for the PdgfraGFP/ I heart. N= 
6 per group . 
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Figure 5.21 Comparison of actual cell numbers isolated by flow cytometry for 
PDGFRA GFPMEDI UM and PDGFRA GFPHIGH cells in sham hearts and day 5 post MI 
(D5 MI) - PdgfraGFP/m!GF hearts. 
Numbers of PDGFRA GFPIIIGII and PDGFRA GFPM EDI UM cells increased significantly 
post MI (p<0.05) . Also shown is the increase in PECAM-/PDGFRAGFP- fraction 
(labelled as D in figure 5.19). The increase in this fraction cou ld be represented by 
an influx of inflammatory cells post infarct as explained in section 5.5. * indicates 
p<0.05 . N=6 per group. 
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Figure 5.22 Primmy colony fonnation from the PDGFRA GFPHIGH populations in 
PdgfraGFPI+ and PdgfraGFP/mJGF mice in sham operated control s and 5 days post MI 
(D5 MI). 
Although there was an increase in colony fom1ing abi lity post infarct for 
Pdgfracn>/mlGF mice as previously described for Pdgji-aCFPI+ mice , the increase was 
only significant for small colon ies (increasing from 0. 18% ± 0.004 to 0.34% ± 0.005 , 
p<0.05) and large colon ies (increasing from 0.76% ±_0.007 to 1.02% ± 0.0 I 0, p<0.05). 
The increase in colony forming activity from large colonies post MI in the 
Pdgji-acFP/mJGF was particu larly pronounced. *denotes p<0.05 . 8 hea1ts used in this 
analysis for each Sham and MI group and 5 plates counted per popu lation per heart. 
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Figure 5.23 Comparison of primary colony formation for the PDGFRA GFPMEDIUM 
popu lation in PdgfraGFP/I and PdfgraGFP/m!GF hearts 5 days post Ml. 
PDGFRA GFPMEDIUM cells formed primarily micro colonies, with only a few small 
and large. However the percentage colony formation in PdgfraGFP/m!GF hearts was 
significantly higher for small and large colonies (p<0.05) . * denotes p<0.05 . 8 mice 
were used for each transgenic group and 5 plates counted per population per hemt. 
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5.10 Secondary and tertiary colony formation from 
PdgfraGFP/m/GF hearts post MI 
Comparison of secondary colony formation from the PDGFRA GFPMEDIUM and 
PDGFRA GFPIIIGH populations in sham and MI heat1s is shown in figure 5.24a. In contrast 
to the PDGFRA GFPMEDIUM population isolated from the Pdgfi·aGFPI+ mice, the same 
population of cells in the Pdgfi·acrP/m/GF mice were capable of forming secondary 
colonies, although these tended to be the micro and small colony types. The 
PdgfracrP/m!GF hearts gave an increased number of micro, small and large secondary 
colonies from small primary colonies compared to Pdgfi·acrP!+ hem1s, however this 
difference was not statistically significant. Notably, large pnmary colonies from 
P I I . GFP/1 I d I I f d fi GFP I G cg ra 1em1s an a so t 1ose rom P g ra ;m/ F hem1s gave rise to 
predominantly large colonies, but there was a particularly notable increase in large 
colonies from Pdgfi·acrP/m/GF hearts subject to myocardial infarction (p<0.05) (figure 
5.24b) .. On analysis of tertiary colonies it can be noted in figures 5.25 (a) and (b) that 
PDGFRA GFPMEDIUM cells fi·om Pdgfi·aGFPI+ hearts did not give rise to te11imy colonies 
however those from Pdgfi·aGrP/m/GF hearts did form predominantly micro and small 
colonies. In addition large secondary colonies gave rise to predominantly large tertiary 
colonies, with a marked increase in PdgfraGFP/miGF hearts post Ml (p<0.05). 
These data suggested that the heart contained a Sea 11/PECAM UPDGFRA GFPHIGH 
population which possessed within it cells capable of self renewal and proliferation, and 
also a Scai"1/PECAM UPDGFRA GFPMEDIUM population which had a restricted self 
renewal and proliferation potential. The numbers and phenotypic profile of these cells 
changed in response to myocardial infarction and particularly in hearts which over 
expressed miGF-1, in a manner which suggested an increase in the regenerative capacity 
of the hem1. Candidate stem cells that show such quantitative and qualitative changes 
may be expected to also change their anatomical distribution (Urbanek et al., 2005) . In 
order to investigate whether PDG FRA GFP+ cells showed such changes, their distribution 
in the normal and infarcted heart were assessed by fluorescence microscopy. 
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Figure 5.24 (a) Secondary colony 
formation from sma ll pnmary 
colonies m PdgfraGFPI+ and 
PdgfraGFP/mlGF mice in sham and 
day 5 post MI (D5 MI) . 
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Figure 5.24 (b) Secondary colony 
formation from large pnmary 
colonies 111 PdgfraGFP!t and 
PdgfraGFP lm!GF mtce 111 sham 
and day 5 post MI (D5 Ml). 
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Figure 5.24 In PdgfraGFP/mlGF hearts the PDGFRA GFPMEDIUM population was capable of 
fo rming secondary colonies, although these tended to be the micro and small colony types. 
The PdgfraGFP/mlGF hearts gave an increased number of micro, sma ll and large secondary 
colonies from small primary colonies compared to PdgfraGFPI+ hearts, however this 
difference was not statistically sign ificant. There was a particularly noticeable increase in 
large co lonies from PdgfraGFP/mlGF heatts subject to myocardial infarction (p<0.05), 
indicated by*. This is summarised again in section 5. 13. 3 mice were used fo r each type of 
heart and 30 colonies were counted for each colony type per heart. 
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Figure 5.25 (a) Tertiary co lony 
formation from small secondary 
co lonies m PdgfraGFPI+ and 
PdgfraGFP/m!GF mice in sham and 
day 5 post MI (D5 Ml). 
Figure 5.25 (b) Tertiary colony 
formation from large secondary 
colonies m PdgfraGFPI+ and 
PdgfraGFP/m!GF mice in sham 
and day 5 post MI (D5 MI). 
Figure 5.25 PDGFRA urrMEDIUM cells from PdgfraGFPI+ hearts did not give rise to tertiary 
colonies however those from PdgfraGFP/mJGF hearts did form predominantly micro and 
small colonies. In addition large secondary colonies gave rise to predominantly large 
tertiary colonies, with a marked increase in PdgfraGFP/miGF hearts post MI (p<0.05) 
indicated by*. This is summarized again in section 5. 13. 3 mice were used for each type of 
heart and 30 colonies were counted for each colony type. 
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5.11 Anatomic location of PDGFRA GFP+ cells 
Normal adult hearts from Pdgfi·aGFPII tmce were assessed for GFP expresston by 
fluorescence microscopy. As can be seen in figures 5.26a-d, PDGFRA GI'PI cells were 
found distributed throughout the adult heart, including the atria and ventricles, the atrio-
ventricular valves and peri-aortic adventitia. This pattem is similar to that reported for the 
embryonic heart, where, although the PDGFRA GI'PI cells are found primarily in the 
proepicardium at E9.0 and also on the epicardial surface of the heart from late E9.0 to 
E I 0.5, from E 12.5 they are prevalent throughout the interstitium of the myocardium 
(personal communication Or Owen Prall, Victor Chang Cardiac Research Institute, 
Australia). In order to address whether the quantitative changes observed by flow 
cytometry following Ml were reflected by changes in tissue distribution, the infarcted 
heart was investigated also by fluorescence microscopy. As can be seen in figure 5.27, 
compared with ventricle wall remote from the infarct site, the peri-infarct area 
sunounding the site of ischaemic injury was rich in PDGFRA GI'P+ cells. Quantitative 
assessment was carried out by counting PDG FRA GI'PI cells per high power field (x 40) in 
sequential sections taken from the left ventricular (LV) free wall (below level of coronary 
atiery ligation in those mice subject to MI), an area remote from the LV free wall (remote 
LV), in the peri-infarct area (or equivalent anatomical location of the peri-infarct area for 
the sham and non-operated hearts). Sham operated and non-operated hearts showed no 
differences in cell counts. At day 5 post Ml, there was a significantly increased number 
of PDGFRA GI'PI cells in the peri-infarct area (p<0.05), with no significant changes in 
other regions. At day 12 post MI, although the number of PDGFRA GI'PI cells counted per 
high power field was significantly increased in the peri-infarct area compared to sham, 
normal and day 5 post infarct, there was actually a greater number of PDGFRA GI'P+ cells 
in the infarct area itself (figure 5.28) (p<0.05). The previous results from flow cytometry 
showed that although there was an increase in PDGFRA GI'Pf\·IEDIUM and PDGFRA GI'PIIIGII 
cells post infarct, the predominant population post infarct was PDGFRA GFPIIIGII_ These 
quantitative changes as assessed by fluorescence microscopy were consistent with the 
observations for PDGFRA GI'P+ cells by flow cytometry (section 5.4). 
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Figure 5.26 Sections tlu·ough PdgfraGFP!t- heatt examined by fluorescence 
tmcroscopy . 
(a) Reconstructed longitudinal section demonstrates the widespread distribution 
throughout the atria and ventricles of PDGFRA GFP I cells and also their perivascular 
position around the aotta. Scale bar= Lmm. 
Magnified images shown in panels b-d futther illustrate the PDGFRA GFP+ cells 
distributed throughout the heart including within the va lves and peri- aortic adventitia. 
A-V = Atrioventricular. LV= Left ventricular. GFP = green. Hoechst nuclei staining = 
blue. Scale bar = 50)lm. Reconstruction by Dr M Xaymardan, Victor Chang Cardiac 
Reseacb Institute, Australia. 
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(a) Remote left ventricle 
Figure 5.27 Fluorecence microscopy of PdfgraGFPll heart 5 days post MI. 
The PDGFRA GFP+ cells were primarily located in the peri-infarct area at day 5 post 
infarct. (a) remote left ventricle (b) Peri-infarct area 5 days post infarct (MI D5) 
Green= GFP. Hoechst nuclei stain= blue. PdgfraGFP/1- heart. Scale bar = 20)-lm. 
(c) Photograph showing cross section of ventricle demonstrating region from which 
sections taken . Thinning of the free wall and loss of nonnal muscle architecture can be 
noted in this photograph at 5 days post MI. 
-- -~--------------
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Sham (a) Normal and Sham operated hearts 
- Non -operated heart 
(b) Day 5 post Ml (c) Day 12 post Ml 
* 
Figure 5.28 PDGFRA GFP I cell counts per high power field (x 40) m PdgfraGFPI+ 
hearts. 
(a) Sham operated and non-operated hearts showed no difference in cell counts. At 
day 5 post MI (b), there were significantly increased numbers of PDGFRA GFP I cells in 
the peri-infarct area , with no significant changes in other regions. At day 12 post MI 
although the number of PDGFRA GFP I cells counted per high power field was 
significantly increased in the peri-infarct area compared to sham, normal and day 5 
post infarct, there was actually a greater number of PDGFRA GFP+ cell s in the infarct 
area itself(p<0.05) . * denotes p<0.05. 
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5.12 Differentiation assays in vitro 
Cells which formed primary colonies from the PDGFRA GFPHIGH and PDG FRA GFPMEDIUM 
fractions were subject to cardiogenic, smooth muscle, endothelial, adipogenic and 
osteogenic differentiation assays as described in chapter 2. PDGFRA GFPHIGH cells showed 
an ability after exposure to the differentiation conditions described in chapter 2 to 
differentiate into cells expressing appropriate markers of all these cell types, whereas 
PDGFRA GFI'MEDIUM cells had much more limited ability and showed ability to 
differentiate only into cells with adipocyte markers (figures 5.29-5.33). No spontaneous 
contraction was observed however in the cells expressing the biochemical marker of a-
sarcomeric actinin. 
5.13 Discussion 
A CFU-F assay has been used to delineate a population of cells which demonstrate self-
renewal and proliferation in vitro. In this assay, after plating of cells, each colony fanned 
was generally assumed to arise from a single cell, therefore plating cells to form primary, 
secondary and tettiary colonies gave an indication of their potential for proliferation and 
self renewal. At each passage colonies contained both self renewing cells and more 
differentiated cells. Together with differentiation assays, this enabled a distinction to be 
made between those cells which may be putative stem cells and those which could be 
progenitors by their ability to self renew. This assay has been applied in the examination 
of heatts in a normal state, post infarct and a proregenerative model. 
As identified in Chapter I, there have been a number of different markers used in 
attempts to try to identify cardiac stem cells which may be resident in the heart, however 
there does not appear to be any specific marker or group of markers to encompass this 
population. Hence, although cell specific markers may be useful, this thesis has used 
markers in conjunction with a CFU-F assay, which enabled enrichment of the initial 
population by assessment of self renewal and proliferation potential. Brent Reynolds' 
group have performed similar assessments on putative neural stem cells (Louis et al., 
(a) 
(b) 
(c) 
Figure 5.29 Adipocyte differentiation assay 
(a) Negative control cells not exposed to differentiation media. (b) 
PDGFRA GFPHIGH cells. (c) PDGFRA GFPMEDIUM cells. Lipid droplets within both 
PDGFRA GFPHIGH and PDGFRA GFPMEDIUM cells can be seen stained red with Oil 
red 0. The PDGFRA GFPIIIGII cells proliferated at a faster rate and associated with 
this, the large lipid droplets dispersed much quicker in this population in 
comparison to PDGFRA GFPMEDIUM cells. Scale bar= lOJ..I.m. 
Cu ltures grown and photographed by Dr V Chandrakanthan, Victor Chang Cardiac 
Research Institute, Sydney. Cel ls isolated from PdgfraGFPI+ heart. 
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Figure 5.30 Osteogenic differentiation assay . 
(a) Negative control-cell s not exposed to differentiation media. (b) PDGFRA GFPIITGH 
cells. (c) PDGFRA Gr-PMEDIUM ce lls. Ca lcium deposits in the differentiated cells 
complexed with alizarin red were seen visible as orange/red stain in the 
PDGFRA GFPHIGII ce ll s on ly. Scale bar = l Oflm. 
Cultures grown and photographed by Or V Chandrakanthan, Victor Chang Cardiac 
Research Institute, Sydney. Cells isolated from PdgfracFPI+- heart. 
(a) 
(b) 
(c) 
Figure 5.31 Endotheli al di fferentiation assay . 
(a) Negative control-cell s not exposed to differentiation media. (b) PDGFRA GFPHIGH 
cells (c) PDGFRA GFPMED IUM ce lls (d) Ab Control-PDGFRA GFPHIGH cell s exposed to 
endothelial differentiation medium, secondary antibody only. Positive staining for 
PECAMl was observed in the PDGFRA GFPIIIGH population only. PECAM staining 
shown in red . Hoechst nuclei staining shown in blue. Scale bar= 1 011m. 
Cultures grown and photographed by Dr V Chandrakanthan, Victor Chang Cardiac 
Research Institute, Sydney. Cells isolated from Pdgfi-aGFPI+ heart. 
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(a) 
(b) 
(c) (d) 
Figure 5.32 Smooth musc le differentiation assay. 
(a) Negative control -cells not exposed to differentiation media. b) PDGFRA GFPIIIGII 
cell s. (c) PDGFRA GFPM EDIUM cells . (d) Ab Control. PDGFRA GFPHIGH ce lls exposed to 
differentiation medium, secondary antibody only. Positive staining for smooth muscle 
myosin heavy chain seen in PDGFRA GFPHIGI-I cells only. Smooth muscle myosin heavy 
chain sta ining shown in green . Hoechst nuclei staining shown in blue. Scale bar = lO~m. 
Cultures grown and photographed by Dr V Chandrakanthan, Victor Chang Cardiac 
Research Institute, Sydney. Cells isolated from PdgfraCFPI+ heart. 
(a) 
(b) 
(c) 
Figure 5.33 Cardiomyocyte differentiation assay. 
(a) Negative control-ce ll s not exposed to differentiation media. (b) PDGFRA GFPHIGH 
cells. (c) Ab Control. PDGFRA GFPHIGII cells exposed to differentiation medium, 
secondary antibody only. Positive staining for a-sarcomeric actinin shown in red . 
Hoechst staining shown in blue (nuclei). Scale bar= I 0~-tm. 
Cultures grown and photographed by Dr V Chandrakanthan, Victor Chang Cardiac 
Research Institute, Sydney. Cells isolated from PdgfraGFPI+ heart. 
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2008). Louis et al used a colony forming assay and divided colonies according to size (ie 
their proliferative ability) as in the present study, to try to discriminate between putative 
progenitor cells and putative stem cells in the brain, which, like the hemt, was once 
thought to be a tem1inally differentiated organ with very limited regenerative potential. 
Louis et al showed that as well as having different self renewal and proliferative 
potential, the different size colonies also had differences in their differentiation capacity, 
with colonies <2mm being unipotent and colonies >2mm being multipotent. Altogether, 
they concluded the size of colonies enabled them to make a distinction between stem 
cells and progenitors. Similarly, in the present study, different colony sizes also reflected 
differences in self renewal and proliferation. PDGFRA GFPIIIGII and PDGFRA GFPMEDIUM 
populations had different rates of proliferation and abilities to self renew, and in addition 
the PDGFRA GFPHIGH cells which primarily formed large colonies had a broader 
differentiation capacity in vitro in comparison to the PDGFRA GFPMEDIUM population 
which primarily formed the smaller colonies. Although previous studies have suggested 
that demonstration of secondary or tertiary self renewal may be adequate to satisfy the 
stem cell requirement of self renewal, in this experiment a more rigorous approach was 
taken and colonies were passaged over 15 times if possible to assess self renewal ability. 
Large PDGFRA GFPHIGII colonies showed prolonged self renewal by being able to be 
passaged over 15 times, however small colonies from this fraction only passaged to P4 
with microcolonies not even fom1ing secondary colonies. PDGFRA MEDIUM cells in 
PdgfraGFP/+ hearts did not fom1 secondary colonies, however in the PdgfraGFP/miG F 
proregenerative model, secondary and tertiary colonies did fom1 from this population 
suggesting an increased 'stemness' of this population in the proregenerative model. 
In an effort to enrich the CFU-F population isolated from the whole heart, it was 
fractionated into a Sca-1 1/PECAM 1-/PDGFRA GFPIIIGH sub population. Sea-l was selected 
as previous work has identified a Sea-l+ cardiac resident population which were CD45 
negative (as were the cells isolated in the present study) which showed in vitro evidence 
of being able to express a-sarcomeric actin and cardiac Troponin I. Futther work by the 
same group showed that these Sea-l 1 cells could home to the infarct area after systemic 
injection and show some degree of contributing to new cardiomyocyte formation (Oh et 
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al., 2003). Furthermore, consistent with the present findings, Wang et a! have 
demonstrated a Sea 11/PECAM ,- population in the adult mouse heart which are reported 
to increase in number in the infarct and peri- infarct area post MI. In addition they were 
able to demonstrate differentiation in vitro into cells expressing cardiomyocyte and 
endothelial markers in agreement with present data (Wang et al., 2006). An interesting 
observation by Wang et al which was not tested in this thesis was that flow cytometry 
analysis of Sca-1 1/PECAM ,- cells from bone marrow and circulating blood did not 
change post infarct providing weight to their hypothesis that the Sca-1 1/PECAM I- cells 
are cardiac resident and do not migrate in from extracardiac tissue such as bone marrow. 
Notably in the present study no PDGFRA GFPI cells were found in the bone marrow of 
Pdgfi·aGFPll mice (data not shown). In addition to previous work using Sca-11/PECAM I" 
cell populations isolated from the adult mouse heart, the present study has also taken a 
smaller subpopulation of PDFGRA GFP+ cells from the Sca-1 1/PECAM 1- population to 
assess changes post infarct in this population as well as assess the colony forming ability 
as described above. Note that colony forming ability was only found in the PDFGRA GFI'I 
subfraction indicating a potential of these cells to have stem cell characteristics. Although 
other literature has not quantitated the colony forming ability of Sea-l+ cells as in the 
present study, interestingly, recent work by Tateishi and eo-workers also examined a 
functional phenotype of a putative stem cell population in the heart (Tateishi et al., 2007). 
They reasoned that a putative stem cell population in the heart would express telomerase 
reverse transcriptase (TERT), and by using a transgenic mouse that expresses GFP under 
the control of the TERT promoter, the TERTGFPI fractions of clonal cells from the heart 
were found to be enriched for Sea-l+ cells. The cells isolated were negative for 
PECAM I, CD34 and CD45, however they did express CD90, an antigen commonly 
found on mesenchymal stem cells as did the colony forming fraction in the present study 
(data not shown). As previously documented in Chapter I, a specific progenitor 
population has been identified known as the side population (SP), characterized by their 
intrinsic capacity to efflux Hoescht dye. Pfister and colleagues examined this population 
and found that Sea-l was widely expressed, but it was largely negative for CD45 and 
CD34, and negative for c-kit. Similar to the present study they found an enrichment for 
colony forming activity in the Sca-1 1 fraction compared to the whole population and in 
158 
addition only the PECAM ,- fraction of Sca-1 1 cells exhibited in vitro cardiomyogenic 
potential. Due to the overlapping behaviour of the populations discussed, it is likely that 
an overlapping population of Sca-1 1 cells is being examined by these investigators and 
also in the present study. 
In comparison to the cardiac c-kit1 population which has been extensively studied by 
Anversa and colleagues, the PDGFRA Gr=P+ population studied here were distributed 
throughout the myocardium, whereas Anversa and colleagues reported that the majority 
of ckit1 cells they found were located at the apex of the heart and in the atria (Urbanek et 
al., 2005). Although a proportion of c-kit 1 cells do express Sea-l, in the present study 
very few c-kit cells could be isolated from the adult mouse heart. It must be noted 
however that as well as the work in the present study other investigators have also found 
difficulty locating c-kit 1 cells in the adult heart (Li et al., 2008; Plister et al., 2005) 
which may be attributable to enzymatic cleavage of the c-kit receptor from the cell 
surface during the digestion process (Pfister et al., 2005), or due to the fact that c-kit 1 
cells only migrate into the heart after ischaemic injury as reported by Faze! et at (Fazel et 
al., 2006).1n addition when c-kit +cells have been localized to the myocardium up to 30% 
have been found to be CD45 positive (Faze! et al., 2006) . Hence it appears less likely 
that the population being studied in this study correlate with the c-kit 1 population 
described by others. 
In an effort to enrich the colony forming fraction flllther, and also to attempt to isolate a 
putative cardiac resident population, the PDGFRA GFP+ population was taken from the 
Sca-11/PECAM r fraction. PDGFRA Gr=r+ cells in the adult may be derived from the same 
population that appear in the embryonic cardiac interstitium at E 12.5. The anatomic 
location of the PDGFRA GFP+ cells in the hea1t of the embryonic and adult Pdgfi-cPFPll 
mice together with the phenotypic changes of death by E I 0.5 with multiple cardiac 
defects in Pdgfi·a-l- mice, suggest an important developmental role for these cells in the 
developing hemt and potentially a continuing stem cell role in the adult, particularly as all 
of the colony forming activity was isolated to the PDGFRA GI'PI cells in the heart. Post MI 
there was a shift in colony forming potential, which could also be interpreted as an 
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. I I ' ' ' . . I Tl PDGFRAGFPIIIGH 11 mcrease 111 t 1e 1eart s stemness or regenerative potentia . 1e ce s 
showed the cardinal features of stem cells - proliferation, long term self renewal and 
multi potency, with the PDGFRA GFPMEDIUM cells having a phenotype consistent with a 
more restricted downstream progenitor type cell with its limited proliferation, self 
renewal and differentiation capacity. In a similar manner to other studies this putative 
stem/progenitor population increased in number post infarct and appeared to localize in 
the peri-infarct and infarct area (Faze) et al., 2006; Wang et al., 2006). 
The importance of platelet derived growth factor signaling post MI has been outlined 
earlier from work by Zymeck and colleagues (Zymek et al., 2006). They found that 
platelet derived growth factor receptor alpha and beta were both involved in post infarct 
repair, primarily in modulating fibrosis and angiogenesis. It is known that cardiac over 
expression of the PDGFRA ligand PDGF-C induces fibrosis (Ponten et al., 2003) and that 
inhibition of PDGFRA significantly decreases collagen deposition in the infarcted 
myocardium. Hence it appears that PDGFRA and its ligands are crucial not only in 
cardiac development but also in the well orchestrated response post injury which 
regulates fibrous tissue deposition and facilitates scar formation. Work by Santini et al 
has shown that in a a.MHC/m/GF-1 transgenic mouse there appeared to be a modulation 
of the inflammatory response which enabled restoration of cardiac function and reduced 
scar formation, however although they found an increase in the number of proliferating 
cells at 4 weeks post infarct it is not yet clear whether these cells contributed to tissue 
reconstruction after myocardial injury (Santini et al., 2007). Of note from the present 
study was that in the PdgfraGJ·-r/m!GF hearts, there was an increase in number of 
PDGFRA GFPMEDIUM cells and colony fom1ing potential of both PDGFRA GFPHIGII and 
PDGFRA GFPMEDIUM cells compared to Pdgfi·aGFPI+ hearts. IGF-1 has previously been 
implicated in the ischaemic heart as being cardioprotective and reducing apoptosis m 
surviving myocytes (Li et al., 1997), however with the results of the present study 111 
combination with the data gathered by Santini et al ((Santini et al., 2007), there is a 
possibility that as well as reducing death in local myocytes and activating prosurvival 
signaling, mlGF overexpression may also be implicated in increasing the regenerative 
and repairative ability of the heart post MI. The effect of IGF-1 overexpression is 
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strengthened by work by Anversa and colleagues who showed that IGF-1, together with 
Hepatocyte growth factor (HGF) stimulated migration, proliferation and differentiation of 
endogenous cardiac stem cells. Specifically IGF-1 intramyocardial injection at the time of 
Ml showed anti-apoptotic and proliferative effects on cardiac stem cells in the heart 
resulting in cardiac regeneration and improved survival and function (Urbanek et al., 
2005). 
In humans no cardiac phenotype related to PDGFRA mutation has been described 
however it is noted that mutations in PDFRA are found in patients with gastrointestinal 
stromal tumours (Heinrich et al., 2003) and also expression of PDGFRA has been found 
to be associated with tumour progression in renal cell carcinoma(Sulzbacher et al., 2003). 
In this respect the tyrosine kinase inhibitor sunitinib has been used in treatment of 
patients with metastatic renal carcinoma (Motzcr et al., 2006) and gastrointestinal stromal 
tumours (Demetri et al., 2006), however there has been an accumulation of evidence of 
sunitinib associated hem1 failure (Khakoo et al., 2008). It must be noted that sunitinib 
would also act on the tyrosine kinase receptor c-kit also and may affect cardiac function 
in a tyrosine kinase independent manner. At present the mechanism of Sunitinib 
associated hem1 failure has not been elucidated, however without any described cardiac 
phenotype in humans for mutations in PDGFRA this remains an interesting observation. 
In contrast to the PDGFRA GFP+ population described in the present study, Is II' cells, 
although being shown to be an important cell in development, primarily contributing to 
the right ventricle and outflow tract (Cai et al., 2003) very few Is II +cells are found in the 
postnatal heart (Laugwitz et al., 2008). In addition, lsll + cells are found in the second 
heart field and not in the proepicardium of the embryonic heart as are PDGFRA urr+ cells 
(Cai et al., 2008). 
Hence it appears that the PDGFRA GFI'I population examined in the present study 
overlaps with other work which has investigated Sea I' cells and side population cells in 
the heart and isolates a population which is largely separate from the Isll' and c-kit1 
population described in previous studies. The PDGFRA GFPI population has been shown 
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to have stem/progenitor cell characteristics which further underlines the possibility that 
the heart remains capable of adaptation to stress and ischaemic injury through adult life 
via a stem cell mechanism. 
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Chapter 6 
Final discussion 
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6.1 Discussion 
It is common knowledge that the regenerative capacity of human myocardium is 
inadequate to compensate for the significant loss of heart muscle that occurs in acute 
myocardial infarction (Murry et al., 2006). Other tissues which arc known to have stem 
cells such as the gut also respond poorly to ischaemic injury, therefore failure to 
regenerate after such an injury does not necessarily mean that the growth reserve of the 
myocardium is insufficient for reconstitution. Many scientists have now demonstrated 
that the adult myocardium may have within it putative cardiac stem and progenitor cells 
as outlined in Chapter I. The fact that regenerative mechanisms have been shown to exist 
in the adult heart points to the problem of the barriers that may be preventing 
regeneration and exacerbating the injury such as ischaemia, inflammation and fibrosis. 
This hostile microenvironment may prevent the activation and function of cardiac stem 
cells described in the literature as well as adding to the injury burden. Interestingly 
Santini et al studied the ability of locally acting lGF-1 on the restoration of heart function 
after injury (Santini et al., 2007). They concluded that the apparent improved function of 
the transgenic mice at 2 months post injury was facilitated by modulation of the 
inflammatory response and increased anti-apoptotic signaling, however no evidence was 
shown of new regenerating myocytcs in this study, simply that the hearts appeared to 
recover better than in the WT. Note that as well as the inflammatory response having 
deleterious components, it also has a useful role post infarct, with granulation tissue 
formation being a critical step in infarct repair. A fler coronary occlusion macrophages 
phagocytose necrotic myocytes and myofibroblasts and endothelial cells migrate into the 
infarct zone. This granulation tissue provides a matrix rich in proteoglycans and matrix 
proteins which is eventually replaced by a deposition of collagen by myoftbroblasts 
(Virag and Murry, 2003). The amount of granulation tissue peaks at 7 clays after which it 
is replaced by scar tissue. As well as modulating deleterious components of post infarct 
inflammation, modulation of this inflammatory granulation tissue fonnation could also 
improve remocleling and post infarct mechanics. Faze! and colleagues postulated that the 
ckit1 cells they isolated post infarct influenced cardiac function after ischaemic injury by 
-------------------------------------
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contributing to angiogenesis and therefore granulation tissue mediated infarct 
stabilization (Faze) et al., 2006). 
In light of these findings an initial investigation was made into the efficacy of an 
antibody against the human CSaR (7F3 mAb) which had been previously shown to 
dramatically reduce the inflammation in a mouse model of rheumatoid arthritis (Lee et 
al., 2006). At the time of myocardial infarction the intense inflammatory reaction that 
results actually causes neutrophil mediated damage to the tissue at the site of the infarct 
(Frangogiannis et al., 2002). A potent anaphylatoxin for neutrophil infiltration is CS 
hence the CS/CSaR axis was an interesting target to aim to reduce inflammation and 
therefore reduce myocardial damage and infarct size, possibly by modulation of a stem 
cell or granulation tissue response. The complement system has been used as a target 
previously (as documented in Chapter I) however, results have been mixed in animal and 
human studies using small molecules and antibodies against C3, CS and CSa. It was 
hoped that such a specific target of the CSaR would have similar positive outcomes to 
those shown by Lee et al in their rheumatoid arthritis model (Lee et al., 2006), and also 
would not have the potential immunodeficiency outcomes of inhibitors which act at C3. 
This was the first time a monoclonal antibody was being used against the CSaR in the 
setting of myocardial ischaemia. As shown in chapter 4, inflammatory influx of 
neutrophils was significantly reduced, however this did not influence infarct size 
measured at 3 days post surgery. Hence although inflammation is a major contributor to 
myocardial injwy, it was shown that inhibition of this process using 7F3 mAb was not 
enough to reduce ischaemic damage or trigger regenerative events at the time points 
examined, and other mechanisms must be studied to evaluate ways post ischaemic 
damage or repair could be influenced. 
Hence a putative stem cell population within the heart was investigated. The myriad of 
cardiac resident cell types that have been put forward as potentially being candidate 
putative stem cells for the heart point to the as yet unsolved question of which cell type is 
the most appropriate and how their ability may be harnessed (Segers and Lee, 2008). It 
was therefore important to examine the myocardium in the context of work by others to 
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search for cells which may have the potential to repair and regenerate the heart after 
ischaemic insult, to quantitate any changes in number and examine changes in phenotype 
after myocardial infarction. Although there are a number of cells which have been 
isolated from the heart as stem cell candidates, the majority of investigators have used 
surface markers to isolate them before assessing any phenotype in vitro or in vivo. In the 
present study a colony forming assay was used in a manner similar to which Louis et al 
had successfully demonstrated self renewal and proliferation in a population of neural 
stem cells. They showed that differences in colony size reflected self renewal and 
differentiation ability, enabling the distinction between putative progenitor and stem cells 
to be made (Louis et al., 2008). Recent work has demonstrated the importance of the 
epicardium as a source of cells which may be able to contribute to cardiac regeneration 
(Cai et al., 2003; Lepilina et al., 2006; Zhou et al., 2008) and in this regard cells have 
been found in the proepicardial organ, epicardium and interstitium of the developing 
heart which express PDG FRA (personal communication, unpublished data, Or 0 Prall 
Victor Chang Cardiac Research Institute). Due to the similar anatomic location of these 
cells in pm1icular stages of the embryo and adult hearts and also the fact that the Pdgji-c/· 
phenotype was found to be lethal with cardiac defects including aortic malformations and 
septal defects, it could be suggested that as well as being important at a developmental 
level these cells may have a role in regeneration of the adult heart. In addition PDGFRA 
and associated ligands have been found to be involved in modulation of fibrosis and scar 
formation in post infarct repair (Zymek et al., 2006), which as pointed out by Virag and 
Murry is a critical step in the repair mechanism after myocardial infarction (Virag and 
Murry, 2003). It is useful to note that the c-kit1 putative stem cell population isolated by 
Faze! and colleagues was reported to improve post infarct function by primarily 
contributing to the angiogenesis aspect of granulation tissue repair (Faze I et al., 2006). 
The phenotype of the population of cells isolated by flow cytometry in this thesis from 
Pdgfi·aGFPl• hearts was Sca-1.1/PECAM-;PDG FRA GFP 1 • As annotated in Chapter 5 this 
population did have characteristics which overlapped with other Sea-l+ populations 
isolated by previous investigators and less phenotypic similarities to the c-kit+ or Isll + 
populations (Fazel et al., 2006; Laugwitz et al., 2008; Pfister et al., 2005; Tateishi et al., 
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2007; Urbanek et al., 2005; Wang et al., 2006). In a similar way to how Louis et al (Louis 
et al., 2008) made assessment of their putative stem and progenitor cells, 
PDGFRA GI'PHIGII and PDGFRA GrPMEDIUM cell populations were shown to have markedly 
different abilities to form large colonies, which had greater self renewing potential than 
smaller ones, indicating that of these two populations the PDGFRA GFPIIIGH population 
had characteristics more associated with putative stem cells, pmticularly with its broader 
in vitro differentiation potential in comparison to PDGFRA GFI'MEDIUM cells which 
although formed colonies had limited ability to self renew and limited diiTerentiation 
capacity Ill the assays which were used in the present study, suggesting 
PDGFRAGI'PMEDIUM b . I . - may ea progemtor type popu atton. 
6.2 Conclusions 
This thesis set out to examine the effect of an anti-inflammatory C5aR antibody in the 
setting of acute MI and also to examine the adult heart for cells which may be putative 
stem cells or progenitor cells. Initially a model of murine myocardial infarction was 
shown to be successfully established with a relatively low mortality and reproducible 
infarct size which could be used in future experiments. The intense inflammatory 
response post MI was targeted with a C5aR antibody and although this was shown to 
reduce the neutrophil infiltration, a significant change in infarct size was not shown at the 
3 day time point analysed. It was apparent that other factors needed to be targeted to 
improve heart function and influence recovery from myocardial injury. To assess the 
presence of a stem cell population in the adult heart a simple yet reproducible and robust 
assay (CFU-F) was used in conjunction with markers of Sea-l, PECAM I and PDGFRA 
to isolate a population which may remain from the developing heart. A Pdgji·aGFPii 
mouse was used to enable localization of the cells expressing PDGFRA. Two populations 
were found which formed colonies, the PDGFRA GFPHIGII population which had 'stem 
cell' like properties in terms of proliferation, prolonged self renewal and multipotent in 
vitro differentiation, and the PDGFRA GFPMEDIUM population which had 'progenitor cell' 
properties in that although it had proliferative ability, the potential of this population to 
continue to self renew and differentiate into multiple lineages was restricted. Hence in a 
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similar way to the in vitro work from Louis et al (Louis et al., 2008), this suggested the 
PDGFRGrPIIIGII population could be a putative stem cell population isolated from the 
I d I PDFGRGFI'MEDIUM I 0 b 0 0 I 0 1eart an t 1e · popu at1on may e a putat1ve progemtor popu atwn. 
Interestingly the number of cells from both these populations increased significantly post 
M! and the colony fonning ability of the PDGFRA c;rrHIGH population was significantly 
enhanced. Fwthermore in a model which has been associated with a proregenerative 
status by its overexpression of IGF-l and enhanced recovery post Ml, the numbers 
isolated from both these populations was significantly increased after myocardial 
0 c 0 0 I I I' I PDGFRAGFPMEDIUM I 0 0 I 0 d 0 m.arct1on, part1cu ar y o t 1e ~ · popu at1on, w1t 1 an assocwte mcrease 
in colony forming ability of both populations and self renewal ability of the 
PDGFRA GrrMEDIUM population. 
These results suggest that although reducing the inflammatory response by inhibiting 
C5aR reduces infarct associated neutrophil infiltration , this was inadequate to reduce 
myocardial injury at the time point of 3 days post infarct. However, a population of 
putative stem and progenitor cells, whose stem cell-like phenotype appears to change in a 
manner which increases the heart's 'stemness' post Ml , particularly in the prescence of 
IGF-l expression, can be found in the myocardium, which may be able to enhance repair 
and regeneration after ischaemic injury. Further studies would help to evaluate in detail 
their role, pm1icularly in an in vivo environment. 
6.3 Future directions 
Many possibilities for future study have arisen as a result of this research and it would be 
opportune to use this as a platfonn from which to investigate further the mechanics 
involved in post infarct repair and regeneration. 
In relation to the work using the C5aR mAb (7F3 mAb), despite the outstanding results 
demonstrated by Lee et al in using 7F3 mAb in a rheumatoid arthritis model (Lee et al., 
2006), the outcome of the present study showed no change in size of MI at 3 days despite 
a significant reduction in neutrophil infiltration. It would be useful to examine long term 
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outcomes of infarct size and mortality after using 7F3 mAb, pmticularly in the light of 
findings from the COMMA trial showing that despite no difference in myocardial injury, 
there was a difference in 90 day mortality between treated and untreated groups (Granger 
et al., 2003). In addition it would be interesting to examine changes in phenotype of the 
PDGFRA population in mice which were treated with 7F3 mAb and if the antibody was 
to be considered for clinical use it would be impotiant to show efficacy when 
administered after an ischaemic event and also in the setting of ischaemia reperfusion. 
In regard to analyzing the PDGFRA Gf'PI population, although in vitro differentiation data 
is useful, in tem1s of interpreting a cell's phenotypic potential, it is important to realise 
that growing cells in tissue culture can result in cell states that are unlike those seen in 
vivo (Jaenisch and Young, 2008), and represent a proxy for the in vivo situation. Hence it 
would be useful for the PDGFRA GFP+ cells to be transplanted into heart in an in vivo 
environment and assess their ability to differentiate into cells which contribute to the 
cardiac architecture such as endothelium, cardiac myocytes, smooth muscle and 
fibroblasts, as well as how well they integrate with native tissue and demonstrate 
functional phenotypes for example synchronous contractility and demonstration of 
calcium transients. This would then add strong evidence to the hypothesis that these may 
be putative cardiac stem cells. Although some investigators have had promising results 
using cell transplantation of putative cardiac stem cells (Dawn et al., 2005), many others 
have shown that unfortunately cells transplanted have simply fused to native cells without 
changing their phenotype or functionally integrating (Oh et al., 2003). Despite many 
studies where putative cardiac stem cells have been transplanted into an infarcted heart, 
the majority show that regardless of cell type, approximately 90% of cells successfully 
delivered to the heart die within the first week (Laflamme and Murry, 2005). In specific 
relation to Sea-l 1 cells Wang and colleagues found that in the first 2 weeks following 
transplantation, only 2'% of cells were found in the heart and after 3 weeks the number of 
identifiable engrafted cells decreased to less than I% (Wang et al., 2006). Despite this, 
Wang et al, showed cell transplantation was associated with improved LV function and a 
significant increase in myocardial neovascularisation and modest cardiomyocyte 
regeneration suggesting effects seen may have had a paracrine mechanism. In suppott of 
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such a mechanism, work by Gnecchi et al found that just the conditioned media from 
cultured mesenchymal stem cells could reduce the infarct size when injected into the 
myocardium 30 minutes after Ml (Gnecchi et al., 2005). Hence with this and other 
evidence demonstrating the effects of IGF-1 in the heart post infarct (Santini et al., 2007; 
Urbanek et al., 2005), pm1icularly in the light of the changes in the PDGFRA GrP+ 
populations post infarct and in the prescence of IGF-1, it would seem appropriate to 
analyse in further detail the effect of PDGF ligands and miGF-1 on the phenotype of 
PDGFRA Grr+ cells in vitro and in vivo in healthy and diseased hearts to see if restorative 
changes can be brought about by influencing the cells within the hem1 itself, rather than 
relying on the integration of transplanted cells. This would be particularly useful as it 
would avoid technical issues of cell delivery and problems with cell rejection, and more 
conveniently it would harness the heat1's endogenous mechanisms to initiate repair. 
Although the most appropriate intervention at the time of acute ischaemia is restoration 
of blood flow by revascularisation, it is still possible that cells within the heat1 may be 
able to influence cardiac remodelling at this crucial time and influence outcomes by 
modulating the granulation tissue response, hence influencing repair as well as instigating 
regeneration. This has been shown by Faze! and colleagues in relation to c-kit' cells 
(Faze! et al., 2006). Taking into account the fact that PDGF is an important hub in 
stimulation of fibroblast migration, proliferation and activation and also vascular 
maturation, the PDGFRA Grr+ cells investigated in this thesis would be well placed to take 
part in such a response also (Zymek et al., 2006). Translating this to a clinical level it 
may mean that influencing such a cell type using PDGFR ligands or IGF-1 could also be 
a means of regulating the granulation tissue response especially as an increase in their 
number and self renewal ability is seen post Ml. 
Finally, despite the fact that the adult heart has been shown to contain cell populations of 
putative stem cells, the exact lineage relationships between these adult cardiac progenitor 
cell populations and embryonic cardiac stem and progenitor cells is unknown. 
Sophisticated genetic approaches in mice are now available and provide a unique 
oppottunity to detetminc embryonic and lineage origins, as well as the fate of cardiac 
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stem and progenitor cells, which could bring the sc1ence of mammalian cardiac 
regeneration a step closer to clinical reality. 
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